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The capacity for regeneration in the central nervous system is limited, with little functional 
recovery following injury or disease.  Upon injury, the CNS responds by releasing myelin 
associated inhibitory factors (MAIFs), including Nogo, MAG and OMgp, which act to 
suppress axonal regrowth by binding to the Nogo receptor (NgR) complex. The complex 
consists of the Nogo receptor (NgR), p75 neurotrophin receptor (p75NTR)/ (or an alternative 
protein, TROY) and LINGO-1, a leucine rich repeat (LRR) and Ig domain containing protein.  
Signalling through the complex leads to activation of RhoA, resulting in actin 
depolymerisation and growth cone collapse. However, the specific mechanisms by which the 
complex exhibits its effects remain unclear, particularly as more recent data suggest that 
specific members of the AMIGO family of proteins may be critical mediators of the inhibitory 
signaling pathway. Mammalian expression and subcellular fractionation and co-
immunoprecipitation experiments established binding between both NgR and p75NTR with 
AMIGO-1, -2 and -3 and have shown the AMIGO proteins are expressed in the cell membrane 
as are NgR and p75NTR. Interestingly LINGO-1 was also shown to be expressed intracellularly. 
Furthermore, injection of soluble LINGO-1, AMIGO-1 and AMIGO-3 in surface plasmon 
resonance (SPR) approaches confirmed direct and specific interaction with surface bound 
NgR. Finally, to gain a more in depth molecular understanding of the AMIGO proteins and 
their role in the NgR complex, the structure of the human AMIGO-1 ectodomain, including 
LRR and Ig domains was determined to 1.9Å resolution. The protein formed a dimer in 
solution and crystal form and comparisons with structurally similar LRR and Ig domain 
containing proteins, combined with electrostatic properties and localisation of glycosylation 
sites, was used to ascertain likely ligand binding sites on the surface of the protein and 
AMIGO family in general.  
Collectively these results indicate that the AMIGO proteins may form a component of the 
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1.1 Spinal cord injury  
Every year between 250,000 and 500,000 people around the world are affected by spinal cord 
injury (SCI) [1], which is mostly the result of trauma but can also be caused by tumours, 
inflammation or degenerative disease. The consequences vary widely from person to person 
and may include loss of motor, sensory, or autonomic function (such as breathing and bladder 
control). SCI also brings with it the risk of developing secondary conditions such as pressure 
sores and urinary tract infections [2], which can have further debilitating effects. Clinically, 
with most spinal cord injuries, the secondary damage, caused by inflammation after injury, 
contributes significantly to the final impact of the neural damage and in turn the extent of the 
long term disability [3].  
SCI can be segregated into 4 phases, these are; (i) acute, from 2 – 48 hours after injury, (ii) sub-
acute, from 2 days to 2 weeks post injury, (iii) intermediate, which occurs between 2 weeks 
and 6 months after SCI and (iv) a chronic phase which begins at around 6 months after injury 
and persists thereafter [4].  
The acute phase is characterised by haemorrhage, oedema and inflammation [5] into the lesion 
site which can contribute to further axonal injury and cell death. This stage is associated with 
an increase in the permeability of the blood brain barrier (BBB), caused by the direct 
mechanical disruption at the site of the SCI and the local effects of upregulated inflammatory 
mediators. The acute phase after SCI is likely to be the best time to administer neuroprotective 
interventions for two reasons, first the BBB is disrupted during this phase, which allows 
increased perfusion of therapeutic agents into the central nervous system (CNS) at this time 
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point than if they were to be given once the BBB had returned to normal. Lastly, at this stage 
tissue scaring is not established yet.  
The subacute phase is characterised by the removal of cell debris by macrophages, which also 
enables the removal of growth inhibitory components found in the myelin debris. The 
phagocytic response, and therefore removal of some inhibitory factors, is greater following 
injury in the peripheral nervous system (PNS) than that seen in the central nervous system 
(CNS), and this could account for some of the differences in their respective regenerative 
abilities. During this phase astrocytes in the lesion start to proliferate and will form the bulk 
of the glial scar [4] which forms a physical barrier against regeneration. During the 
intermediate phase the astrocytic glial scar continues to grow, with the result that axons are 
no longer able to transverse the lesion core, completing the injury response which now enters 
the chronic stage.  
1.1.2. A definition of ‘regeneration’? 
It is important to clarify what the term regeneration means when discussing it as part of this 
body of work. According to the Oxford English Dictionary, regeneration refers to the growth 
of new animal or plant tissue. In the nervous system neuroregeneration refers to the regrowth 
and/or repair of nervous tissues and cells including neurons, axons, myelin and glia, and in 






1.2 Processes limiting axonal regeneration in the damaged CNS. 
The ability of the central nervous system (CNS) to regenerate after injury is poor with damage 
to the brain or spinal cord being considered irreversible. Failure of axons to regenerate in the 
CNS is the main reason spinal cord injuries result in a permanent loss of sensation and 
paralysis. This contrasts to the regenerative capacity of the PNS which is generally able to 
regenerate successfully after injury. The putative biochemical and cellular mechanisms 
underlying these differences are complex, and are a subject of substantial interest, as a better 
understanding of them could lead to new therapeutic opportunities.  
In contrast to the human CNS, many lower vertebrate species are capable of CNS 
regeneration, leading many to question whether the ability to regenerate was a trait that was 
present in our metazoan ancestors, which has been lost during evolution, or whether it was 
not present in our ancestors and arose during evolution. That is, is it an ancestral trait or an 
evolutionary one? [6]. There are many arguments for each of these theories but as yet we can 
only speculate on why these differences occur.  
In the human CNS, the brain and spinal cord are protected from trauma by encasement in 
bony structures, the skull and vertebrae, and are protected from peripheral infection and 
chemical influences by the BBB which maintains the stability of the internal environment of 
the brain and spinal cord. However, the actual response to injury in the nervous system is 
muted when compared to the rest of the body, and also when compared to responses 
mediated by invertebrates. The limited ability to repair neural tissue after injury suggests that 
selection has not acted to the same extent on the processes that occur after injury as it has on 
those that protect the nervous system from such trauma [7] i.e. we have evolved only to 
prevent injury. Evolutionarily, any ancestors who suffered CNS trauma likely died, due to 
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lack of supportive medical interventions, and therefore natural selection would not have been 
able to act, so adaptive responses to injury would have been impeded. Even if survivable the 
chance of reproduction after injury is unlikely. Additionally, damage to the CNS as the result 
of diseases that were not commonly experienced by ancestors, due to their shorter and less 
sedentary lives, means that these diseases are unlikely to have shaped the evolution of 
regeneration.  Indeed it has been suggested that the injured CNS does not favour a strategy of 
regeneration but rather one of minimising further damage and it seems likely that 
evolutionarily, pressure to prevent damage would have outweighed the potential benefits of 
axonal regeneration [7]. In contrast, damage to the peripheral nerves may have been 
associated with injuries that were survivable and hence these nerves have adapted to be able 
to regenerate after injury.  
 
The inflammatory reaction after injury has been shown to contribute to progressive tissue 
damage. The infiltration of inflammatory cells such as neutrophils, macrophages and 
lymphocytes in the minutes and hours post injury causes the accumulation of soluble 
inflammatory mediators such as chemokines and cytokines at the injury site. This response in 
part removes damaged cells and pathogens from the injury site, but in doing so also damages 
the surrounding healthy tissue [7]. This is also true in the PNS; however, damage to 
surrounding tissue here is not as detrimental because the damaged tissue can be repaired over 
time. Furthermore, the removal of cellular debris from the CNS may take weeks, compared to 
days in the PNS, therefore prolonging the effects of the inhibitors of regeneration which may 
partially explain why CNS regeneration is limited. The differences between the CNS and PNS 
neurons’ ability to regenerate can be ascribed to differences in intrinsic factors of the neurons  
[8] , however, it is well established that myelin breakdown products are largely responsible 
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for failure of CNS axons to regenerate [9] and CNS neurons can regenerate when given a 
permissive environment to be able to do so.  
 
1.2.1 The environment in the CNS prevents regeneration 
Using certain experimental protocols, CNS axons can be induced to grow through the area of 
post-injury scarred tissue, demonstrating that the inability of axons to regenerate cannot be 
primarily attributed to intrinsic neuronal factors [10]. It has been shown that adult CNS 
neurons can re-grow after injury if they are given access to a permissive environment [11, 12], 
which suggests that failure of adult CNS neurons to regenerate is not an intrinsic deficit of the 
neuron but a characteristic feature of the damaged environment [13]. Identifying the specific 
inhibitory factors of the external environment in the CNS after neuronal injury is key. Upon 
damage in the CNS, a number of events occur, immediately and over the course of days and 
weeks which contribute to an inhibitory environment. A physical barrier to regeneration is 
composed in the form of a glial scar which is established over a few weeks. The main cell types 
involved are astrocytes, oligodendrocyte precursors, and microglia which arrive to the injury 
site at different times as the scar evolves. The first cells to the injury site are macrophages and 
microglia from the bloodstream and surrounding tissue, respectively, which are seen within 
a few hours of injury[14]. After 3-5 days, oligodendrocytes are recruited, followed by 
astrocytes which fill the cavity [14]. A framework of interwoven astrocytes is formed which 
are bound together by tight junctions and in which there is little extracellular space [14]. The 
astrocytes within the glial scar also upregulate the production of several extracellular matrix- 
associated inhibitors of regeneration [15] including chondroitin sulphate proteoglycans 
(CSPGs), which are important in the development and maintenance of the normal CNS, and 
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are also the main inhibitory molecules to axon regeneration in the glial scar  [16].  Two 
receptors have been identified as being important in mediating CSPG inhibition, these are 
Protein Tyrosine Phosphatase, PTPσ and LAR, to which CSPGs bind with high affinity to 
mediate their suppression of axon elongation [17]. Furthermore, by use of the bacterial 
enzyme Chondroitinase ABC the function of CSPGs has been inferred as promoting axon 
regeneration in the CNS [18, 19]. In contrast, myelin associated inhibitory proteins are released 
immediately following damage to the CNS and collectively inhibit regeneration before the 







Figure 1.1. Spinal Cord Injury Response.  
Upon injury to the CNS, myelin associated inhibitory factors (MAIF’s) including Nogo, 
Myelin Associated Glycoprotein (MAG), Oligodendrocyte myelin glycoprotein (OMgp) and 
Chondroitin sulphate proteoglycans (CSPGs) are released creating an environment inhibitory 





1.3 Myelin Associated Inhibitory Factors 
Several growth inhibitory proteins present in the CNS play a crucial role in preventing axonal 
regeneration in the injured adult mammalian CNS.  These include Nogo, myelin associated 
glycoprotein (MAG) and oligodendrocyte myelin glycoprotein (OMgp), which account for a 
significant fraction of the inhibitory activity from CNS myelin (Figure 1.2). However, removal 
of some or all of these myelin associated inhibitors in knockout mice results in poor or 
inconsistent regeneration [20, 21]. Indeed, MAG knockout mice only display a limited 
enhancement of axon regeneration in the CNS [22], likewise a blocking antibody to Nogo 
resulted in a low level of axon regeneration [23] suggesting that other myelin derived 
molecules may also be involved.  Presumably in these situations, other myelin-derived 
molecules are still present, acting  to prevent axons from regenerating [15].  There may also 
be a relative lack of regeneration-promoting trophic factors in the CNS as compared to the 
PNS, but this issue does not detract from the different profile of inhibitory molecules in the 
CNS and PNS.  
Nogo proteins were first discovered as a high molecular weight (250kDa) species extracted 
from spinal cord myelin which was shown to inhibit neurite outgrowth [24]. Nogo is a 
member of the Reticulon (RTN) family of proteins, which are membrane-associated proteins 
present in all eukaryotic organisms [25] and are products of the Reticulon 4 (RTN4) gene. 
There are 3 Nogo isoforms named Nogo-A, -B and –C which are generated by alternative 
splicing, resulting in multiple isoforms [26] sharing a 188-amino acid reticulon homology 
domain (RHD) at their C- terminus [27]. Nogo- A is the longest isoform of the Nogo proteins 
and is highly expressed in oligodendrocytes but is not expressed in Schwann cells [28]. 
Importantly, Nogo-A expression levels are increased after spinal cord injury, suggesting their 
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importance in recovery after injury [29]. In addition, the monoclonal antibody, IN-1 was raised 
against a 250kDa myelin extract corresponding to Nogo-A, and this antibody was shown to 
neutralise neurite outgrowth inhibition [30], further illustrating that the Nogo-A protein is a 
major factor in neurite outgrowth inhibition. The topology of the Nogo protein is unusual 
(Figure 1.2), with the conserved C-terminal containing two hydrophobic domains separated 
by a 66-residue hydrophilic segment [31, 32]. It is predicted that the N- and C- termini of the 
protein are cytosolic while the short 66- amino acid loop protrudes into the extracellular space.  
Nogo-A possesses two inhibitory domains, the Nogo-66 domain and the amino-Nogo 
domain. The Nogo-66 domain can also interact with the paired immunoglobulin-like receptor 
B (PirB) on the surface of neurons [33] to mediate at least part of its inhibitory activity in 
certain neuronal types [33, 34]. The amino-Nogo domain has also been detected on the surface 
of oligodendrocytes and is thought to act via an independent mechanism to disrupt neuronal 
integrin function [34, 35]. This demonstrates that Nogo-66 is able to limit axon regeneration in 
vivo [36]. The method by which Nogo-A is responsible for the inhibition of axonal regeneration 
is through high affinity binding of the Nogo-66 loop to the Nogo receptor, NgR [37]. The NgR 
acts as a point of convergence for several myelin associated inhibitors which act upon NgR to 
inhibit neurite regeneration through the RhoA pathway.  
MAG is a sialic acid binding- SIGLEC (sialic acid- dependent immunoglobulin- like family 
member lectin) protein [38] and is a transmembrane protein with 5 Ig-like domains [39] 
(Figure 1.2) expressed in both the CNS, by oligodendrocytes, and the PNS, by Schwann cells 
[40]. MAG binds to gangliosides GD1a and GT1b on neuronal cell bodies and axons [41] and 
has roles in axon stability, controlling axon cytoarchitecture and regulating axon outgrowth 
[41]. Interestingly, embryonic neuronal expression of MAG suggests that outgrowth is 
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actively promoted by MAG but switches to inhibition around birth [42] [43]. The function of 
MAG appears to be complex, inhibiting specific axon growth pathways and it has been found 
to be a ligand for the Nogo receptor (NgR), which it binds with high affinity.  
OMgp is a 120kDa leucine rich repeat (LRR) containing glycoprotein [44] and is GPI anchored 
to the surface of oligodendrocytes and myelin adjacent to axons. OMgp is expressed in both 
the developing and adult CNS and is a relatively small component of myelin again found to 
be inhibitory to axon regrowth [45]. It has been suggested that OMgp is involved in the 
formation and maintenance of myelin sheaths [44].  In vitro experiments showed MAG, OMgp 
and Nogo are all members of the myelin associated inhibitory family that bind NgR, with 
























Figure 1.2. Illustrations of myelin associated inhibitory proteins 
There are three isoforms of Nogo- A, B and C, however only Nogo-A is enriched in 
oligodendrocytes. Nogo- A contains two inhibitory domains; Nogo-66, which is common 
among all isoforms and amino-Nogo which is unique to Nogo-A. Myelin associated 
glycoprotein (MAG) contains multiple  Ig domains and exists as two isoforms; large (L) and 
small (S) which differ only in their cytoplasmic sequences.  Oligodendrocyte myelin 
glycoprotein (OMgp) is  a GPI-linked LRR domain containing protein expressed on the 
surface of oligodendrocytes.  
Diagram adapted from [15] 
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1.4 The Nogo receptor 
The Nogo receptor (NgR) is a GPI-anchored protein and is one of a family of three receptors 
(NgR-1, -2 and -3) which display high level of sequence identity. The NgR protein is predicted 
to contain 473 amino acids [28]. The protein ectodomain contains 8 leucine rich repeats flanked 
by cysteine rich C- (LRRCT) and N- (LRRNT) terminal domains (Figure 1.3) [46]. The leucine 
rich repeats conform to the motif xLxxLxxLxLxxN/CxLxxLPxxFx where X can be any amino 
acid and L can also be occupied by V, I and F.  Nogo Receptor (NgR) proteins are expressed 
throughout the CNS in a distribution complementary to Nogo-A. The other myelin associated 
inhibitory factors MAG and OMgp also mediate their inhibitory actions through the Nogo 
receptor [37], which is surprising, as these inhibitory proteins do not share any sequence 
similarities with Nogo-A. However, the co-ordinated distribution between Nogo-A and NgR 
contrasts to that of MAG and OMgp, which are expressed in many tissues where there is little 
or no NgR expression [29] indicating that these inhibitory proteins may also engage other 
receptors. This suggestion is supported by research showing that deletion of NgR does not 
completely abolish the inhibitory effects of Nogo, MAG and OMgp [33] as limited 
regeneration, largely in rubrospinal tracts after spinal cord injury was seen. The data 
suggested that NgR is important for mediating some of the inhibitory effects of the myelin 
inhibitors, but that further redundancy may exist. The roles of NgR-2 and NgR-3 are 
unknown, with the only common ligands being MAG which binds to NgR-1 and NgR-2 [47] 
CSPG which binds NgR-1 and NgR-3 [48] and amyloid beta precursor protein (APP) which 




Ligand binding to NgR causes activation of RhoA, a small GTP binding protein, leading to 
actin depolymerisation and growth cone collapse which ultimately leads to inhibition of axon 
regeneration. Neurones cultured from NgR knockout mice, which interestingly are viable, do 
not bind Nogo-66 and do not undergo growth cone collapse in the presence of myelin 
inhibitors. Furthermore, these mice show improved recovery of motor function after spinal 
cord transection compared to wild type mice [50]. Additionally, blocking the binding of 
ligands to NgR has also been shown to improve neurite outgrowth, for example by blocking 
interactions using either an NgR antibody or using a soluble NgR antagonist peptide which 
competes with the neuronal receptor for binding to myelin derived inhibitors. Both methods 
have been shown to promote axonal regeneration by preventing the signal for inhibition being 
transduced into the neuron [51] [31].  
Binding studies between Nogo-66 and NgR, involving domain deletions throughout the NgR 
ectodomain have identified which domains facilitate binding. These studies demonstrate that 
both the LRRCT and LRRNT of NgR are necessary for binding to occur and that deletion of 
any two LRR domains also abrogates binding [32]. The crystal structure of NgR suggests that 
there is a conserved putative ligand binding site within the concave face of the LRR domain 
[46]. Two hydrophobic regions were identified on the LRR concave surface as being possible 
areas of binding. The same study also postulated that the promiscuous ligand interactions of 
the protein involving binding to the structurally unrelated ligands MAG, OMgp and Nogo, is 
due to the broad region of exposed residues in the concave face which allows for binding to a 






Figure 1.3 Domain organisations of the members of the NgR complex, including NgR, 
p75NTR, TROY and LINGO-1.  
NgR contains 9 leucine rich repeats (LRR) in its extracellular domain flanked by leucine rich 
N- and C terminal capping domains (LRRCT and LRRNT) and is GPI linked in the 
transmembrane region. p75NTR extracellular domain contains four cysteine rich domains 
(CRD), and intracellularly there are chopper (CD) and death domains (DD).  TROY is similar 
to p75NTR and contains three cysteine rich domains (CRD) in its extracellular portion. LINGO-
1 is a LRR domain containing protein, having 12 LRRs flanked by cysteine rich LRRCT and 




1.5 The Nogo Receptor complex 
Since NgR is GPI anchored and the entire protein is extracellular with the exception of a 
short stalk region, a co-receptor is needed to transmit any signals received into the cell.  
Wang et al. [53] discovered that p75NTR, a 399-amino acid type 1 transmembrane protein and 
a member of the tumour necrosis factor receptor family (TNFR), specifically interacts with 
NgR [53]. NgR/P75NTR binding was demonstrated using cell surface binding assays where an 
alkaline phosphatase fusion protein containing the extracellular domain of p75NTR was able 
to specifically bind to NgR expressed on the surface of CHO cells. Controls using the AP 
protein alone and control CHO cells not expressing NgR showed no binding. In addition, 
p75NTR was shown to be necessary in mediating all myelin associated inhibitory factor 
signalling through NgR, as neurons from p75NTR -/- mice did not show neurite outgrowth 
inhibition in the presence of MAG, Nogo and OMgp [53]. 
Since its discovery almost 30 years ago, p75NTR has been implicated in a wide number of 
cellular processes, although its exact physiological role has remained undefined as many of 
the associated processes are apparently contradictory. For example, p75NTR  has been shown 
to transduce signals from neurotrophins to promote nerve growth, while conversely 
transducing signals  from myelin derived growth inhibitory factors to trigger growth cone 
collapse [54].  P75NTR is widely expressed in the developing nervous system but expression is 
switched off in most adult cells, however, some cells retain expression at low levels, for 
example basal forebrain cholinergic neurons, sensory neurons and spinal cord motor neurons 
[55]. Adult tissues re-express p75NTR in many cell types after injury or cellular stress, including 
peripheral nerve crush [55]. A significant increase in expression is seen after spinal cord injury, 
highlighting the role of p75NTR in mediating the inhibitory effects of myelin.   
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Whilst NgR and p75NTR have been shown to immunoprecipitate with each other in a number 
of experimental models, the formation of the complex between NgR and p75NTR was shown 
to be enhanced in the presence of soluble MAG protein, which suggests that the complex is 
formed in response to inhibitory myelin breakdown products [53]. Within the Nogo receptor 
complex, p75NTR allows activation of RhoA through the recruitment of the Rho inhibitor Rho-
GDI. Upon the association of myelin associated inhibitory factors to the NgR-p75NTR complex, 
Rho-GDI binds the p75NTR death domain which causes the release of RhoA-GDP from Rho-
GDI. RhoA then becomes active by exchanging GDP for GTP and the activated RhoA causes 
growth cone collapse and inhibition of axonal growth via phosphorylation of various 
substrates including LIMK (Lin-11, Isl-1, and Mec-3 kinase), MLC (myosin light chain) and 
CRMPK (collapsin response mediator protein-2 kinase) (Figure 1.4) [56-58]. Growth cones are 
thus able to combine a number of molecular signals in order to make a decision to extend or 
retract.  
The intracellular domain of p75NTR is critical in transmitting inhibitory signals into the cells; 
truncated p75NTR lacking an intracellular domain expressed in complex with NgR has been 
shown to allow neurite outgrowth in the presence of myelin inhibitory molecules [53]. 
Interestingly, blocking the association between the extracellular regions of p75NTR and NgR 
reduced the effects of the myelin breakdown products MAG, OMgp and Nogo-66 [53], 
confirming that the extracellular domain is also crucial. The crystal structure of the 
ectodomain of NgR showed that the concave surface of the LRR domain contains the aromatic 
residues Tyr, Phe and His, with this surface involved in high affinity ligand binding [32]. In 
addition, a large acidic patch on the NgR concave face has been identified as being in contact 
with a basic LRRCT subdomain of a second NgR molecule. This suggests that this area may 
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be responsible for ligand-independent receptor-receptor binding which has previously been 
identified at the cell surface [32, 59]. Furthermore, an area, at the C-terminal end of the NgR 










Figure 1.4. Signalling cascade of myelin associated inhibitors acting on the NgR complex. 
Myelin associated inhibitors bind to NgR, co-receptors p75NTR and LINGO-1 to mediate the 
inhibitory signals which prevent axon regeneration by activating Rho and ROCK which in 
turn leads to the phosphorylation of several substrates LIMK; Lin-11, Isl-1, and Mec-3 kinase, 
MLC; myosin light chain and CRMPK; collapsin response mediator protein-2 kinase,  




It was therefore hypothesised that depletion of p75NTR should help to reduce the impact of 
myelin associated inhibitory proteins and enhance regeneration in the CNS after injury. 
Blocking the effects of p75NTR in vitro with neutralizing antibodies prevented death of neurons 
after axotomy. However, p75NTR knockout mice exhibited little enhanced neuroregeneration 
after spinal cord injury [60] indicating that other proteins may be able to substitute for p75NTR  
in vivo. Further evidence supporting the notion of a substitute protein is derived from the 
tissue distributions of NgR and p75NTR.  Expression of p75NTR does not correspond fully to the 
distribution of NgR, which is expressed throughout the CNS [61] whereas expression of 
p75NTR in the adult CNS is very low and only increases after injury [55]. In some neurons the 
expression of p75NTR remains low even after injury[62].  The absence of p75NTR from neuronal 
cell types that respond to myelin inhibition led many to question how inhibitory signals are 
transduced in neurons lacking p75NTR [63], and it is possible that NgR can partner with other 
receptors. 
  
Subsequent studies have shown that, in neurons that lack p75NTR, TROY can serve to 
functionally substitute in the NgR complex to activate RhoA and induce growth cone collapse 
causing inhibition of axonal regeneration [64, 65]. TROY has been shown to be widely 
expressed in the adult brain [64-66] and binding between TROY and NgR and LINGO-1 
(Leucine rich repeat and Ig domain-containing Nogo receptor interacting protein) has been 
demonstrated in vitro indicating that the proteins can form a functional receptor complex that 
can mediate the effects of myelin associated inhibitors [64, 65]. Furthermore, it was 
demonstrated that TROY has a higher affinity for NgR than p75NTR [64]. The importance of 
TROY has been highlighted in experiments demonstrating greater outgrowth of neurons from 
mice deficient in TROY in the presence of myelin associated inhibitors [64]. TROY is a TNF 
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receptor family member [64] selectively expressed in the adult CNS [66]. Structurally related 
to p75NTR, it is a single pass type I transmembrane protein 416 aa in size. TROY mRNA is 
strongly expressed in the brain, with lower levels being seen in the heart, lungs and liver [66]. 
Within the CNS, TROY is more widely expressed in postnatal and adult neurons than  p75NTR 
[67].  
As described previously, NgR has two structurally related homologues, NgR2 and NgR3. It 
has been shown that MAG binds NgR2 selectively and with a greater affinity than NgR, to 
mediate axon inhibitory effects [47]. Furthermore, it has been suggested that NgR2 can 
mediate its effects independently of p75NTR however; no co-receptors for NgR2 have been 
identified [47]. It is possible that, TROY could act as a co-receptor for NgR2 to mediate the 
effects of MAG or perhaps that there are more, as yet unidentified, co-receptors for NgR. 
Indeed, in a subset of neurons where p75NTR is not expressed but TROY is, it has been 
demonstrated that TROY-/- mutant neurons showed no significant difference in neurite length 
than wild-type neurons when assessed using MAG as an inhibitor. This suggests that, in this 
case, TROY does not functionally substitute p75NTR and indicates that other receptors are 




1.6 LINGO-1  
Co-expression of p75NTR with NgR in reconstituted non-neuronal systems fails to demonstrate 
activation of RhoA in response to myelin breakdown products [68] suggesting that although 
p75NTR is necessary for the negative regulation of neurite outgrowth, it is not sufficient, 
therefore other components must be involved in order to activate RhoA. LINGO-1 has been 
shown to be the third component of the Nogo receptor complex with p75NTR [68], as co-
expression of NgR, p75NTR and LINGO-1 in non-neuronal cells conferred responsiveness to 
OMgp allowing activation of RhoA [68].  
LINGO-1 (Leucine rich repeat and Ig domain-containing Nogo receptor interacting protein) 
is a central nervous system-specific single transmembrane spanning glycoprotein [69], also 
described as LERN1 [70]. LINGO-1 has been shown to bind both NgR and p75NTR in vitro and 
as part of the tertiary complex that enables activation of RhoA, an intracellular regulator of 
the cytoskeleton which mediates the effects of signals of myelin inhibition [68]. The activation 
of RhoA correlates with the inhibition of axon growth whereas inactivation of RhoA correlates 
with axonal outgrowth and extension [71]. This demonstrates that LINGO-1 is a key 
component of the Nogo receptor complex.  
LINGO-1 has been shown to be exclusively expressed in the neurons and oligodendrocytes of 
the central nervous system [68, 70] in a non-uniform distribution, with highest expression in 
the cortex of the brain and lowest levels in the spinal cord [68]. LINGO-1 expression is 
exclusively CNS-specific with no expression observed in non- neuronal tissues by northern 
blot analysis [68].  During development, LINGO-1 mRNA levels were shown to peak at 
postnatal day 1 and decline thereafter into adulthood where they remain at background levels, 
until after axonal injury when an increase in expression is observed [68], indicating the 
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potential importance of the protein after injury. LINGO-1 knockout mice have more 
myelinated axon fibres in their spinal cords than wild type mice, however there are no 
differences in the peripheral (sciatic) nerves, suggesting that the myelination effects are CNS-
specific [72].   
The functional importance of LINGO-1 within the NgR/p75NTR complex has been 
demonstrated by blocking experiments using soluble LINGO-Fc, administered after spinal 
cord injury in rats, resulting in significantly improved functional recovery due to increased 
axonal sprouting and reduced RhoA activation [73]. In subsequent in vitro experiments, 
soluble LINGO-1-Fc was also shown to reverse the inhibitory effects of OMgp on neurite 
outgrowth [68]. Blocking the effects of LINGO-1 by use of a monoclonal antibody, mAb 1A7 
has similar effects to those observed using soluble LINGO-1-Fc proteins [74]. Clinically, 
LINGO-1 is an attractive target for drug trials for the treatment of CNS diseases, such as the 
demyelinating disease multiple sclerosis (MS), with antibodies being preferred for their 
potency and selectivity. Consistent with LINGO-1 being a therapeutic target in this context, 
over-expression of LINGO-1 in vivo can decrease myelination, possibly due to the extracellular 
domain of LINGO-1 being able to self- associate in trans [75], providing an inhibitory signal 
for myelination [76]. However, problems can arise with the use of antibodies against CNS 
diseases because of their poor penetration into the CNS after systemic administration as only 
approximately 0.1% of the administered drug reaches the target [77] due to the selectivity of 
the BBB. Anti-LINGO-1 antibody, Li81, has been shown to enter the CNS after systemic 
administration sufficiently, at 0.1%-0.4% of blood levels [78], to promote remyelination in rats 
[77]. As yet, there is very little convincing in vivo evidence for the functional effects of LINGO-
1 blockade on CNS injury, with one published phase 2 trail [79], and 1 published phase 1 trial 
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[80] [81]. Furthermore, it has been shown that the expression of LINGO-1 in dorsal root 
ganglion neuronal cells (DRGN) does not rise until 14 days post injury [68] supporting the 
notion that other co-receptors for NgR/p75NTR may mediate axon growth inhibition before 
that.  
 
Human LINGO-1 is a 614 aa protein and  it has three paralogs; LINGO-2, LINGO-3 and 
LINGO-4 [82]. It is highly conserved, with human and mouse LINGO-1 being 99.5% identical 
[68]. LINGO-1 is a leucine rich repeat (LRR) containing protein, which contains 12 LRRs, each 
23-25 residues in length. The LRRs are flanked by cysteine rich N- and C- terminal capping 
domains (Figure 1.3), each of which contain two disulphide bridges, followed by an Ig domain 
at the C- terminal end, followed by a single pass transmembrane domain and a short 
cytoplasmic tail [77]. Structurally the LINGO-1 ectodomain folds into a two module structure 
composed of the LRR and Ig domain connected by a flexible linker region, the LRR domain 
forming a horseshoe shape typical of other LRR domain containing proteins [83]. The Ig 
domain is composed primarily of β sheets with one α helix and is positioned at a near 90o 
angle to the LRR domain [69]. LINGO-1 has been shown to exist in a number of forms, under 
physiological conditions, including dimers and higher order oligomers. Determination of the 
crystal structure of LINGO-1 ectodomain illustrated that the protein forms a tetramer, where 
the four monomers interact in a circular ring-like fashion, forming a closed structure [69]. The 
monomers link together head-to-tail and back-to-back, meaning that the convex faces of the 
monomers form the protein-protein interfaces and the concave faces are solvent exposed [69]. 
However, the protein has also been identified in monomeric, dimeric and tetrameric states in 
solution [77] but, in the presence of ligand, no tetrameric form was observed, indicating that 
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the ligand prevented formation of the tetramer [77]. Indeed, the tetrameric form observed may 
have been influenced by crystallisation conditions.  
By measuring the lengths of processes formed by oligodendrocyte precursor cells (OPCs) 
transfected with LINGO-1 missing either its ectodomain, cytoplasmic domain or LRR domain 
it has been demonstrated that the inhibitory actions of LINGO-1 in the NgR/p75NTR complex 
are abrogated upon deletion of the entire ectodomain or the cytoplasmic domain of LINGO-
1, but surprisingly not by the deletion of either the LRR domain [84]. This indicates that the 
LRR domain does not contribute to the inhibitory potential, which is surprising considering 
that LRR domains are typically involved in protein-protein interactions. Furthermore, it has 
been suggested that the Ig domain of the protein is sufficient for its activity [68, 77, 84], and 
those sites identified as being potential binding sites in the Ig domain are solvent exposed 
[77].  
  
1.7. Leucine rich repeats 
LINGO-1 is part of a broader family of proteins containing leucine rich repeats. Leucine rich 
repeats (LRRs) are present in over 60,000 proteins from viruses, bacteria, archae and 
eukaryotes [85] and include cell adhesion molecules, receptors and enzymes, with evidence 
suggesting that they mediate diverse protein-protein and protein-ligand interactions [86] in a 
variety of processes such as DNA repair, signal transduction, cell adhesion and apoptosis. 
LRR motifs were first identified in the protein leucine rich α2 glycoprotein (LRG) [87], so 
named because 66 of the 312 amino acids were leucine residues [87],[88]. Leucine rich repeats 
are, as expected, distinguished by a consensus sequence containing many hydrophobic 
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leucine residues, and can vary in length, typically between 20 and 29 amino acids but most 
commonly 24 residues [89]. These repeats contain 11 conserved residues with the sequence 
LxxLxLxxN/CxL where x denotes any amino acid and the leucine residues can be substituted 
for other hydrophobic residues: isoleucine, valine or phenylalanine (Figure 1.5). This ability 
to substitute Leucine, coupled with the fact that, apart from the 11 conserved residues, the 
other parts of the repeats may vary quite considerably between LRR proteins, means that LRR 
motifs are often overlooked when examining protein sequences [89].  
 X ray data analysis of the ribonuclease inhibitor (RI) protein, which is composed entirely of 
LRRs, was the first to reveal the structure of the repeats. The primary structure of this protein 
shows 15 leucine rich repeats that alternate between 29 and 28 residues long, named type A 
and type B repeats respectively [90]. Individual leucine rich repeats each consist of a β strand 
and an α helix and in proteins with multiple repeats these are arranged in such a way so that 
all the β strands and the α helices are parallel to a common axis, which results in a non-
globular horseshoe-shaped molecule with curved parallel β sheets lining the concave face and 
the α helices located at the convex surface [89, 91, 92]. Proteins with fewer repeats tend to be 
less curved in shape, i.e. more banana-like, and those with a larger number of repeats form a 
more horseshoe-like structure (Figure 1.5). However, the length of the individual LRRs also 
influences the shape of the domain and the longer the individual repeats are, the more curved 
the domain. For example, when comparing the structures of the RI (Figure 1.5a), which 
contains 15 LRRs of 28-29 residues in length [93], and NgR (1.5d), which contains 9 LRRs of 
24-25 residues each [32], the differences in curvature of the LRR domains are quite noticeable, 
with the former being much more curved than the later. Other LRR domain containing 
proteins of interest are decorin (Figure 1.5b), which contains 12 LRRs of varying length (from 
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21-30 residues) [94], and LINGO-1 (Figure 1.5c) which contains 12 LRRS 23-24 residues long 
[69].  
The hydrophobic residues of the LRRs are normally packed in the core of the protein 
providing stability to allow for protein-protein interactions that most commonly occur at the 
concave face of the protein. The core LRR domain is commonly flanked at either end by 
cysteine-rich capping domains, which serve to protect the most N- and C- terminal leucine 
rich repeats [92]. These LRRCT and LRRNT flanking domains tend to be cysteine-rich and are 
distinct in structure from the central LRRs. The consensus residues, mostly leucine or other 
hydrophobic amino acids, are normally buried at the core of the structure, while residues at 
the variable positions are mostly solvent exposed [95] .  
All LRRs contain a highly conserved and a variable region, suggesting the existence of leucine 
rich repeat subfamilies which contain the same conserved regions. With only one type of 
repeat being observed per protein it has been suggested that each type has evolved 
individually [92]. Subfamilies include the RI-like and the more common ‘typical’ subfamilies 
which include repeats containing 28-29 and 24 residues respectively, and which also differ in 
the variable region of the repeat [91]. Other subfamilies include one represented by the yeast 
SDS22+ protein, which contains 22 residue repeats that have less regular structures, and the 
cysteine-containing LRR subfamily that is represented by the protein Skp2 and contains LRRs 
of between 23 and 27 residues in length [91, 92]. Also, there are bacterial- and plant-specific 
LRR subfamilies, which contain 20-22 and 23-25 residues respectively, and the leucine rich 




Figure 1.5. Leucine rich repeat domains  
a) The structure of the ribonuclease inhibitor which contains 15LRRs (PDB code 1DFJ)  [93]. 
b) The Decorin dimer, each monomer contains 12 LRRs (PDB code 1XCD) [94]. c) The crystal 
structure of LINGO-1 which contains 12 LRRS (PDB code 2ID5, 4OQT) [69, 77] d) The crystal 
structure of the NgR which contains 9 LRRs (PDB code 1P8T) [32]. Proteins with a larger 
number of LRR domains tend to be more horseshoe shaped whilst those with fewer LRRs the 




1.8. The AMIGO family of proteins.  
LINGO-1 is part of a group of CNS enriched, LRR domain containing type 1 cell surface 
proteins [96]. Other members of the group include Netrin G1 Ligand (NGL-1), and AMIGO-1 
(Amphoterin Induced Gene and Open reading frame (ORF)) which, like LINGO-1, include Ig 
domains. While LINGO-1 and NGL-1 are well characterised, AMIGO-1 and its family 
members, are less well understood.  
1.8.1. Discovery 
The AMIGO genes were identified by several independent research groups in the last decade. 
Firstly, Kuja-Panula, et al. [97] used ordered differential display [98] to identify AMIGO as a 
gene in rat hippocampal neurons that was upregulated on an amphoterin matrix but not a 
laminin matrix. The group subsequently designated the gene as Amphoterin Induced Gene 
and Open reading frame (ORF), AMIGO. Amphoterin, also known as HMGB1 (high motility 
group box protein 1) is known to be involved in a number of physiological processes including 
functioning as a neurite outgrowth promoting factor originally isolated from perinatal rat 
brain [99]. Sequence data obtained from the AMIGO clone led to the identification of two 
closely related proteins named AMIGO-2 and AMIGO-3. Independently, another group 
identified the AMIGO-2 gene in cerebellar granule neurons as an activity-dependent gene that 
promoted survival of neurons, and termed it Alivin-1 after alive and “activity- dependent 
leucine- rich repeat and Ig superfamily survival related protein” [100]. The same group also 
noted the existence of Alivin-2 and Alivin-3 as homologues for Alivin-1 which corresponds to 
AMIGO-1 and AMIGO-3. The following year AMIGO-2 was described by a third research 
group as ‘DEGA’ meaning ‘novel cDNA differentially expressed in human gastric 
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adenocarcinomas’ following analyses of cDNA expression levels in normal versus tumour 
tissues, including gastric adenocarcinoma and other cancer cell lines [101].   
1.8.2. Expression and function 
Each of the AMIGO family members displays discrete expression patterns in mammalian 
tissues (Figure 1.6a): AMIGO-1 is essentially nervous system-specific, where it is expressed in 
the cerebellum, cerebrum and retina [97]. AMIGO-2 mRNA is also mainly expressed in the 
nervous system, with highest levels in the cerebellum; however, expression was also 
identified in the retina, liver and lung. Finally, AMIGO-3 displays more broad expression and 
is detected in most tissues [97]. Within the CNS, all three of the AMIGO proteins are found in 
a wide variety of brain neurons in different areas of the adult brain and spinal cord as well as 
astrocytes and oligodendrocytes [102]. However, Kuja-Panula et al. [97] found that the 
AMIGO proteins were specifically detected in axonal fibers. The expression patterns indicate 
that the proteins may have similar functions in the CNS however the differing expression 
outside of the CNS indicates that the AMIGO family of proteins may have context dependent 
functions. 
AMIGO-2 is the best studied of the family and appears to possess a diverse range of functions. 
AMIGO-2 expression in certain areas of the hippocampus particularly resistant to neuronal 
injury may suggest a role in neuroprotection [100, 103]. Additionally, AMIGO-2 is a 
downstream target of calcium- dependent survival signals hinting at neuroprotective 
functions [100, 103]. Similarly, expression of Alivin 1 (AMIGO-2) appears to promote 
depolarisation dependent survival of cerebellar granule neurons [100].  
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The above evidence could imply that mutations in AMIGO-2 may result in neurodegenerative 
effects. Indeed, mutations in Alivin 1 (AMIGO-2) have been identified as possibly playing a 
role in the onset of the neurodegenerative diseases Alzheimer’s and Parkinson’s, with genetic 
loci mapped to within the same region of chromosome 15 as Alivin 1 (AMIGO-2) [100]. It has 
also been suggested that haploinsufficiency of AMIGO-2 is responsible for mental retardation, 
seen in a single patient study [104].  
As described above, microarray experiments using murine cancer cell lines and 
corresponding normal tissue found that AMIGO-2 mRNA is expressed in gastric 
adenocarcinoma [101], and led to the group undertaking the research to name the gene 
‘DEGA’ [101]. DEGA (AMIGO-2) was identified as being differentially expressed in 45% of 
gastric adenocarcinoma samples, with a very low level of expression in normal tissue. This 
suggests that DEGA (AMIGO-2) may be required for tumorigenesis in human gastric 
adenocarcinomas [101]. Furthermore, expression of antisense DEGA (AMIGO-2) clones in a 
gastric adenocarcinoma cell line was associated with altered morphology, increased size and 
ploidy, chromosomal instability, decreased cell adhesion and migration and a nearly complete 
inhibition of tumorigenicity. This therefore suggests that inhibition of AMIGO-2 expression 
negatively impacts tumour growth [101]. AMIGO-2 is also over expressed in other cancer cell 
lines when compared to normal tissue, including thyroid, pancreatic, breast, ovary and lung 
cancers [101].  
A possible role for AMIGO-1 in dendritic outgrowth has been suggested due to elevated 
expression levels being observed during periods of dendritic extension [102]. AMIGO-1 
silencing resulted in attenuation of dendritic elongation including a lower dendrite number, 
and lower total dendrite lengths [102]. Neuroprotective functions for AMIGO-1 were 
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suggested in experiments using neuroblastoma cell lines, which express AMIGO-1, which 
were more resistant to apoptotic insult [102]. 
AMIGO-1 has also been identified as being essential for the development of neural circuits in 
zebrafish where it is thought to be involved in homophillic interactions [105]. Furthermore, 
AMIGO-1 was shown to localise at the neuronal plasma membrane with the potassium 
channel subunit Kv2.1 and is thought to be involved in schizophrenia-related abnormalities 
[106].  
Finally, AMIGO-3 mRNA levels have been shown to be raised in retina immediately following 
optic nerve crush and dorsal column lesions in rat, additionally AMIGO-3 levels were reduced 
in models of regeneration suggesting this protein has a dynamic role in the CNS injury 
response [107].  
Structurally, the extracellular part of AMIGO proteins contains 6 leucine rich repeats (LRRs), 
flanked on either side by cysteine rich LRRCT and LRRNT domains, and one immunoglobulin 
(Ig) domain next to the transmembrane region (Figure 1.6b) [97]. The AMIGO-1 protein was 
detected as a 65kDa polypeptide in brain extracts although its calculated molecular mass 
based on its primary sequence is 56kDa.  
The amino acid sequence homology between rat and mouse AMIGO is 95% and these are 89% 
identical to the human form [97] with the most conserved extracellular regions restricted to 
LRRs 1-3 and the LRRNT domains, the transmembrane and cytoplasmic tail (Figure 1.6c). 
AMIGO homologues exhibit lower sequence identity, with AMIGO-1 and -2 48% 
homologous, AMIGO-1 and -3 50% homologous and AMIGO-2 and -3 48% homologous [97]. 
Here, the most conserved regions are the LRRs, transmembrane and cytoplasmic regions [97].  
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BLAST searches [97] using the extracellular domain of the AMIGO proteins indicates that the 
nearest homologues were NgR [37] and Slit [108]. The Slit family proteins are secreted 
glycoproteins that play important roles in the development of the nervous system. Slits, like 
NgR, contain LRR domains, and activate receptors of the Robo family through the binding of 






Figure 1.6. Expression, domain organisation and alignment of the AMIGO proteins. 
a) AMIGO-1, AMIGO-2 and AMIGO-3 are expressed in many tissues. However different 
expression patterns are shown, with AMIGO-1 being almost completely nervous system 
specific and AMIGO-3 being expressed in almost all tissues. b) AMIGO-1, -2 and -3 
extracellular domains contain 6 LRRs flanked by LRRNT and LRRCT domains and an Ig 
domain.  The protein also has a transmembrane region and a short cytoplasmic tail. Diagram 
is not to scale. c) AMIGO-1, AMIGO-2 and AMIGO-3 are 48-50% similar at the amino acid 
level with the largest similarity in the LRR domain, transmembrane region and cytoplasmic 
tail. 





1.9 Treatments in SCI 
Therapeutic interventions are most effective in the early stages after injury, i.e. in the acute 
and sub- acute phases, and should be given as early as possible after injury, before formation 
of the glial scar. The treatments given in acute and sub- acute phases focus on neuroprotection, 
compared to those given in the chronic stage focusing on neurorestoration [110]. 
Neuroprotective treatments must be given alongside treatments which reduce secondary 
injury caused by inflammation. A number of neuroprotective treatment approaches are being 
investigated, but basically aim to remove the growth inhibition, manipulate intracellular 
signalling and deliver neurotrophic factors [13]. There is currently only one drug used in the 
treatment of SCI, intravenous methylprednisolone is given to reduce inflammation at the site 
of injury. The drug aids in the reduction of cellular damage  if given within 8 hours of injury 
[110].  
 
1.9.1 Clinical studies 
Numerous preclinical and a more limited number of clinical studies have examined the 
therapeutic potential of multiple drugs and/or protocols to improve recovery after SCI, 
including those that focus on either the ligands or the receptors that inhibit regeneration. One 
approach aims to target myelin associated inhibitory factors, for example with an NgR decoy 
receptor, to attempt to overcome myelin inhibition and improving neurological function [21]. 
There are two broad approaches to blocking the effects of myelin associated inhibitory 






1.9.2 Therapies targeting ligands 
Clinical studies targeting Nogo-A and MAG have given promising results, with 
administration of an anti- Nogo-A antibody in a stroke model associated with an accelerated 
recovery from neurological damage [111]. An anti- MAG antibody promotes in a stroke model 
a more rapid recovery of dexterity, the effects are seen as early as 3 days after treatment, 
suggesting the antibody has a neuroprotective effect rather than a neuroregenerative one. In 
general, however, the efficacies are relatively low in vivo possibly a consequence of the 
available inhibitory proteins Nogo-66, MAG and OMgp. Treatments that could block all three 
proteins may therefore be a more attractive therapy.  
 
1.9.3 Therapies targeting the receptors 
The human NgR decoy receptor sNgR310-Fc is designed to block the binding of all three 
myelin associated ligands to NgR.  Experimental use has been shown to improve functional 
recovery and facilitate the growth of axons when used to treat spinal contusion injury in rats 
[112]. Further, the anti NgR antibody, 7E11 is also a strong inhibitor to NgR and promotes 
CNS axonal regeneration [113].  
 
Treatments targeting other members of the NgR complex may also give promising results. 
Clinical trials targeting LINGO-1 are being undertaken for drug companies aiming to find an 
effective treatment for multiple sclerosis. It is thought that the antibody works by blocking the 
LINGO-1 protein which inhibits the production of myelin, and in doing so the drug spurs 
myelin growth [114]. In multiple sclerosis the myelin sheath that insulate axons are damaged 
by immune mediated processes. Using an anti- LINGO-1 antibody after SCI may help to 
prevent neurodegeneration by blocking signals from the myelin associated inhibitory proteins 
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being transmitted into the axon. Phase II clinical trials of an anti-LINGO-1 antibody initially 
gave promising results (RENEW trial, Biogen), with improved signalling in optic nerves, a 
possible sign that the myelin sheath had been regenerated [114]. However, results of a Phase 
II clinical trial for patients with relapsing and remitting MS (SYNERGY trial, Biogen) gave 
disappointing results, with the treatment failing to provide any improvement in disability or 
physical or cognitive function. Using an anti- LINGO-1 antibody after SCI may help to prevent 
neurodegeneration by blocking signals from the myelin associated inhibitory proteins being 
transmitted into the axon.  
 
1.10. Rationale, hypothesis and aims 
It is clear from the literature that further investigations of the NgR complex must be 
undertaken since in vivo treatments targeting the known components do not result in 
significant regenerative effects. Recent studies determining the intracellular location of 
LINGO-1 highlights contradictions in the established NgR/p75NTR/LINGO-1 complex. 
Additionally, the negative response seen in clinical trials and recent indications that the LRR 
and Ig domain containing protein AMIGO-3 may have a role in the complex, need to be 
explored further.  
1.10.1 Hypothesis 
The AMIGO proteins are key members of the NgR complex and can substitute LINGO-1 in 





To express AMIGO-1, AMIGO-2, AMIGO-3 and LINGO-1, NgR and p75NTR in human cell lines 
in order to examine their expression and binding profiles.  
To produce human AMIGO-1, AMIGO-2, AMIGO-3 and LINGO-1, NgR and p75NTR in 
drosophila in order to determine their binding properties via surface plasmon resonance 
experiments. 
Finally, to determine the structures of human NgR, LINGO-1, p75NTR and AMIGO family 


































Materials and Methods 
2.1: Molecular Cloning 
2.1.1 Expression Plasmids 
Figure 2.1. Plasmid maps of the expression plasmids used.  
Plasmid maps of the pAAV-IRES-hrGFP plasmid (Agilent) and pcDNA3 (Invitrogen) used to 
express AMIGO-1, -2 and -3, LINGO-1, NgR and p75NTR in HEK293T cells and the pmt-BiP-
V5-His plasmid (Invitrogen) used to express human AMIGO-1, -2 and -3, LINGO-1, NgR and 
p75NTR in Drosophila S2 cells.  
 
pAAV-IRES-hrGFP (Agilent) and pcDNA3 (Invitrogen) vectors (Figure 2.1) were used in the 
eukaryotic expression of human AMIGO-1, AMIGO-2, AMIGO-3, LINGO-1, NgR and p75NTR 
. The pAAV-IRES-hrGFP vector contains a FLAG (3 x FLAG) tag at the 3’ end of the MCS for 
detection of proteins.  pMT/BiP/V-5-His (Invitrogen) was used for eukaryotic expression in S2 
Drosophila cells, this vector contains a poly-histidine (6 x His) tag for detection and purification 
of proteins. pCoHygro, a selection plasmid, was co-transfected into Drosophila S2 cells, this 
plasmid consisted of a bacterial hygromycin B phosphotransferase gene and was used to 




Polymerase chain reaction (PCR) was used to amplify AMIGO-1, AMIGO-2, AMIGO-3, and 
p75 cDNA (GeneService) and LINGO-1 and NgR cDNA (Thermo Scientific). Primers (Listed 
in table 1.1 in Appendix) were reconstituted in dH2O to 20pmol/µl and stored at -20oC. 
Amplification was carried out using either the Expand High Fidelity enzyme (Roche), Pfu 
Turbo enzyme (Agilent) or Velocity (Bioline) DNA polymerase enzymes. PCR reactions were 
performed using a 3770 thermal cycler (Applied Biosystems international) with the following 
cycling conditions: an initial denaturation step of 96oC, followed by 18 cycles of 96oC for 30 
seconds (denaturing), 55oC for 30 seconds (annealing), and 72oC for 90 seconds (extension). A 
final 5-minute 72oC extension was used to complete the reactions. Typical PCR reactions 
consisted of 200ng Template DNA, 2μl each of forward and reverse primers (at 20pmol/μl), 
200nM dNTPs (Invitrogen), 1 x polymerase buffer (1.5mM MgCl2), 2 units of DNA polymerase 
enzyme and 1.5μl DMSO. 
2.1.3 Overlap extension PCR 
Overlap extension PCR was used to introduce mutations or add tags to DNA. This approach 
uses three PCR reactions, the first two reactions create two halves of the full-length sequence, 
and the third fuses these together to create the full-length sequence. The first set of reactions 
used; A: an external forward primer and an internal reverse primer containing a mutation, or 
B: an internal forward primer containing a mutation and an external reverse primer. The 
internal primers were designed to have complementary mutations and an overlapping region 
of 36 base pairs. The third reaction used the products (A and B) from the first set of reactions 
as template DNA and fused them together using just the external primers. The full-length 
protein therefore contained the desired mutation.  
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2.1.4 Restriction digests 
DNA was digested using restriction enzymes in their appropriate buffers and at their 
recommended concentrations according to manufacturer’s instructions. Digests were carried 
out at 37oC for 2 hours.  
2.1.5 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to separate DNA fragments according to their size; 
electrophoresis was performed in 1% agarose gels in TBE buffer (89mM Tris base, 89mM Boric 
acid and 2mM, EDTA), with the addition of 0.5µg/ml ethidium bromide in the gel to allow 
visualisation of the DNA bands. Electrophoresis was performed using a current of 80mA until 
clear separation of PCR products, which were prepared by adding an appropriate volume of 
10x DNA loading buffer (30% glycerol, 0.25% bromophenol blue) to the DNA sample, was 
observed. DNA ladders, of appropriate size (100bp and 1kb), were loaded alongside the DNA 
samples to allow sizing of PCR products. Agarose gels were visualised under a low-level UV 
light source and recorded using the Syngene documentation system, following which, 
appropriate bands were excised. 
2.1.6 Gel purification 
Excised DNA bands were purified using Qiaquick spin columns (Qiagen) based on the 
standard spin protocol. The purified DNA was eluted into 20µl elution buffer and stored at -






Digested vectors were pre-treated with Antarctic Phosphatase (NEB) at 37oC to prevent self-
ligation of the vector. DNA inserts were ligated into appropriate vectors digested with the 
same restriction enzymes as their insert and purified as above. Ligations were carried out at 
differing insert: vector ratios and in conditions varying from 1 hour at room temperature to 
overnight at 20oC.  
2.1.8 Lysogeny Broth media and pouring plates 
Lysogeny broth (LB) media (10g bactotryptone, 10g NaCl and 5g yeast) was mixed with 1 litre 
deionised water and autoclaved. To make LB agar plates, 15g agar was added to the LB media 
and autoclaved. The media was cooled to ~55oC and the appropriate antibiotic was added 
typically ampicillin (100μg/ml) or kanamycin (50μg/ml), the media was poured into plates 
and left to cool at room temperature before storing at 4oC.  
2.1.9 Transformation of bacteria 
Ligation mixes were transformed into chemically competent DH5α E. coli (Novagen) via heat 
shock treatment. Cells were thawed on ice for 20 minutes, following which 10-50ng of plasmid 
DNA was added and left for a further 30 minutes on ice, following this, cells were heat 
shocked at 42oC for 90 seconds before being placed back on ice for 2 minutes. Next, 250µl of 
rich growth media SOC (super optimal broth with catabolite repression = SOB+ glucose) was 
added. The cells were incubated in an orbital shaker at 37oC for 1hr at 220 rpm to allow the 
antibiotic resistance gene to be expressed and plated onto LB agar plates containing the 
relevant antibiotic and incubated overnight at 37oC. 
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2.1.10 Plasmid mini/maxi preparation 
Single bacterial colonies were inoculated into 5mls of LB medium containing 100μg/ml 
ampicillin and incubated overnight at 37oC in an orbital shaker at 220rpm. 3ml of the 5ml 
culture was centrifuged using a bench top centrifuge (Heraeus Biofuge Fresco 21) and from 
the resulting pellet, plasmid DNA was extracted using a QIAprep Spin Mini Kit (Qiagen), 
according to the manufacturer’s guidelines. DNA was eluted into 50µl of elution buffer (Tris-
EDTA) and stored at -20oC. To obtain higher yields of plasmid DNA, midi (Nucleobond), maxi 
or mega preps (Qiagen) were performed with correspondingly higher culture volumes (100-
500ml). Protocols were followed according to manufacturer’s instructions. 
2.1.11 Test digests 
Test digests were performed on mini prep DNA to ensure DNA inserts had ligated into the 
plasmid vector prior to sequencing and/or larger scale expression. Briefly, 2μl DNA was 
added to 1μl appropriate buffer (NEB), 0.1μl bovine serum albumin (BSA, NEB) and 0.5μl 
each of 5’ and 3’ enzyme and made up to 10μl with H2O. Since the volumes are small a master 
mix of the buffer, enzymes, BSA and H2O was made up which was then divided equally before 
the DNA was added. The reactions were incubated at 37oC for 1hr and run by agarose gel 
electrophoresis to allow separation of vector and insert.  
2.1.12 DNA sequencing 
DNA sequencing was used to ascertain if any mutations were introduced into the DNA 
during the PCR and cloning process. Sequencing reactions were set up by adding 2µl of the 
mini prep DNA to 7µl of H2O and adding 1µl of the appropriate sequencing primer 
(4pmol/µl). Sequencing was performed by Functional Genomics (University of Birmingham) 
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using a high throughput capillary electrophoresis system which can produce read lengths of 
up to 1000bp. Sequences were analysed using Sequencher software.  
2.1.13 DNA quantification 
DNA obtained from midi and maxi preps was quantified using Nanodrop apparatus (Thermo 
scientific) which measures absorbance readings at 260nm. Concentrations were calculated in 
ng/μl following which all samples were normalised to 1μg/μl using elution buffer (50mM Tris 
pH7.5).  
 
2.2 Functional studies 
2.2.1 Eukaryotic cell transfection 
Eukaryotic cell transfection was carried out using HEK293T cells using Polyethylenimine 
(PEI; Polysciences) in 6 well plates, 10cm dishes or rollerbottles. Cells were plated at a density 
of 1.2 x 105 cells per well in Dulbecco’s Modified Eagles Medium (DMEM, Sigma) plus 8% 
Fetal calf serum (FCS) 48hrs before transfection corresponding to around 90% confluent for 
transfection. For transfection, for 6 well plates, 2μg DNA was mixed with 15μl PEI (1mg/ml) 
and 150μl Opti-Mem medium (Invitrogen) and left for 10minutes at room temperature. This 
was then added drop wise to cells, which had been pre-washed with PBS and were now 
covered in 3mls Opti-Mem medium. In 10cm dishes the amount of DNA needed was 16μg 
which was mixed with 100μl PEI (1mg/ml) and 1000μl Opti-Mem. Following transfection cells 
were incubated for a further 48-72hrs at 37oC before cells and supernatants were collected. 
Cell supernatants were centrifuged at 13000rpm for 5 minutes to remove cell debris and stored 
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at -20oC until use. Cells were harvested and washed 3 times in PBS before being lysed with 
lysis buffer for 30 minutes at 4oC (50 mM Hepes pH 7.5, 150 mM NaCl, 1.5 mM MgCl2, 1mM 
EGTA, 1% Triton X) following which lysates were stored at -80oC.  
For rollerbottle transfection, typically for collection of secreted protein, cells were added to 
rollerbottles which had been coated with poly-l-lysine, two days before transfection. Cells 
were transfected with 435μg DNA, 2.7ml PEI (1mg/ml) and 27mls Opti-Mem, into a total 
volume of 250ml, cells were incubated for 1 week following transfection before the 
supernatant was collected.  
2.2.2 SDS- PAGE  
SDS-PAGE was used to separate proteins according to their size. SDS resolving acrylamide 
gels (12-15%) (0.765M Tris PH8.8, 0.2% SDS, 5ml 30% w/v acrylamide (Geneflow), 0.1% 
ammonium persulphate and 4ul TEMED (Sigma)) were prepared in 1mm BioRad gel 
cassettes. Isopropanol was used to cover the resolving gel to level the gel and remove air 
bubbles. Once the resolving gel had set the isopropanol was removed and the stacking gel 
(150mM Tris pH 6.8, 0.12% SDS, 0.1% ammonium persulphate, 1% acrylamide and 4ul 
TEMED) was added on top followed by the insertion of a 1mm 10 well comb.  
Protein samples were prepared by mixing protein 1~10μl protein (depending on 
concentration) with 5x loading buffer (60mM Tris pH 6.8, 10% glycerol, 2% SDS, and 0.01% 
bromophenol blue, +/- 200mM DTT) and water up to 10-20μl. Reduced samples (+DTT) were 
boiled at 95oC for 5 minutes and centrifuged for 30 seconds, non-reduced samples (-DTT) were 
not boiled before loading onto the SDS-PAGE gel alongside an appropriate ladder (medium 
range protein ladder, BioRad or PageRuler prestained protein ladder, Thermo). Gels were run 
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in a mini Protean 3 multi casting chamber system (BioRad), 10 x running buffer (0.1% SDS, 
90g Tris, 183g glycine) was diluted to 1 x with H2O and a voltage of 110V was applied while 
the proteins migrated through the stacking gel and increased to 180V while the proteins 
migrated through the resolving gel. The current was stopped when the sample had reached 
the bottom of the gel. To visualise the proteins, the gels were stained with 10ml Coomasie blue 
stain (Instant blue, Expedeon) for 30 minutes at room temperature then washed in water. Gels 
were imaged using Syngene gel documentation system (Syngene).  
The SDS-PAGE gel was also used to separate proteins for further analysis by western blot, 
described below.  However, in this case, precast gradient gels were used (4-15% TGX stain 
free protein gels, BioRad) which fit into the same gel chamber and used the same buffer as 
above.  
2.2.3 Western Blotting 
Protein samples were separated by SDS-PAGE as described above. Proteins were 
subsequently transferred via a wet transfer system onto polyvinylidine fluoride (PDVF) 
membrane (Hybond LFP, GE Healthcare) using transfer buffer (10% methanol, 190mM 
Glycine, 25mM Tris) and blocked in 5% milk in TBS+  0.1% Tween-20 (Sigma) for 1hr at room 
temperature or overnight at 4oC. After blocking the blots were incubated with primary 
antibody (see table below) in TBS + 0.1% Tween-20 + 3% BSA for 1hr at room temperature. 
The membrane was then washed again, three times with 0.1% Tween-20 in TBS and the blot 
was incubated with secondary antibody (HRP conjugated goat anti-mouse mAb) at 1:20 000 
(Sigma) or HRP conjugated goat anti-rabbit mAb (1:2000, Sigma) in 5% milk in TBS + 0.1 % 
Tween-20 for a further 1hr at room temperature before a final 3 washes in TBS + 0.1% Tween-
20.  Fluorescence was visualised using enhanced chemiluminescence (ECL) reagent (EZ-ECL 
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Chemiluminescence Detection Kit for HRP, Biological Industries). Briefly, 1ml reagents A and 
B were mixed in equal measures and incubating at room temperature for 5 minutes, before 
adding to the membrane and incubating for a further 5 minutes. The membrane was then 
analysed by autoradiography.  
2.2.4 Antibodies 
Antibody Dilution Supplier 
Mouse anti FLAG 
(Monoclonal) 
1:20 000 Sigma F3165 
Mouse Anti- HA 
(monoclonal) 
1:1000 Sigma H9658 
Rabbit Anti- HA 
(Polyclonal) 
1:1000 Abcam (Ab13834) 
Rabbit Anti- β Actin 1:1000 Sigma A5441 
Rabbit Anti-AMIGO-1 
(Polyclonal) 
1:1000 Abcam ab93676 
Mouse Anti- AMIGO-2 
(Polyclonal) 
1:1000 Sigma SAB1400868 
Rabbit Anti- AMIGO-2 1:1000 Abcam Ab84416 
Rabbit Anti- AMIGO-3 1:1000 Abcam Ab90058 
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Mouse Anti- AMIGO-3 
(Polyclonal) 
1:1000 ABNOVA H00386724 
Rabbit Anti- LINGO-1 1:1000 Millipore 07-678 
Mouse Anti- NgR 
(Polyclonal) 
1:500 R&D systems 
MAB1208 
Rabbit Anti- NgR 
(Monoclonal) 
1:1000 Abcam Ab184556 
Rabbit Anti- p75NTR 1:1000 Sigma N3908 
Rabbit Anti- Na K ATPase 
(Monoclonal) 
1:10 000 Abcam Ab76020 
Rabbit Anti- Lamin B1 
(Polyclonal) 
1:5000 Abcam Ab16048 
Mouse Anti-α tubulin 
(monoclonal) 
1:10 000 Abcam Ab7291 
Table 2.1. Table of Antibodies used including concentrations used and supplier catalogue numbers.   
2.2.5 Quantification of Protein  
Protein concentrations produced from HEK293T cell lysates were quantified using a BioRad 




2.2.6 Co-Immunoprecipitation Experiments 
For co-immunoprecipitation experiments HEK293T cells were grown in 6 well plates as 
described above and transfected with 2μg of each DNA construct being assessed. The 
transfected cells were incubated for 48hrs before they were harvested and lysed using CO-IP 
lysis buffer (50mM Hepes pH 7.5, 150mM NaCl, 1.5mM MgCl2, 1mM EGTA, 1% Triton X, 
10% glycerol). Cell lysates were mixed with 20μl of anti-FLAG (anti-FLAG M2 affinity gel, 
Sigma) or anti-HA (EZview Red anti-HA affinity gel, Sigma) beads for 2 hours at 4oC. The 
lysates were then centrifuged and supernatant was discarded, the beads were then washed 
with 500μl PBS three times before being suspended in 40μl lysis buffer. Next, 10μl of 5 x SDS 
buffer +DTT was added to the samples which were boiled for 5 minutes at 95oC. Samples were 
stored at -20oC and analysed by western blot.  
2.2.7 Cell fractionation 
Cell fractionation allows subcellular protein localisation. Transfected HEK293T cells were 
divided into 4 subcellular fractions using the Subcellular Protein Fractionation kit for cultured 
cells (Cell Signalling Technology). The four fractions obtained were; whole cell lysate 
cytoplasmic, membrane and nuclear. Once divided, fractions were analysed by western blot 
and stored at -20oC.  
2.2.8. MO3.13 cells 
The human glial oligodendrocyte cell line MO3.13 (obtained via CELLutions Biosystems Inc, 
Ontario, Canada) was used to assess the expression of the proteins of interest in the human 
CNS. Cells were plated at a density of 1.2 x 105 cells per well in Dulbecco’s Modified Eagles 
Medium (DMEM, Sigma) plus 8% Fetal calf serum (FCS) and incubated for 48-72hrs (until 
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~90% confluent) at 37oC before cells were collected. Cells were washed 3 times in PBS before 
being lysed with lysis buffer for 30 minutes  at 4oC (50 mM Hepes pH 7.5, 150 mM NaCl, 1.5 
mM MgCl2, 1mM EGTA, 1% Triton X), following which lysates were stored at -80oC until 
needed when 15μl of cell lysate was analysed by western blot.   
2.2.9. Human brain tissue 
Human Brain tissue (control tissue) obtained from MS Society Tissue Bank, Imperial College 
London, Multicentre Research Ethics Committee 08/MRE09/31. Brain tissue was prepared 
according to standard protocols by MS brain bank staff, with fresh brain was cut into 1-cm-
thick coronal slabs before either cryopreserving in cold isopentane on a bed of dry ice. 
Tissue originated from a donor with a non-primary neurological cause of death (cardiac 
arrest following pneumonia), considered to be a “non-neurological control” [115]. Upon 
receipt, brain tissue was lysed, aliquoted into 10μl aliquots and stored at -80oC until needed. 
Samples were mixed with 5x SDS buffer and analysed by western blot as described 
previously.  
 
2.3 Protein production in insect cells 
2.3.1 Expression in S2 Drosophila cells 
The Drosophila system ensures high level expression of soluble recombinant proteins which, 
when expressed with a histidine tag, allows quick and simple purification of large quantities 
of protein. Expression vectors (pMT/BiP/V5-His, Invitrogen) encoding the protein of interest 
and a selection plasmid, pCoHygro, conferring resistance to Hygromycin B were co-
52 
 
transfected into the S2 Drosophila cell line. Cells were grown in a selecting medium 
(Schneider’s Drosophila Medium modified with L-Glutamine, Lonza) and supplemented with 
10% fetal calf serum and 300μg/ml hygromycin. Cells were subcultured every 4-5 days into 
fresh medium containing 5-10% conditioned medium (media which has been used in growing 
parental cells and so contains proteins released from parental cells which help enable frozen 
cells to grow back after a freeze thaw without all the cells dying off), with cells seeded at 1.2 
x 106 cells/ml in 15-20ml media in T75 culture flasks. For expression, cells were grown in 
250mL medium containing 300μl/ml hygromycin plus 0.05% Pluronic F-68 surfactant (Gibco) 
to prevent the cells from clumping together. Typically, 1 litre of medium split in 4 x 1L 
Erlenmeyer flasks were produced and incubated at 27oC, gently shaking at 70rpm for 3 days 
(or reached 4-6 x 106 cells/ml).  Protein expression was then induced via the addition of 500μM 
CuSO4 (final concentration) and incubated for a further 4 days before the medium was 
harvested and cells pelleted by centrifugation at 100g for 15 minutes. Supernatants were 
stored at 4oc with 0.02% sodium azide until further purification was performed. 
2.3.2 S2 cell Protein Test expression 
S2 cell expression of protein was tested by inducing a small volume (6ml) of cells with 500μM 
CuSO4. Supernatant collected at days 2, 3 and 4 was analysed by western blot with a C- 
terminal anti-His antibody to detect the His tag on the expressed protein.  
 
 




In order to successfully purify the expressed protein, smaller compounds present in the 
culture medium, which can bind to and clog the affinity column, must first be removed. 
Compounds such as surfactants, free amino acids and excess copper sulphate were removed 
from the cell media by dialysis. The supernatants were loaded into 10kDa dialysis tubing 
(Sigma), and dialysed into 10 x volume of PBS buffer overnight at 4oC. Following this the 
supernatant was removed from the dialysis tubing to undergo further purification.  
2.4.2 Nickel affinity chromatography 
Econo columns (Biorad) were loaded with 1ml of Nickel beads (Ni-NTA agarose stored in 
20% ethanol, Qiagen) per 1 litre of supernatant to be processed over the column. Following 
this, the column was washed with 1 column volume (10ml) of 1xPBS + 10 mM Imidazole. The 
dialysed S2 supernatant was flown over the beads by gravity at 4⁰C overnight with a slow 
flow-rate (approx 1ml/min). The following day, the column was washed with 1xPBS + 10 mM 
Imidazole to remove non-specific proteins, and once the UV OD280 of the wash flow through 
was zero (using PBS+ 10mM imidazole as a blank), the beads were incubated with elution 
buffer (1xPBS + 250 mM Imidazole (~7 ml))  for 30 minutes. After the incubation period the 
eluted proteins were collected in 1ml fractions and quantified by spectrophotometry using 
UV absorbance (280nm). The fractions were then either buffer exchanged or filtered and 
loaded straight onto the FPLC for further purification as described below.  
 
 
2.4.3 Buffer exchange 
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PD-10 desalting columns (GE healthcare) were used to buffer exchange the protein into more 
suitable buffer conditions.  PD10 Columns were washed with three column volumes of the 
desired buffer; the first three fractions of the eluted protein in the 250mM imidazole buffer 
were then added to the column and the eluate allowed topass through the column. Finally, 
3.5ml of the desired buffer was added to the column and the flow through was collected.  
2.4.4 Gel filtration 
Expression of recombinant proteins with histidine fusion tags is a useful way of facilitating 
purification of that protein by use of immobilised metal ion affinity chromatography (IMAC). 
Size exclusion chromatography was performed using a FPLC system (ÄKTA, GE healthcare), 
Superdex 200 (>1mg) and HR200 (<1mg) columns were used. Columns were washed and 
equilibrated with desired buffer prior to the protein being loaded. Samples were filtered using 
a 0.45μm filter disc immediately prior to gel filtration. The purification step was carried out 
at room temperature using a flow rate of 3ml/min and fractions were collected as either 0.5ml 
(HR200) or 5ml (S200) aliquots using the fraction collector. The resulting elution profile 
showing absorbance (mAu) of the eluted protein fractions were analysed using Unicorn 
(version 4) software (GE Healthcare), allowing identification of the peak fractions to be 
analysed by SDS-PAGE to assess purity.   
2.4.5 Protein quantification 
The concentration of protein at all points during purification was determined by measuring 
the absorbance of the protein solution at OD280 using Biophotometer (Eppendorf) compared 
to a blank encompassing the buffer alone. From the absorbance reading the concentration of 
the protein can be determined using the calculation of OD280 = ε x c x l where ε is the extinction 
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coefficient (cm-1 M-1), c is the concentration (M) and l is the length of light path through the 
sample (1cm). If the extinction coefficient is known then the concentration of the protein can 
be worked out using the calculation c = OD280/ ε x l. The ε value is calculated from the number 
of tyrosine (Y) and tryptophan (W) residues and the number of disulphide bonds (SB) within 
the protein using the following calculation; ε = ((nY x 1490) + (nW x 5500) + (nSB x 125)).  
2.4.6 Protein concentration  
Centrifugal filter units (Millipore) with a 10kDa molecular weight cut off were used to 
concentrate proteins, 15 ml units were used initially, at a speed of 4000g, to reduce the volume 
of protein solution to around 1.5ml followed by smaller, 0.5ml units (micron, 10kDa), at a 
speed of 14000g, were used to further concentrate the protein. Absorbance was calculated after 
each spin cycle of 10 minutes to check the concentration of the protein at all times.  
 
2.5. X-ray crystallographic studies 
2.5.1 Small scale crystallisation trials  
Small scale crystallisation trials were initially set up using the ‘hanging drop vapour diffusion’ 
method using 100nl protein + 100nl crystallisation buffer aided by the nanolitre mosquito 
robot (TTP LabTech).  To identify the optimal conditions needed for formation of crystals 
commercial screens were used (Table 2.2), with each screen contained 96 different conditions 
of which 100μl of each was added to a 96 well plate (Iwaki). The mosquito robot then pipetted 
100nl from each condition and 100nl of the concentrated protein onto a plate seal. The plates 
were then sealed with the protein/buffer drops hanging above their corresponding wells and 
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incubated at 23oC. After 4 days the 96 well plates were visualised using a light microscope 
(Leica) to determine crystal formation.  
Screen Name Company 
JCSG+ Molecular Dimensions Ltd (MDL) 
Wizard I + II Emerald Biosystems 
PEG/ ION Hampton Research 
INDEX Hampton Research 
Structure Screen I + II MDL 
Table 2.2. Commercial screen used for small scale crystallisation trials 
2.5.2 Large scale crystallisation trials 
Large scale trials were set up in 24 well Linbro plates (MDL) using both the ‘hanging drop 
and ‘sitting drop’ vapour diffusion methods. Briefly, 1ml of crystallisation buffer was added 
to each well and the edges of each well were coated with vacuum grease (MDL). The protein 
and the corresponding buffer were mixed on a   cover slip or sitting drop columns in ratios of 
1:1, 1:2, 1:3 and 2:2 (μl, protein: buffer). For the hanging drop set up the cover slips were then 
inverted over the wells and sealed.  For sitting drops the sitting drop bridges were placed in 
the well and a clean cover slip was used to seal the well. The 24 well plates were incubated at 
23oC and examined after 3 days using a light microscope then subsequently every week. IM50 
software (Leica) was used to document crystal formation. 
2.5.3 Cryoprotectant soaking 
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Once protein crystals had formed they were transferred into reservoir solution and allowed 
to soak for 5 minutes using a 0.2 mm nylon loop. The crystals were then soaked in reservoir 
solution supplemented with increasing concentrations of glycerol (starting at 5% followed by 
15%, 20% and 25%). Crystals were left to soak in for 5 minutes in each condition and soaked 
for 30 minutes in the final condition of 25% glycerol in mother liquor. Crystals were soaked 
in a cryoprotectant prior to exposure to X rays in order to prevent the solvent surrounding the 
protein crystal from forming ice crystals and protect the crystal from radiation damage. 
Following these series of soaks, the crystals were flash cooled in liquid nitrogen and stored in 
a cryogenic dewar (MDL), ready for X-ray data collection.  
2.5.4 X ray data collection and Processing 
X-ray diffraction experiments were performed using either the ‘in house’ Micromax 007HF 
rotating anode X-ray generator (Rigaku) and Saturn charged coupled device, or X-ray 
diffraction data were collected remotely (at University of Birmingham) or the Diamond Light 
Source (Oxford).  All data collection manipulations were carried out using the CrystalClear 
(Rigaku) software. Intensity data were integrated, scaled and merged using programs of the 
XDS suite [116].  
 
 
2.5.5 Structure Determination and Refinement 
The structures of hAMIGO-1 LRR and hAMIGO-1 LRR + Ig were determined by molecular 
replacement with MOLREP (Collaborative Computational Project No 4 1994) [117], AMORE 
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[118] and CNS [119] packages  using the previously determined structure of mAMIGO-1 [120] 
as the phasing model. For both structures, the molecular-replacement calculations yielded 
unambiguous rotation and translation function solutions. The molecular models were refined 
with CNS [119] and REFMAC5 [117], the progress of which was verified by monitoring the 
reduction in the Rfree value [119] calculated from an independent set of reflections (5%), set 
aside for cross validation. The models underwent several rounds of alternating simulated 
annealing and positional refinement which were followed by isotropic B factor refinement. 
Examination of the resulting electron-density maps showed unbiased features in the electron 
density, which confirmed that the molecular replacement solutions were correct. Once R 
factor values were reduced below 30%, solvent molecules were included in the models, if they 
appeared in Fo-Fc maps contoured at over 3σ and were within hydrogen-bonding distance to 
chemically accepted groups. Model manipulations were performed with COOT [121]. The 
quality of final models were verified with PROCHECK [117], structural models were 
produced using Pymol (http://www.pymol.org), and molecular surfaces generated using 
DELPhi [122]. All structural analysis were performed with programs of the CCP4 suite [123].  
 
2.6 Surface plasmon resonance (SPR) 
SPR is a highly sensitive technique used for the detection of real time binding. The process 
allows for the determination of binding affinities and kinetic measurements.  
2.6.1 Biotinylation of Proteins 
The protocols used in surface plasmon resonance binding experiments require that proteins 
are biotinylated via the BirA tag contained in the expressed constructs. This involved buffer 
59 
 
exchanging soluble proteins purified previously by Ni-NTA +/- size exclusion 
chromatography, into biotinylation buffer (100mM Tris pH 7.5, 20mM NaCl, 5mM MgCl2) as 
described in section 2.4.3.  For the biotinylation reactions; to the 3ml protein in biotinylation 
buffer 0.5mM Biotin (Sigma), 1mM ATP (Sigma), 1 x protease inhibitors (25X concentrate, 
Roche) and BirA enzyme (In house product ([124])) were added and incubated at room 
temperature for 1 hour, followed by an overnight incubation at 4oC. Excess biotin was 
removed from the sample by size exclusion chromatography the following day.  
2.6.2 Experimental Procedure 
SPR studies were performed at 25oC using the University of Birmingham BIAcore 3000 
machine (BIAcore, GE Healthcare). To perform a protein binding experiment HBS-EP running 
buffer (10mM HEPES pH7.4, 150mM NaCl, 3.4mM EDTA. 0.0005% surfactant P20) was used. 
Firstly, a new CM5 sensor chip was docked in the machine and the system was primed with 
H20. Next, BIA normalising solution was injected at 10μl/min to normalise the signals 
obtained from the instrument and streptavidin was immobilised onto the chip by standard 
amine coupling at pH 5. This involved injecting a mix of equal volumes of 0.2M N-ethyl-N5 
(3-diethylaminopropyl)-carbodimide (EDC) and 0.5M N-hydroxysuccinimide (NHS) over the 
sensor chip at 10μ/min. Following this, 60μl streptavidin (0.5mg/ml in 10mM Sodium Acetate 
pH 5.5) was injected over the chip followed by 70μl of 1M ethanolamine pH 8.5 which blocked 
any remaining active carboxyl-esters on the surface, and 500μl Glycine-HCL pH 2.5 to remove 
uncoupled streptavidin. Final streptavidin levels were shown in response units on 
BIAevaluation software. Purified biotinylated protein samples (NgR-Bt) at 1.2mg/ml, were 
diluted in HBS-EP buffer and injected at 5μl/minute over the immobilised streptavidin, the 
levels of immobilised protein on each flow cell was kept as consistent as possible over each 
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cell. Analyte proteins were stored on ice and centrifuged at 13000 rpm immediately prior to 
injection over flow cells at 10μl/min; a total of 30μl was injected. Serial dilutions of protein 
were used to obtain affinity measurements. Data was analysed using BIAevaluation software 





































Unlike those in the PNS, axons in the CNS are unable to regenerate because the environment 
in the CNS after injury is inhibitory to regeneration. In the initial stages post injury, inhibitory 
signals originate from the environment created as a result of cell damage whereas in the weeks 
following injury the formation of a glial scar causes a physical barrier to regeneration. Indeed, 
it has been well documented that CNS neurons are able to regenerate if given a permissive 
environment [11, 12]. Inhibitory effects result in part from the release and upregulation of 
myelin derived axon inhibitory proteins Nogo, MAG and OMgp [125], and cause growth cone 
collapse via Rho GTPase signalling through the Nogo receptor (NgR) complex.  
The tripartite NgR/p75NTR/LINGO-1 complex inhibits axon regeneration in the injured CNS 
by activating Rho A, with each member of the complex necessary for successful inhibition.  In 
vitro expression of NgR and p75NTR alone in non-neuronal cells fails to activate Rho A [68] 
indicating that another, neuronally expressed, protein is necessary for inhibition. LINGO-1 
was identified as an additional essential component of the NgR/p75NTR complex [68] which, 
when expressed alongside NgR and p75NTR provided responsiveness to the myelin associated 
inhibitory protein, OMgp. The functional importance of LINGO-1 within the complex is 
suggested primarily from in vitro experiments using a range of methods to manipulate 
expression or ligand binding (RNAi, dominant negative LINGO-1 transfectants, LINGO-1 Fc 
fusions or blocking antibodies). Experiments examining the in vivo functional consequences 
of LINGO-1 blockade are limited to a single study using LINGO-Fc in a model of CNS injury 
[73]. More definitive evidence for an in vivo functional role for LINGO-1 is lacking, which is 
of concern, particularly as the time course of LINGO-1 expression is delayed by up to two 
weeks following injury [107]. These findings may suggest functional redundancy, either via a 
LINGO-1 paralog (i.e. LINGO-2, LINGO-3, LINGO-4) or an alternative protein substituting 
63 
 
for LINGO-1. Further complications are evident, with more recent data suggesting that 
LINGO-1 is in fact intracellular and competes with NgR for binding to p75NTR [126].  
In one example examining gene expression profiles in a rat CNS injury model, AMIGO-3 was 
identified as upregulated following injury [127], and importantly was further identified as 
downregulated in a modified CNS injury protocol promoting axon regeneration [127]. The 
same group also confirmed that LINGO-1 expression remained low in all models. Rat 
AMIGO-3 was also shown to be able to participate in the NgR/p75NTR complex, indicating a 
potential role for this protein in mediating axon growth inhibition.  
3.1.1. LRR proteins and interactions  
Leucine rich repeats are frequently involved in the formation of protein-protein interactions. 
The repeats are present in numerous proteins with diverse functions; both NgR and LINGO-
1 are LRR domain containing proteins as are the AMIGO proteins. LINGO-1 and the AMIGO 
proteins also contain an Ig domain and are referred to as LRR and Ig domain containing 
proteins.  
Three members of the AMIGO family of proteins have been described; AMIGO-1, AMIGO-2 
and AMIGO-3, which are single pass transmembrane proteins each containing 6 leucine rich 
repeats (LRRs) and one Ig domain. AMIGO-2 and AMIGO-3 are homologous to AMIGO-1 
with similarities at the amino acid level of 48% and 50% respectively [97]. The most conserved 
regions of the proteins are the LRR domain, transmembrane region and cytosolic tails, with 
conserved features observed across mammalian species. The three proteins are differentially 
expressed, with AMIGO-1 being relatively CNS specific and AMIGO-2 and AMIGO-3 being 




3.2 Specific aims and methods 
This chapter outlines several biochemical and cellular approaches to determine whether 
human AMIGO family members are functional interactors within the NgR/p75NTR complex. 
cDNA constructs were engineered for protein expression in mammalian cells to permit 
transient cell expression followed by co-immunoprecipitation studies on cell lysates. The 
availability of high quality antibodies to AMIGO family members is a major limiting factor, 
so the majority of the expression studies were therefore performed using constructs which 
included engineered protein tags to permit efficient immunoprecipitation and/or western 
blotting analyses. Once transfected into cells, expression patterns (including glycosylation) 
and the respective subcellular localisations were determined. Protein-protein interactions 
were determined using co-transfection of differentially tagged proteins. Similar studies were 
then attempted using cultured cell lines (in which the proteins are endogenously expressed), 
and native tissue using available polyclonal antibodies to native proteins.  
 
3.3. Determining expression and binding profiles of AMIGO proteins 
3.3.1. Cloning of AMIGO-1, AMIGO-2 and AMIGO-3 
Homophillic and heterophillic binding between AMIGO family members has been examined 
via co-immunoprecipitation studies using GFP and V5 tagged AMIGO proteins expressed in 
HEK293T cells. In a complimentary study, proteins were also bound to protein A-coated 
beads, and signs of aggregation examined [97]. These experiments demonstrated that the 
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AMIGO family of proteins display both heterophillic and homophillic binding, as 
demonstrated by both bead aggregation and immunoprecipitation of corresponding proteins. 
This approach, although successful is subject to a major limitation, as GFP (used as a tag) 
forms a dimeric structure. This makes a definitive interpretation of the results complex.  
First, two designs were used: AMIGO constructs were produced fused to a C-terminal FLAG 
tag sequence. The relevant cDNA was inserted into the multiple cloning site (MCS) of pAAV-
IRES-hrGFP plasmid (Figure 3.1), leading to fusion with a 3 x FLAG tag. The FLAG epitope 
can be detected using the highly specific M2 antibody. A second set of constructs were also 
produced to incorporate an N-terminal HA tag according to Figure 5.1. The HA tag was 
inserted into the vector following (i) a secretion signal sequence and (ii) a cleavage sequence. 
The signal peptide derived from preprotrypsin, MSALLILALVGAVAAVA, and epitope tag 
sequence (HA), YPYDVPDYA, were inserted upstream of the multiple cloning site (MCS), as 
described previously by Wang et al 2002 [128], inserted into the mammalian expression vector 
pcDNA3.  
Plasmids were transfected into HEK293T cells at 90% confluence using polyethylenimine 
(PEI) and cells were left to express the protein for 72 hours, whereupon cells and cell 
supernatants were collected for analysis by SDS-PAGE and western blot.  
3.3.2 Cloning of LINGO-1, NgR and p75NTR 
LINGO-1, was similarly cloned into (i) pAAV-IRES-hrGFP vectors or (ii) pcDNA3 vectors to 
produce constructs with either C-terminal 3x FLAG or N-terminal HA tags respectively. NgR 
and p75NTR were cloned as N-terminal HA tags only.  As before, all constructs were transfected 
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into HEK293T cells using PEI and cell lysates and supernatants were analysed by SDS-PAGE 





Figure 3.1. Cloning of AMIGO-1 proteins with FLAG and HA tags. 
a) Map of paav-IRES-hrGFP vector into which the gene of interest was cloned.   
b) Multiple cloning site information 





3.3.3 Western Blot analysis of HEK293T expression  
Following transfection, cells were lysed and analysed by western blot using antibodies against 
FLAG (Mouse anti FLAG M2) and HA tags. Whilst the FLAG antibody (Sigma F3165) was 
efficient and reliable, there were initial difficulties with determining the optimal anti-HA 
antibody. After trials, where the two HA antibodies were added at differing concentrations 
and developed for varying times the most reproducible antibody was determined to be Mouse 
Monoclonal Anti-HA, Sigma H9658.  
Whole cell lysates were analysed by western blot, to detect AMIGO family members, LINGO-
1, NgR and p75NTR (Figure 3.2). The AMIGO family of proteins were shown as doublets at 
around 70kDa in size when detected using both HA and FLAG tagged antibodies. The 
predicted mass of the AMIGO proteins are 55.2kDa, 57.9kDa and 55.2kDa respectively. The 
3x FLAG tag is around 3kDa in size as is the HA tag, leaving a discrepancy of around 10kDa 
between the expected sizes and the actual sizes displayed on SDS-PAGE. This discrepancy is 
likely due to differential glycosylation suggested previously for AMIGO-1 [120]. While the 
predicted size for the expressed LINGO-1 construct is 67kDa, in the absence of tags, it migrates 
at around 100kDa, indicating that, like the AMIGO family members, it is also glycosylated. 
Similarly, the NgR and p75NTR constructs are also expressed as doublets and both are shown 
at around 70kDa, a similar size to that previously detected [53, 59, 129, 130].   In addition, 
bands are seen at around 140kDa for AMIGOs -1,-2 and -3 which are likely to be dimers. There 
doesn’t appear to be a similar band in LINGO-1 however there are also large molecular weight 
bands in NgR and p75NTR which at around 130kDa are also likely to be dimers.  
AMIGO-1 has 5 N-linked glycosylation sites, 1 in LRR1, 1 in the LRRCT and 3 in the Ig domain. 
AMIGO-2 has 8 N-linked glycosylation sites 1 in the LRRNT, 1 in LRR2, 1 in the LRRCT and 
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5 in the Ig domain. AMIGO-3 also has 5 N-linked glycosylation sites with 1 in LRR2, 1 in the 
LRRCT and 3 in the Ig domain. Finally, LINGO-1 has 10 N-linked glycosylation sites with 1 
in LRR4, 1 in LRR6, 2 in LRR8, 1 in LRR9, 1 in LRR11, and 4 in the Ig domain. Glycosylations 
are predicted to add around 2kDa each to the mass of the protein they are attached to, 
therefore the mass of the proteins may be altered substantially [131].  
To examine glycosylation dependent effects on gel migration, cell lysates were treated with 
Peptide N-Glycosidase (PNGaseF), an amidase which removes all N-linked oligosaccharides 
from proteins. The treated lysates were analysed by western blot, as compared to their 
untreated counterparts (Figure 3.3) with the deglycosylated cell lysates showing the native 
size of the expressed proteins. Following deglycosylation AMIGO proteins migrate at around 
55kDa, considerably closer to the predicted size of these proteins. Similarly, a large shift in 
observed sizes for LINGO-1 (100kDa) and the deglycosylated version (70kDa) was observed, 
with the latter now substantially closer to the predicted size of 67kDa. Finally, NgR and p75NTR 
were also treated with PNGaseF, which had little effect on the size of p75NTR but altered the 




Figure 3.2. Expression of proteins of interest in HEK293T cells.  
HEK293T cells were transfected with C-terminal FLAG (Left panel) and N-terminal HA (Right 
panel) tagged constructs. Cells were lysed and lysates were analysed by western blot. Proteins 
were detected using antibodies directed against the FLAG (left panel) and HA tags (right 
panel) demonstrating effective protein expression.  * indicates a cleaved form of AMIGO-2 
FLAG at around 20kDa in size.  
1. AMIGO-1- FLAG  6. HA-AMIGO-2 
2. AMIGO-2-FLAG  7. HA-AMIGO-3 
3. AMIGO-3-FLAG  8. HA-LINGO-1 
4. LINGO-1-FLAG  9. HA-NgR 
5. HA-AMIGO-1   10. HA-P75NTR 
b) PVDF membranes were stripped and re-probed with β- actin antibody as a loading 
control.  








Figure 3.3 Enzymatic deglycosylation of HEK293T expressed proteins 
Transfected 293T cell lysates were treated with PNGase F, treated samples were examined by 
western blot alongside untreated samples. a) FLAG tagged protein lysates analysed using 
anti-FLAG antibody. b) HA tagged protein lysates analysed using anti HA antibody. Samples 
treated with PNGaseF are smaller in size than untreated samples and where there are multiple 
bands in the untreated samples, these are reduced to a single band upon treatment with 
PNGaseF.  
1. AMIGO-1   7. LINGO-1   
2. Deglycosylated AMIGO-1  8. Deglycosylated LINGO-1 
3. AMIGO-2    9. NgR    
4. Deglycosylated AMIGO-2  10. Deglycosylated NgR   
5. AMIGO-3    11. p75NTR 




3.4 The presence of a band in AMIGO- 2 lysate suggests cleavage and release of the protein 
cytoplasmic region.  
Western blot analysis consistently revealed the presence of a band at around 20kDa in the cell 
lysate of the C-terminal FLAG tagged AMIGO-2 transfected cells. However, this band was not 
observed in the N-terminal HA tagged AMIGO-2 cell lysate, indicating that the protein was 
cleaved and the HA tag was released with the fragment not available for detection in the 
lysate. Considering the fragment was around 20kDa in size it was most likely that the 
fragment detected is the intracellular portion of the protein, cleaved extracellularly, adjacent 
to the cell membrane. Using Expasy and Uniprot to predict molecular weights for different 
fragment of the protein it was possible to estimate where the protein might be cleaved, for 
example the cytoplasmic domain of the protein, comprising residues 420-522, is predicted to 
be 10.8kDa in size. But at around 20kDa in size, the fragment detected was significantly larger 
than the cytoplasmic domain. The addition of the transmembrane domain (residues 399-419) 
only increased the predicted fragment size to 13.1kDa indicating that the cleavage must occur 
somewhere in the extracellular region. If the Ig domain, at 9.1kDa, is included the size 
becomes somewhat closer to that of the fragment and it is possible that the fragment could be 
of the intracellular domain plus the Ig domain. This approach is not definitive however, as for 
example charged amino acids may lead to anomalous migration of the protein fragment 
through the SDS-PAGE.   
To investigate further, the supernatant of HA-AMIGO-2 transfected HEK293T cells was 
analysed by western blot (Figure 3.4). The HA tag is located at the N-terminal end 
(ectodomain) of the protein, so western blots were probed using an anti-HA antibody. A faint 
band was reliably observed at around 70kDa, which is akin to the size of the mature protein 




Figure3.4 Western blot analysis of N-terminal HA tagged AMIGO-2 transfected HEK293T 
cell supernatant. 
a) Western blot analysis of HEK293T cell supernatant using anti HA antibody identified 
a faint single band at around 70kDa which corresponds to the full length glycosylated 
version of AMIGO-2.  
b) Western blot analysis of HA-AMIGO-2 transfected HEK293T cell whole cell lysate 
(WCL) alongside the transfected cells supernatant treated with anti HA beads (Left 
lane). A more prominent band is seen at 70Kda after addition of anti HA beads, akin 
to the band seen in a).  
1. Full length AMIGO-2. Glycosylated. 
2. Full length AMIGO-2. Partially glycosylated. 






Addition of anti-HA beads to the supernatant resulted in the band at 70kDa becoming more 
prominent, furthermore an additional band was detected at around 60kDa and thought to 
represent the non-glycosylated form of AMIGO-2.  
The release of an intact (full length) protein into the cell supernatant can only really indicate 
the budding or release of cell fragments or vesicles into the cell supernatant (see Figure 3.5). 
The physiological significance is uncertain as this phenomenon could be an artefact of cell 
transfection/ protein overexpression.  
LINGO-1 displays similar signs of being degraded in mouse brain tissue lysate, in data 
provided by Abcam for analysis of the anti-LINGO antibody (ab23631). In western blot 
analysis, bands are seen at the expected size of 83kDa representing the full-size protein, but 
bands are also seen at 34kDa and 17kDa potentially representing degradation and cleavage 
products respectively. It is not known which part of the protein the 17kDa cleavage product 
represents; it is larger than the predicted size of the intercellular and transmembrane domains 





Figure 3.5 Diagram representing possible modes of AMIGO-2 cleavage. 
a. Cleavage may occur intracellularly. 
b. Cleavage may occur extracellularly. 
c. The protein may be cleaved both intracellularly and extracellularly. 
d. The protein may be released as a whole, in a vesicle.  
ECD = Extracellular domain, 40.8kDa 
ICD = Intracellular domain, 10.8kDa 
TMD = Transmembrane domain, 2.3kDa 
Ig domain – 9.1Kda 
cytoplasmic domain of the protein, comprising residues 420-522, is predicted to be 10.8kDa 
in size. But at around 20kDa in size, the fragment detected was significantly larger than the 
cytoplasmic domain. The addition of the transmembrane domain (residues 399-419) only 
increased the predicted fragment size to 13.1kDa indicating that the cleavage must occur 
somewhere in the extracellular region. If the Ig domain, at 9.1kDa, is included the size 
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becomes somewhat closer to that of the fragment and it is possible that the fragment could 
be of the intracellular domain plus the Ig domain  
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3.5 Subcellular fractionation 
It is thought that both NgR and p75NTR are expressed at the neuronal cell surface, where myelin 
associated inhibitory factors can bind and mediate axon outgrowth inhibition. However, the 
cellular location of the third member of the axon inhibitory complex, LINGO-1, remains 
contentious. Recently it has been suggested that LINGO-1 is located intracellularly [126], 
which questions the tripartite complex model as LINGO-1 would not be freely available to 
associate with the other proteins in the complex. However, this contradicts previous evidence 
which appears to show the necessity of the protein at the cell surface- where the actions of 
LINGO-1 are inhibited when an antibody against LINGO-1 is used [78]. Since the antibody 
acts extracellularly the protein must presumably be expressed at the cell surface. However, 
the ability to endocytose antibodies has been reported previously with anti-ganglioside 
antibodies shown to be endocytosed at nerve terminals [132].  
Determining the subcellular location of a protein is  critical when examining its biological 
function, [133]. There are several approaches to separating subcellular compartments, 
including (i) separation based on centrifugation, using differences in sedimentation co-
efficiencies and densities, and (ii) separation based on a chemical properties using a series of 
detergents with increasing solubilisation efficiencies [133]. It is also possible to use a 
combination of both approaches, with consideration as to the coverage of the proteome, the 
reproducibility and ease and speed of processing.  
Subcellular fractionation was performed on HEK293T cells transfected with FLAG- or HA- 
tagged proteins to determine the cellular location of expression. From available options, the 




Figure 3.6. Subcellular fractionation controls 
a) Subcellular fractionation was performed on HEK293T cells. A series of buffers were added 
to the cells to extract the cytoplasmic, membrane and nuclear fractions.  
b) To ensure efficient fractionation and particularly lack of cross contamination purified 
fractions were analysed by western blot. Anti-tubulin antibody was used to detect tubulin 
expressed in the cytoplasmic fraction (top panel), which is where it was detected, with very 
little seen in other fractions. Anti NA+ K+ ATPase was used to detect the NA+K+ channel In the 
membrane fraction (middle panel), no Na+K+ was seen in membrane or nuclear fractions but 
was seen in whole cell lysate. Finally, anti lamin was used to detect lamin in the nuclear 
fraction (bottom panel) which is where it was detected, no Lamin was identified in any of the 
other fractions. Some images appear pixelated due to the longer exposure time required, due 
to a combination of the low level of expression of the protein of interest and the sensitivity of 
the antibody used.  
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membrane and nuclear, followed by analysis by western blot using antibodies against the 
FLAG or HA tags. The performance of the protocol was tested with proteins with known 
cellular locations as controls, including tubulin, Na+ K+ ATPase and lamin, which are situated 
in the cytoplasm, membrane and nucleus respectively. Each of these proteins was easily 
identifiable in the respective fractions predicted (Figure 3.6); furthermore, there was no 
significant cross-contamination into other fractions. Panels representing α tubulin and lamin 
appear pixelated due to the longer exposure time needed to identify the proteins; this may be 
due to the low levels of these proteins in the cells, the poor sensitivity of their antibodies, or a 
combination of both. The proteins being identified in these panels were likely to be diluted in 
the WCL samples and so were not of high enough levels to be identified in the western blots. 
In contrast, Na K ATPase was of high enough concentration to be identified without the need 
for a long exposure therefore the image is not pixelated, furthermore the level of protein and 
specificity of the antibody is high enough that it is identified even when its ‘diluted’ in the 
WCL sample.  
As before, HA- or FLAG- tagged AMIGO-1, -2 and -3 were expressed in HEK293T cells, after 
3 days the cells were trypsinised and washed with PBS, a sample was saved corresponding to 
the whole cell lysate. Next the Cell Signalling Cell Fractionation (Cell Signalling) kit was used 
to separate the cells into three distinct fractions using a detergent-based method as opposed 
to other centrifugation methods. A series of buffers, including (i) cytoplasmic isolation buffer, 
(ii) membrane isolation buffer and (iii) cytoskeletal/nuclear isolation buffers, were added to 
the cells, which were vortexed and centrifuged according to the manufacturer’s instructions. 
The manufacturers protocol was similar to that of ‘Method 2’ in Rockstoh et al (2011) [133]. 
Cytoplasmic, membrane and nuclear fractions were obtained, and samples were mixed with 
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loading buffer (SDS + 200mM DTT) and analysed by western blot alongside the whole cell 
lysate sample, using antibodies against either the FLAG or HA tag.  
HA-tagged AMIGO proteins were identified at 70kDa in size in the whole cell lysate and 
membrane fractions, and to a lesser extent the nuclear fraction (Figure 3.7). However, very 
little expression was observed in the cytoplasmic fractions. This indicates that all of the 
AMIGO proteins are potentially available at the cell surface where they can interact with other 
cell surface membrane proteins, and potentially those of the NgR complex. The expression 





Figure 3.7. Subcellular localisation of HA tagged proteins 
N-terminal HA tagged constructs were transfected into HEK293T cells which then underwent 
subcellular fractionation. Fractions obtained were whole cell lysate (WCL), cytoplasmic, 
membrane, and nuclear.  Fractions were analysed by western blot using an anti-HA antibody 
to determine the locations of the proteins of interest.  All proteins, except LINGO-1, are 
expressed most predominantly in the membrane fraction. LINGO-1 is absent from the 




Figure 3.8. Subcellular Localisation of FLAG tagged proteins 
C- terminal FLAG tagged constructs were transfected into HEK293T cells which then 
underwent subcellular fractionation. Fractions obtained were whole cell lysate (WCL), 
cytoplasmic, membrane , and nuclear.  Fractions were analysed by western blot using an 
anti- FLAG antibody. All three AMIGO proteins are seen predominantly in the membrane 




protein being detected in the cytoplasmic fraction, at around 100kDa.  Bands are also observed 
in the whole cell lysate and a small amount is observed in the nuclear fraction, however, no 
protein was detected in the cell membrane fraction. 
Cells expressing HA-NgR and HA-p75NTR were also analysed, and western blots determined 
that both HA-NgR and HA-p75NTR were expressed in each of the 4 fractions. Larger amounts 
were observed in the membrane fraction, indicating that the protein is predominantly 
expressed at the cell surface. p75NTR has previously been identified at the cell surface [134] as 
has NgR [135].  
Western blot analysis of the C-terminal FLAG tagged proteins (Figure 3.8) revealed similar 
expression patterns. Here, each member of the AMIGO family of proteins was detected in the 
membrane fraction predominantly, with small amounts visible in the WCL, cytoplasmic and 
nuclear fractions. Finally, FLAG tagged LINGO-1, akin to HA-LINGO-1 was expressed in the 
WCL, cytoplasmic and nuclear fractions but was absent from the membrane fraction. This 
evidence, alongside the HA-LINGO cell fractionation results, supports the findings of the 
research by Meabon [126] who suggests that LINGO-1 protein expression is predominantly 
intracellular. The topic of protein transit and localisation has been the subject of intensive 
study for decades, with the particular importance of signaling endosomes highlighted in 
neurons, for example regulating the interactions of NGF with its receptor TrkA 
(Miaczynska2013). To date, there are no detailed mutagenic studies of LINGO-1 permitting 
an analysis of the sequence specific requirements for intracellular localisation or trafficking. 
Using antibodies to the extracellular and intracellular regions of LINGO-1, alongside confocal 
microscopy, de Laat et al (2015) hypothesised that the cytoplasmic region of LINGO-1 binds 
to cytoplasmic proteins that control trafficking through the secretory and/or endolysosomal 
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pathway. The evidence for this remains limited. Henceforth, It may be possible that LINGO-
1 is expressed in the membrane of small organelles such as mitochondria which because of 
their size are extracted as part of the cytoplasmic fraction. Another explanation could be that 
LINGO-1 is rapidly shuttled back and forth from the nucleus to the membrane and therefore 




3.6 Co-immunoprecipitation studies 
Co-immunoprecipitation experiments were performed using HEK293T cells transfected with 
N- terminal HA tagged AMIGO-1, -2 and -3, LINGO-1, NgR and p75NTR in combination with 
C- terminal FLAG tagged AMIGO-1, -2 and -3 and LINGO-1. Three days after transfection, 
cells were lysed; half the lysate was mixed with anti-FLAG beads and half with anti HA beads. 
Bound proteins were eluted and analysed by western blot using the antibody to the 
complimentary precipitating antibody (HA for anti-FLAG beads and FLAG for anti-HA 
beads).  
3.6.1 The AMIGO proteins display homophillic and heterophillic binding 
Western blot analysis of co-immunoprecipitated proteins (Figure 3.9) indicates homophillic 
and heterophillic binding between the AMIGO family members and LINGO-1. These results 
complement and extend previous studies finding homophillic and heterophillic binding 
between the AMIGO family in co-immunoprecipitation studies examining binding between 
GFP- and V5- tagged AMIGO proteins expressed in HEK293T cells.  
Western blots produced using protein purified via anti HA beads and processed with anti-
FLAG antibody were analysed by dividing the membrane into sections. Panel 1 of the western 
blot demonstrates the binding between HA tagged AMIGO-1 and FLAG tagged AMIGO-1, -
2 and -3 and LINGO-1, with bands observed at around 80kDa in size representing AMIGO-1, 
AMIGO-2 and AMIGO-3 FLAG. It is worth noting that AMIGO-2-FLAG appears slightly 
larger in size than AMIGO-1 and AMIGO-3, a likely consequence of the slightly higher Mw 
of AMIGO-2 (57.9kDa) than both AMIGO-1 (52.2kDa) and AMIGO-3 (52.2kDa) and the larger 
number of N-Linked glycosylation sites present on AMIGO-2 than AMIGO-1 and AMIGO-3. 
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Panels 2 and 3 represent binding between HA-AMIGO-2 and FLAG-tagged AMIGO-1, -2 and 
-3 and HA-AMIGO-3 with the FLAG tagged constructs, respectively. Bands are observed at 
around 80kDa, demonstrating binding between HA-AMIGO-2 and HA-AMIGO-3 with the 
FLAG-tagged AMIGO proteins. Differences are observed in the intensity of the bands, this 
could be due to true differential binding or may be the result of technical artefacts. Panel 4 
details the binding between HA-LINGO-1 and the FLAG-tagged AMIGO and LINGO 
constructs; although the intensity of the bands in this blot are weak, binding can be observed 
between AMIGO-1-FLAG and AMIGO-2-FLAG and HA-LINGO-1. 
Analysis of binding using anti-FLAG beads and anti-HA antibody (Figure 5.10) identifies 
binding between all members. Here, bands at around 70kDa can be observed in panels 1 and 
3, which illustrate binding between HA-AMIGO-1 and HA-AMIGO-3 respectively, with the 
FLAG-tagged constructs. HA-AMIGO-2 also binds all members of the AMIGO family and 
LINGO-1-FLAG as observed by bands at 80kDa in panel 2 representing the detection of HA-
tagged AMIGO-2. Finally, binding between HA-LINGO-1 and the AMIGO family members 
was illustrated by bands at around 100kDa in panel 4, representing the HA tagged LINGO-1 
proteins.  
Further western blots confirmed the already established binding between NgR, P75NTR and 
LINGO-1 and further demonstrated binding to the AMIGO family members (Figure 3.11). 
Bands are observed at approximately 70kDa and approximately 100kDa when probed using 






Figure 3.9. Co-immunoprecipitation studies  
N-terminal HA tagged and C- terminal FLAG tagged proteins were expressed in HEK293 
cells. Proteins were immunoprecipitated using anti-HA beads and analysed by western blot 
using anti-FLAG antibody. Panels 1,2, 3 and 4 represent binding between N-terminal HA 











Figure 3.10. Co-immunoprecipitation studies.  
N- terminal HA-tagged and C- terminal FLAG-tagged proteins were expressed in HEK293 
cells. Proteins were immunoprecipitated using anti-FLAG beads and analysed by western blot 
using anti-HA antibody. Panels 1,2,3 and 4 represent binding between N-terminal HA tagged 









Figure 3.11. Co-immunoprecipitation studies 
N- terminal HA-tagged and C-terminal FLAG-tagged proteins were expressed in HEK293 
cells. Proteins were immunoprecipitated using anti-HA beads. Samples were analysed by 
western blot using antibodies against FLAG-tags. Panels 1 and 2 represent binding between 




3.7. Expression of the members of the NgR complex  
The distribution of NgR in the mouse nervous system has been described in detail by Wang 
et al [129] previously, who described the NgR protein as being present in all layers of the 
adult, but not neonatal, neocortex, based on western blot approaches. The group also found 
NgR protein strongly expressed in a number of discrete classes of neurons. Information is also 
available on the expression of NgR in zebrafish, where NgR homologues are found early 
during development, and prominently in the adult brain [136]. However, the expression of 
NgR in human brain is less well established. While the expression of NgR during foetal 
development has been described to some extent, expression of NgR in the adult brain is less 
well known. Research by Halabiah et al [137] found that NgR is expressed during foetal 
development, where the strongest expression is observed in post mitotic cells.  
P75NTR expression has been explored at the mRNA level in the mouse and rat CNS where it is 
detected early during development, however levels of p75NTR decrease in adult stages of 
development. During development NGFRs are expressed in non-neuronal tissues [138]. 
LINGO-1 is exclusively expressed in the neurons and oligodendrocytes of the central nervous 
system [68, 70], whereas it is absent in non-neuronal tissues [68].  Like p75NTR, LINGO-1 
mRNA levels peak during development and decline thereafter into adulthood where they 
remain at background levels until after axonal injury, whereupon an increase in expression is 
seen [68]. At a cellular level, LINGO-1 associates with NgR and p75NTR at the cell surface. Here, 
the actions of LINGO-1 can be inhibited by antibodies and LINGO-1-Fc fusion proteins, which 
further highlight the importance of the protein at the cell surface. However, more recently, in 
more detailed studies it has been suggested that very little LINGO-1 is expressed at the cell 
surface and that the protein is instead primarily expressed intracellularly [126].  In this study, 
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cell surface proteins were biotinylated with a membrane impermeable reagent and detected 
using a fluorescently labelled streptavidin, which failed to detect LINGO-1 at the plasma 
membrane; instead LINGO-1 was located as intracellular punctae, which presumably 
represent intracellular membrane vesicles [126]. Further investigations, using a LINGO-1 
antibody directed against the extracellular domain of LINGO-1, also failed to detect any 
LINGO-1 at the surface of non-permeabilized cells of the developing rat cortex [126].  
The AMIGO family of proteins exhibit variable tissue expression patterns, with AMIGO-1 and 
AMIGO-2 highly expressed in the mammalian CNS and AMIGO-3 more widely expressed in 
a number of tissues [82, 97, 103]. Expression of the AMIGO protein in zebrafish has also been 
investigated, with AMIGO-1 identified as being the predominant member of the AMIGO 
family expressed in the zebrafish CNS [105].  The subcellular location of AMIGO-2 has been 
investigated previously, by fusion with enhanced green fluorescence protein (EGFP). The 
DEGA/ AMIGO-2-EGFP fusion protein was observed in the plasma membrane [101].  
5.7.1. Validating the effectiveness of the native antibodies  
Prior to testing for expression of members of the NgR complex in human tissues and cell lines, 
the antibodies that were to be used were tested on HEK293T cells transfected with N-terminal 
HA-tagged versions of the proteins. Transfected cells were lysed and analysed by western 
blot next to untransfected HEK293T cells, using anti-HA antibody and corresponding native 
antibodies. Detection of each protein would provide an indication of the effectiveness of the 
antibody as well as information about their expected sizes.  Western blot PVDF membranes 
were then chemically stripped, re-blocked and re-probed with anti-HA antibody in order to 
a) confirm that the protein was expressed and b) establish the size of the protein for 
comparison against the native antibodies.  
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Analysis of cell lysates using native antibodies identified AMIGO-1, and AMIGO-3 around 
70kDa (Figure 3.12a); although the AMIGO-1 signal was very weak the apparent size of the 
respective band appeared to correlate with AMIGO-1. When re-probed with anti-HA 
antibody (Figure 5.12b) bands were observed at the same size confirming the bands detected 
in a) represent AMIGO-1 proteins. However, although AMIGO-1 and AMIGO-3 were 
detected as single bands 70kDa in size, AMIGO-2 was detected as multiple bands, likely 
representing non-specific binding or alternatively protein degradation products, with a most 
prominent band observed at around 35kDa. Critically, a similar banding pattern was detected 
in untransfected cells, suggesting that either the transfection protocol does not work for this 
specific construct (unlikely as both HA- and FLAG-tagged constructs are detectable), or 
alternatively that the antibody does not detect AMIGO-2 with any degree of efficiency in 
western blotting. Analysis of the blot using the anti-HA antibody demonstrated the protein 
was expressed as it should have been, with a band observed at around 70kDa, slightly larger 
than those seen for AMIGO-1 and AMIGO-3 as observed previously (Figure 3.2) thereby 
indicating that the native antibody is poor. Analysis of the anti-NgR and anti-p75NTR 
antibodies reveals that they are suitable at detecting the protein in the cell lysates. p75NTR was 
detected as a doublet, with the smaller band observed at around 70kDa and the larger at 
around 100kDa, likely representing unglycosylated and glycosylated species of the protein 
respectively. Analysis of the blot using anti-HA antibody shows a single band at 70kDa as 
observed in previous western blots. The anti-NgR antibody identified the protein in both the 
transfected and untransfected HEK293T samples, demonstrating that a) NgR is expressed at 
high enough levels in the untransfected cells to permit detection, and b) the antibody is 
extremely sensitive. In the transfected samples, NgR is detected as a doublet, with bands 
observed at 70kDa and 100kDa. Of interest, a significantly weaker single band at 70kDa was 
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observed in untransfected cells. The reason for this is unclear, but may suggest low levels of 
endogenous NgR in HEK293T cells, with the smaller MW deglycosylated form of NgR 
detected by the respective antibody. The presence of a primarily neuronal protein such as NgR 
might be seen as unexpected in HEK293T cells, which are thought to be of human embryonic 
kidney (HEK) cell origin. Detailed examination of the RNA and protein expression patterns 
of HEK cells suggest that, in fact, several neuronal proteins such as Neurofilaments are found 
in HEK cells [139]. It is not surprising that other proteins, thought primarily to be of neuronal 





Figure 3.12. Assessing the effectiveness of native antibodies.  
HEK293T cells were transfected with N- terminal HA tagged proteins, cell lysates were 
analysed by western blot alongside untransfected cell lysates (Right lane of each panel, ‘-’).  
a) Lysates were probed with; Anti AMIGO-1, Anti-AMIGO-2, Anti-AMIGO-3, Anti-LINGO-
1, Anti-NgR and Anti-p75NTR. antibodies.  
b) Membranes were then stripped, and re-probed with anti HA antibody. 
The blots demonstrate that the antibodies used to detect AMIGO-1 and AMIGO-2 are poor, 




3.7.2. Expression of members of the NgR complex proteins in human oligodendrocyte cell 
line. 
Some of the challenges in detecting native AMIGO family members were highlighted in the 
HEK293T transfection experiments. Further validation was sought using an immortalised cell 
line, potentially expressing more physiological levels of the respective proteins.  
The human glial oligodendrocyte cell line, MO3.13, was used to test for native expression of 
each of the NgR complex proteins. MO3.13 cells are derived from a human glial 
oligodendrocyte hybrid cell line, furthermore they express the characteristics of primary 
oligodendrocytes and once mature, the cells express myelin basic protein (MBP) [140]. This 
immortalised cell line was used as the biochemical properties of LINGO-1 have been best 
characterised in this type of cell, rather than the more limited experiments in neuronal cell 
lines.  
Expression of NgR, p75NTR, LINGO-1 and the AMIGO proteins in MO313 cells were 
determined by western blot analysis of cell lysates using the antibodies for each native protein 
(Figure 3.13) as discussed in section 3.8. Each protein was detected in MO313 cells at varying 
levels of signal, but this may be due to the effectiveness of the antibody rather than being an 
indication of actual expressed levels of protein. NgR was detected at around 70kDa 
representing the glycosylated form of the protein observed in transfected HEK293T cells, and 
another less prominent band was also observed at around 200kDa which is possibly a dimeric 
form of the protein. P75NTR was also detected at 70kDa, as in HEK293T cells, but also at 
approximately 55kDa, not observed in HEK293T cells, and probably corresponds to a cleaved 
form of p75NTR . The third member of the NgR complex, LINGO-1 was observed as a very faint 
band of approximately 100kDa, likely representing the glycosylated species. The faintness of 
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the band may indicate that either the protein is expressed endogenously at low levels, or the 
antibody is relatively poor. However, having determined the effectiveness of the antibody in 
transfected HEK293T cells it is more likely that the former is true and the levels of LINGO-1 
are low.  
Analysis of the expression of the AMIGO proteins was more complex. The AMIGO-1 protein 
was detected as two bands at 55kDa and 25kDa, the former being akin to the deglycosylated 
version seen in HEK293T expression. The band at 25kDa may represent a breakdown product 
detected by the polyclonal antibody, raised to an unspecified epitope in the C-terminus of 
AMIGO-1.  No bands were observed at 70kDa as expected for a mature protein.  Multiple 
bands were detected in the AMIGO-2 western blot, however the most prominent band was 
observed at around 35kDa, analogous to the species detected previously in HEK293T cells 
analysed using native antibody (Figure 3.12). Finally, AMIGO-3, like AMIGO-1, was observed 






Figure 3.13. Native expression of target proteins in MO3.13 cells 
MO3.13 cell lysates were analysed by western blot to test for the expression of AMIGO-1, -2 







3.8 Expression of NgR receptor complex proteins in human brain lysates.  
The results from the MO3.13 series of experiments further highlighted some of the difficulties 
with the use and interpretation of western blotting of proteins using relatively poorly 
characterised polyclonal antibodies. Furthermore, as the cell line is immortalised and clonal, 
the expression levels for any given protein may not be representative of the expression seen 
within native CNS tissue. 
To determine if AMIGO was expressed in the human CNS at levels that could be detected in 
the laboratory, a human brain lysate was analysed by western blot (Figure 3.14). A sample of 
human brain was lysed and aliquoted, SDS sample buffer was added and SDS-PAGE carried 
out prior to transfer onto PVDF membrane. Each membrane was tested individually using 
antibodies directed against AMIGO-1, AMIGO-2, AMIGO-3, LINGO-1, NgR and p75NTR. The 
blots revealed that each of the proteins of interest was detected in the human brain lysate but 
at varying levels (Figure 3.14).  Again, it was difficult to know whether the levels observed on 
western blot were a true representation of levels of each protein in the brain or due to the 
differing levels of effectiveness of each antibody. 
NgR, which is expressed throughout the CNS, can be observed as a prominent band at around 
70kDa, which coincides with the glycosylated form of the protein observed in previous 
western blots. However, p75NTR was not as easily visualised in the brain lysate using the 
antibody available and appeared as a number of bands of varying sizes suggesting 
fragmentation of the protein, a phenomenon that has been shown a number of times 
previously. P75NTR undergoes a series of proteolytic and intracellular compartmentalisation 
events, with regulated intracellular proteolysis causing shedding of the ectodomain of p75NTR 
by α-secretases resulting in the formation of a C-terminal membrane bound fragment (CTF). 
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The CTF can then be cleaved by γ-secretases, which releases the intracellular domain (p75ICD) 
[141, 142]. Based on previous western blot analysis of p75NTR expression, the bands identified 
by western blot represent the full-length protein, the p75 extracellular domain (P75ECD), the 
p75 C-terminal fragment (p75CTF) and the p75 intracellular domain (P75ICD) [143]. 
Breakdown of proteins is a key issue when examining post mortem brain tissue samples, 
which would be subject to apoptosis and/or necrosis.  
The western blot shows the third member of the NgR complex, LINGO-1, is also identifiable 
and appears at around 100kDa in size, which is similar to that observed previously in human 
brain tissue from MS patients [144]. The AMIGO family members are more difficult to identify 
in the human brain lysate, however, as mentioned previously, this may be due to their variable 
expression and/or antibody specificity/sensitivity. AMIGO-3 is difficult to detect in the lysate 
with no visible bands observed, indicating very little expression as the antibody was 
previously shown to be fairly sensitive in the MO313 lysate as compared to AMIGO-1 and 
AMIGO-2. AMIGO-1 was identified, albeit faintly, at around 55kDa in size, corresponding 
again to the non-glycosylated form of the protein and AMIGO-2 appeared as a more 
prominent band at around 35kDa in size, which suggests that the band observed represented 





Figure 3.14. Expression of proteins of interest in human brain. 
Human brain lysates (non-neurological control) were run on SDS-PAGE and analysed by 
western blot using native antibodies against human AMIGO-1, AMIGO-2, AMIGO-3 LINGO-
1, NgR and p75NTR. The results are variable, with NgR being easily identifiable and the other 
proteins being difficult to identify. AMIGO-1 appears to be present at the expected size of 
55kDa however the band is very faint, the same is true for LINGO-1 which can be seen as a 
very faint band at 100kDa. AMIGO-3 cannot be identified and AMIGO-2 is seen at 35kDa as 
seen in both the MO313 and HEK293T cell lysates. p75NTR has been cleaved and is seen a s 









The LRR and Ig domain containing proteins AMIGO-1, -2, -3 and LINGO-1 were expressed, 
alongside NgR and p75NTR, and their subcellular localisations, and binding abilities were 
assessed. Analysis of the proteins’ expression in human cell lines and tissues was also 
examined to determine whether the AMIGO family members could be functional interactors 
within the NgR/p75NTR complex. The background to this was discussed in the introduction.  
Expression of the AMIGO proteins in HEK293T cells demonstrated glycosylation, consistent 
with previous findings (AMIGO-1 [120, 145]). Indeed AMIGO-1, -2 and -3 contain 5, 8 and 5 
predicted N-linked glycosylation sites respectively, which are thought to add around 2kDa 
per glycan to the mass of the protein [131].  Deglycosylation using PNGaseF demonstrated 
the proteins were approximately 55kDa in size in their unglycosylated forms. Similarly, 
LINGO-1, NgR and p75NTR also displayed varying levels of glycosylation. Expression of 
AMIGO-1 in mammalian cells produces a much more heavily glycosylated form of the protein 
than that produced in insect cell hosts. Drosophila expression of the AMIGO-1 ectodomain 
produced a 40kDa protein compared to the 70kDa species observed from the mammalian host, 
and this observation has been described previously [120].   
An interesting observation on western blots throughout the expression of the AMIGO 
proteins was a band of around 20kDa in size consistently detected in AMIGO-2 cell lysates. It 
is likely that this band represents a cleavage product. By predicting the molecular weights of 
the AMIGO-2 domains using Uniprot and Expasy it was possible identify where cleavage may 
occur. It is likely that the fragment detected is the intracellular portion of the protein, cleaved 
extracellularly. As described in section 3.4 the cytoplasmic domain is predicted to be 10.8kDa 
in size. The addition of the transmembrane domain increases the predicted fragment size to 
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13.1kDa, but at around 20kDa in size, the fragment is significantly larger. Additionally, there 
are no N-linked glycosylation sites present in the intracellular domain so the size difference 
cannot be attributed to these. Therefore, one can deduce that cleavage must occur somewhere 
in the extracellular domain, although cleavage is likely to be membrane proximal based on 
the size of the fragment. It is also worth noting that the migration of proteins through SDS-
PAGE is based on both their mass and overall net charge so proteins may not always migrate 
as expected. To determine the exact nature of the fragment, the band observed at around 
20kDa in WCL samples could be excised and analysed by mass spectrometry. Whilst this was 
planned, it was not performed due to time limitations.  
Upon further investigation of the supernatant of HA-AMIGO-2 transfected HEK293T cells, 
only the mature full-length protein was identified. Addition of anti-HA beads to the 
supernatant only resulted in making the band at 70kDa, representing the full-length protein, 
more prominent. By identifying the intact (full length) protein in the cell supernatant I have 
demonstrated that the protein is released from the cell via budding or vesicles. However, the 
physiological significance of this phenomenon is unknown. Furthermore, absence of the 
cleaved protein from the supernatant confirms that the protein fragment is in fact the 
cytoplasmic portion of the protein.  The supernatant was only analysed using an antibody 
against the N-terminal tag and it would be beneficial to analyse the supernatant of AMIGO-2 
transfected HEK293T cells using an antibody directed against the C-terminal end of the 
protein, to determine if the cleaved fragment, identified in WCL, is released.  
It is interesting that the band was observed only in AMIGO-2 lysates and was absent from 
both AMIGO-1 and AMIGO-3 lysates.  Since each protein was subjected to identical protocols, 
the cleavage must be an intrinsic property of this protein in particular. This leads to the 
103 
 
question of how AMIGO-2 differs from AMIGO-1 and AMIGO-3? The AMIGO proteins 
display similarity at the amino acid level of 48-50% and although only the structure of 
AMIGO-1 ectodomain has been determined, those of AMIGO-2 and AMIGO-3 are predicted 
to be very similar. AMIGO-2 has previously been identified in a number of studies, each 
identifying the protein’s involvement in a different condition. AMIGO-2 mRNA was 
identified in gastric adenocarcinoma [101], where it was differentially expressed in 45% of 
gastric adenocarcinoma samples compared to a very low level of expression in normal tissue 
suggesting that AMIGO-2 may be required for tumorigenisis of human gastric 
adenocarcinomas [101]. Other studies have demonstrated that overexpression of AMIGO-2 
inhibits apoptosis in cerebellar granule neurons [100], thereby promoting survival. More 
recently, AMIGO-2 was identified as significantly upregulated in rheumatoid arthritis 
synoviocytes exposed to IL-17A/TNF, in an ERK-dependent manner, with expression 
correlating with increased cellular adhesion, survival and proliferation [146]. There is no 
information suggesting the involvement of AMIGO-1 or -3 in these studies, highlighting the 
differing functions of the AMIGO family members. Determining the structures of AMIGO-2 
and AMIGO-3 may provide more information regarding the cleavage of AMIGO-2 and the 
varying roles each protein has.  
Cell fractionation experiments demonstrated the cellular membrane localisation of the 
AMIGO proteins which also includes plasma, mitochondria and ER-golgi membranes. 
Similarly, NgR and p75NTR were also identified in the cellular fraction. The matching cellular 
locations increases the possibility of interactions between the proteins of interest. Interestingly 
the cellular location of LINGO-1 was identified as predominantly cytoplasmic, supporting 
previous findings by Meabon et al. [126] who demonstrated native, endogenously expressed 
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LINGO-1, was found exclusively on intracellular membranes, including on membranes of the 
endocytic pathway. The group reasoned that the protein may transiently visit the cell 
membrane.  
As detailed in previous chapters, the specific role of LINGO-1 within the NgR/p75NTR/LINGO-
1 complex remains the subject of ongoing debate and research, due in part to the expression 
of LINGO-1 remaining low until 14 days after injury to the CNS [107]. The same group that 
described the intracellular location of LINGO-1, also describe the apparent competition 
between LINGO-1 and NgR for binding to p75NTR [126]. Since LINGO-1 and NgR are 
structurally related, with both containing both LRR and Ig domains, it is plausible to suggest 
that they bind p75NTR in a similar manner.  However, it is difficult to describe a model detailing 
the sequential binding between NgR/LINGO-1 and p75NTR due to the intracellular expression 
of LINGO-1. There are two possible solutions to this (i) LINGO-1 is shuttled to the cell surface 
when needed, as mentioned previously, or (ii) p75NTR is internalised to allow association with 
LINGO-1 on endosomes [126].  
In this chapter, I also confirmed homophillic and heterophillic binding of the AMIGO family 
of proteins using co-immunoprecipitation experiments, and have demonstrated their ability 
to bind LINGO-1, NgR and p75NTR. Indeed, binding between the AMIGO proteins has been 
demonstrated previously [97] and the indication of a role for AMIGO-3 in the complex has 
also been mentioned before [107]. However, the results in this chapter provide the first 
evidence that each individual AMIGO family member can interact with both NgR and p75NTR 
in vitro, highlighting the possibility of these proteins playing a role within the NgR complex. 
There are numerous methods for analysing protein-protein interactions, each with relative 
advantages and potential for the introduction of methodological artefacts. A comprehensive 
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review of the respective merits of each technique is beyond the scope of this thesis, however, 
it is worth noting that much of the work in this chapter involved overexpression of the 
proteins of interest, meaning that the assembly of protein complexes may not be a true 
representation of physiological conditions. Furthermore, overexpression or tagging may 
cause a protein to become incorrectly localised, therefore it is beneficial to study the 
localisation of endogenous proteins. However, this requires the availability of highly specific 
primary antibodies. A problem with detection of endogenous proteins is that the components 
of the protein complex may not be expressed sufficiently in the cell lines studied [147].  
Whilst the results from HEK293T transfected cells are relatively straightforward to analyse, 
the results obtained from native tissue work were much more challenging, due largely to the 
reliability and sensitivity of the native antibodies. We were able to identify the expression of 
some of the proteins of interest in both the human oligodendrocyte cell line, MO3.13, and in 
human brain tissue lysate but it is difficult to determine if the results obtained were a true 
representation of expression, or were the result of the success or failure of the native 
antibodies. 
If the effectiveness and reliability of the native antibodies had been better, further tests to 
identify the subcellular localisations of the proteins of interest in the human cells would have 
been completed, as would further co-immunoprecipitation experiments.  
The results in this chapter have provided the first indications of binding between the AMIGO 
proteins and NgR and p75NTR. However, to confirm such interactions, further experiments to 
























Crystallisation and structure determination of human AMIGO-1 ectodomain 
 
4.1 Transfection of Drosophila S2 cells 
Previous studies have revealed that LRR and Ig domain containing proteins have been 
expressed in multiple eukaryotic expression systems [69, 148, 149] For example, LINGO-1 and 
LRIG-1 have both been expressed in CHO [148] and HEK-293 cells [149]. Notably, the crystal 
structure of the LINGO-1 ectodomain was generated from protein expressed in CHO cells [69]. 
However, the mouse AMIGO-1 structure, which is the closest existing homologue to human 
AMIGO-1, was derived from protein expressed in Drosophila S2 cells.  Based on these 
considerations, the human AMIGO-1 ectodomain (Figure 4.1) incorporating residues 28-362 
(hereafter referred to as AMIGO-1), was cloned into Drosophila expression vectors by the 
Protein Expression Facility (University of Birmingham).  
4.2 S2 cells expression and induction 
Initial expression of AMIGO-1 in Drosophila S2 cells was performed on a small scale. This 
involved inducing a small volume of cells (7ml at a density of 1x 106/ml) with copper sulphate 
(CuSO4) and retaining samples of supernatant after 2, 3 and 4 days to determine the optimal 
time for harvesting cells. Expression levels were analysed by western blot using an anti-His 
antibody to detect the His tag located at the C-terminal end of the AMIGO-1 ectodomain 
protein (Figure 4.2a). Human AMIGO-1 was shown to be expressed at equivalent levels at 
each time course interval examined as demonstrated by bands on the western blot at 
approximately 40kDa which coincide with the predicted size of the AMIGO-1 ectodomain 
(40.8kDa). The lack of sizeable shift on the SDS-PAGE gel also indicated that the human 






Figure 4.1. Schematic diagram of the domain organisation of AMIGO-1. 
The AMIGO-1 ectodomain contains an Ig-like domain and 6 leucine rich repeats (LRR) 
flanked by cysteine rich capping domains (LRRCT/LRRNT). The predicted size of the Ig –like 
domain is 9.1 kDa and the LRR domain including capping domains is 28.7 kDa, therefore the 
predicted size of both domains together is 37.8 kDa. Drosophila expressed AMIGO-1 
ectodomain is 40.8kDa in size, the difference between these is because the expressed protein 
also contains biotinylation and 6 x His tags which together are 3kDa in size. The positions of 





derived mouse AMIGO-1 ectodomain which was shown to migrate at approximately 43kDa 
by SDS-PAGE [120]. Interestingly, this observation contrasts to mammalian (HEK-293) 
derived full length mouse AMIGO-1 which appears as a band approximately 75kDa in size 
on SDS-PAGE despite the fact that the predicted size is actually 55kDa thereby indicating 
heavy glycosylation.  
Hence in subsequent large scale preparations, to maximise AMIGO-1 expression levels, 
Drosophila S2 cells were harvested after a 4-day induction interval.  
4.3 Purification by Nickel chelate and Size exclusion chromatography 
Recombinant human AMIGO-1 containing supernatant from S2 cells was purified by Ni-NTA 
chromatography. Ni-NTA purification is a simple and a relatively robust technique for 
purifying proteins with a His-tag in sufficient enough quantities for structural studies as 
highlighted for mouse AMIGO-1[120]. To achieve optimal binding of His-tagged human 
AMIGO-1 to the nickel beads, the S2 supernatant was dialysed to remove compounds from 
the supernatant such as excess CuSO4, surfactant and low molecular weight amino acids, 
which may compete with the target protein for binding. The dialysed supernatant containing 
AMIGO-1 was passed over a column containing nickel beads to which the His-tag bound. 
Typically, between 3-6 mg of protein was eluted off the nickel column with Ni-NTA elution 
buffer (250mM Imidazole in PBS) from 1L of Drosophila S2 cells and stored at -20°C. 
Unfortunately, SDS-PAGE analysis of Ni-NTA eluted AMIGO-1 was hampered by the fact 
that approximately 90% of eluted protein was prone to precipitation despite thawing the 
sample on ice. This highlighted that the Ni-NTA elution buffer containing PBS was unsuitable 
for stabilising and maintaining AMIGO-1 in solution. In addition, the Ni-NTA elution buffer 
contained phosphate which has proven in the past to be an undesirable component for 
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crystallisation as it can readily react with metals found in the commercial crystallisation 
buffers resulting in the formation of salt crystals. Based on these considerations the protein 
was buffer exchanged into a suitable buffer free from phosphate. The selection of the 
appropriate buffer for AMIGO-1 was heavily dependent on its isoelectric point (pI). 
Generally, selecting a buffer with several pH units away from the pI of the target protein is an 
ideal start point for identifying a stable buffer that could potentially reduce the precipitation 
effects. Based on the primary sequence, the pI of AMIGO-1 was calculated to be 6.21 using the 
EXPASY server [150]. Hence, in the subsequent production of AMIGO-1, the Ni-NTA eluted 
protein was buffer exchanged into a buffer consisting of 20mM Tris pH 8.5 + 50mM NaCl in 
readiness for size exclusion chromatography.  Notably, the Tris buffer was supplemented 
with NaCl to further reduce the risk of protein aggregation. Additionally, there was 
precedence for successfully using a similar buffer in protein purification and crystallisation 
trials as documented for mouse AMIGO-1 [120]. SDS-PAGE analysis of the eluted protein 
demonstrated a substantial band migrating at ~40kDa (Figure 4.2b), consistent with the 
predicted molecular weight of the human AMIGO-1 ectodomain. In addition, there was a 
noticeable shift in bands observed between the reduced and non-reduced samples suggesting 
that the protein has fully formed disulphide bonds. Furthermore, the gel illustrated low levels 
of large molecular weight contaminants, suggesting that additional purification with size 
exclusion may be necessary before proceeding to crystallisation trials. 
Strikingly, there were no visible signs of AMIGO-1 aggregation/precipitation following the 
buffer exchange step into the new buffer. The size exclusion step was performed with the 
Superdex 200 column on the FPLC which had been pre-equilibrated with 20mM Tris pH 8.5 + 
50mM NaCl. A single peak of 100mAu at 190ml was observed on the resulting S200 elution 
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profile (Figure 4.2c). However, the monomeric form of human AMIGO-1 ectodomain was 
expected to elute at 210ml. Based on molecular weight standards, the peak corresponded to a 
protein that is 80kDa in size. The substantial shift in peak to around 190ml could reflect the 
fact that the AMIGO-1 protein exists as a dimer in solution. This notion is supported by 
previous biophysical and structural studies on the mouse AMIGO-1 ectodomain, which 
formed  dimers  in solution form and within the crystal lattice [120]. In addition, another 
member of the LRRIG family, LINGO-1, formed a tetramer in crystal form which can be 
assembled as either a dimer of dimers or form four monomers [69]. 
SDS-PAGE analysis of the peak fraction at 190 ml, under reducing and non-reducing 
conditions, illustrated a single band of approximately 40kDa in size, which was consistent 
with the predicted size of the AMIGO-1 ectodomain (Figure 4.2d). More importantly, this 
confirmed that the AMIGO-1 ectodomain forms a dimer in solution. Furthermore, following 
size exclusion purification, the purity of the protein appeared significantly increased with the 
high molecular weight contaminants successfully removed. The protein was therefore 
deemed to be of sufficiently high purity for entering crystallisation trials. The peak S200 
fractions were pooled together and concentrated to a final concentration of 10mg/ml. By 
achieving such high concentrations, it confirmed that the TRIS-NaCL buffer at pH 8.5 was 







Figure 4.2 Production of human AMIGO-1 ectodomain.  
a) Western blot analysis of human AMIGO-1 on day 5 after induction with CUSO4. Sufficient 
levels of AMIGO-1 can be seen in the supernatant of the Drosophila.  b) Expressed AMIGO-1 
was purified by Ni-NTA and eluted into PBS + 250mM imidazole, following buffer exchange 
into 20mM Tris pH 8.5 + 50mM NaCl the protein was analysed by SDS-PAGE under reducing 
(R) and non- reducing (NR) conditions. The SDS-PAGE shows large bands running at the 
predicted size of the AMIGO-1 ectodomain (40.8Kda) which indicates that the protein is a 
monomer and is not heavily glycosylated. There are also higher molecular weight bands 
visible which are contaminants that need to be removed by gel filtration. C) Elution profile of 
human AMIGO-1 following purification by size exclusion chromatography. AMIGO-1 
protein was purified by size exclusion chromatography using the S200 column. A single peak 
of ~100 mAu is observed at 190ml which corresponds to a protein with a Mw of 80kDa.  This 
suggests that AMIGO-1 ectodomain exists as a dimer in solution. d)  SDS-PAGE analysis of 
human AMIGO-1 following purification by size exclusion chromatography. Following gel 
filtration peak fractions (elution volume 190ml) were pooled and analysed under reduced (R) 
and non-reduced (NR) conditions.  The high molecular weight contaminants have been 
removed and only bands at ~40kDa are seen which correspond with AMIGO-1 (40.8kDa, black 
arrow).   
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4.4 Overview of X- ray Crystallography 
X- ray crystallography is a widely used technique for determining the three-dimensional 
structure of proteins at a molecular level. The information obtained by X-ray crystallography 
can be used to ascertain the functions of the protein including identifying how they interact 
with other molecules and the knowledge obtained can be used in the design of functional 
studies and drug design. The accuracy of the structures derived by X-ray crystallography can 
be extremely high; however, the amount of structural data that can be extracted from a 
structure is heavily reliant on the quality of the protein crystal. There are numerous steps 
involved in determining the three-dimensional structure of protein using X-ray 
crystallography (Figure 4.3) and these have been highlighted in further detail below.  
4.4.1 Protein crystallisation: Theory 
The first requirement for determination of the protein structure is to generate well-ordered 
diffraction-grade crystals. However, this step represents one of the largest obstacles in X-ray 
crystallography as the identification of crystallisation conditions appropriate for crystal 
growth is largely a multi-dimensional search by trial and error. The overall aim in 
crystallisation is to minimize protein-solvent interactions and maximise protein-protein 
interactions. This can be achieved by bringing the protein solution to a supersaturated state, 
thereby increasing the likelihood of protein molecules interacting with each other. 
Crystallisation occurs in three key stages; nucleation, growth and termination.  Nucleation 
involves the formation of small aggregates, called nuclei which provide a site for crystal 
growth. The growth of the crystal is achieved by protein molecules being recruited to the 




Figure 4.3. An overview of X ray crystallography. 
Protein obtained from the drosophila expression system is purified and subjected to 
crystallisation trials. Suitable crystals are exposed to an X-ray beam which diffracts X-rays that 
are recorded by an X-ray detector.  The diffraction data is processed to produce an electron 
density map. The electron density map is then interpreted allowing model building and 
refinement to take place using a computer graphics workstation.  The molecular structure is 
then subjected to numerous cycles of model building and refinement leading to a final protein 






stage in crystallisation is termination, whereby the crystal ceases to grow due to growth 
defects, presence of contaminants or depletion of protein molecules.  
For proteins to achieve a super-saturation state and potentially crystallise a reduction in their 
solubility is required.  There are several factors that can influence protein solubility including 
pH, ionic strength and presence of precipitants and these are available as part of commercial 
sparse matrix based screens. Ideal conditions will force the protein molecules in the solution 
to interact with one another in a specific manner that may lead to crystallisation. For example, 
pH has a major influence on crystallisation as the solubility of a protein is at its lowest at a pH 
close to the isoelectric point (pI) of the target protein. As a result, the number of protein-
solvent interactions are minimised and protein-protein interactions are more likely to take 
place. 
4.4.2 Protein crystallisation: Vapour diffusion method 
The vapour diffusion method is the most common technique used for protein crystallisation 
and can be utilised in two ways; hanging drop or sitting drop. Using this approach, it is 
possible to screen for many different crystallisation conditions with the aim of identifying 
conditions that yields protein crystals or can at least provide a hint of crystallisation (e.g. 
straight edged needles). This involves mixing equal volumes of protein solution and 
crystallisation reagent (reservoir solution) on the surface of a cover slip which is then inverted 
over the well containing the crystallisation reagent (Figure 4.4a). Since the precipitation 
concentration in the drop is less than in the crystallisation condition, water diffuses out of the 
drop by vapour diffusion until equilibrium is reached between the drop and the reservoir 
solution. As water diffuses out, the protein concentration in the drop slowly increases 
reaching supersaturated levels at which point protein molecules are forced to interact with 
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each other which can potentially lead to nucleation (crystal growth) or precipitation. The 
precipitation effect is a relatively rapid process caused by non-specific protein-protein 
interactions. In such circumstances, the crystallisation trials are repeated but with a different 
crystallisation reagent. The initial screening process is performed on a small-scale in 96 well 
plates utilising nanolitre drop sizes (typically 100nl) with a mosquito nanolitre crystallisation 
robot. This allows screening of a large number of conditions using small quantities of protein. 
The buffer conditions that yield promising hits provide a basis for optimisation. This involves 
altering buffer and/or protein conditions such as salt concentration, precipitant concentration, 
pH and protein concentration. The optimisation stage can be carried out manually using 24 
well Linbro plates with larger drop sizes (typically between 2-3μl in volume).  Also at this 
stage it is possible to use the sitting drop vapour diffusion technique which in principle works 
in the same manner as the hanging drop method but the drop is placed onto a rod which sits 
in the well before sealing with the coverslip (Figure 4.4b). Generally, the time duration for 
crystal growth is heavily dependent on the protein but can typically take between 1 and 14 
days.  
Once protein crystals of a suitable size have been grown they are subjected to X-ray diffraction 
experiments. Prior to X-ray data collection, the crystals must be soaked in a cryoprotectant 
solution which helps to protect the crystal from damage caused by X- ray radiation. The 
cryoprotectant also serves as anti-freeze and prevents solution surrounding the protein crystal 
from forming ice crystals which can diffract X-rays and interfere with downstream data 
processing. The cryoprotectant is made from the reservoir solution supplemented with either 
glycerol, ethylene glycol, PEG 400 or 2-methyl-2, 4-pentanediol (MPD). The identification of 
appropriate cryoprotectant conditions is usually performed by trial and error and is 
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dependent on the components of the mother liquor. Once the crystal has been sufficiently 






Figure 4.4 Schematic of vapour diffusion set ups using hanging and sitting drop 
techniques.   
Large-scale hanging drops (a.) and sitting drops (b.) are set up by mixing varying ratios of 
protein: crystallisation reagent (e.g. 1ul +1ul, 2ul + 1ul, 1ul + 2ul and 2ul + 2ul) . The wells are 
sealed with grease to create an enclosed system.  A difference in precipitant concentration 
between the drop and the reservoir solution causes vapour diffusion where water diffuses out 
of the drop. This causes the concentration of protein in the drop to increase promoting more 
protein- protein interactions which may either lead to crystal formation (specific interactions) 




4.4.3 X-ray and data collection 
Data collection from protein crystals involves mounting the crystal in a nylon loop and 
orientating it so that it is in the direct path of an X-ray beam. During this stage crystals are 
maintained at cryogenic temperatures using a nitrogen gas stream to ensure that the least 
amount of X-ray damage occurs to the crystal. The X- rays strike the crystal and the electrons 
surrounding the atoms in the protein diffract the X-ray beam into many discrete beams. The 
diffracted X-rays are recorded by an X-ray detector. To collect a complete dataset the crystal 
is rotated with respect to the X-ray beam.  
4.4.4 Data Processing 
Data processing firstly involves determining the unit cell parameters and space group. The 
unit cell is the simplest repeating unit and building block of a crystal, of which there are 7 
categories. The unit cell dimensions are described by three cell lengths; a, b and c and three 
angles; α, β and γ. Each of the seven categories of unit cell has different imposed constraints 
on these lengths and angles. It is essential to determine these parameters before further 
structure determination can take place. The distances between the spots on the diffraction 
pattern are used to calculate the unit cell parameters. The space group describes how protein 
molecules are arranged within the unit cell. 
X-rays are simple waves that are described by three parameters; frequency, amplitude and 
phase, and knowledge of all three parameters allows for determination of the protein 
structure. The frequency of the wave is known from the wavelength of the X- ray source and 
the amplitude can be determined during data processing where the intensities of the spots are 
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measured and converted to amplitude. The phase of the wave however cannot be determined 
during data collection. 
4.4.5 Determining Phase Information 
There are several methods available to determine the phase information, the most common 
being molecular replacement. With this method, phases are borrowed from a known 
structural homologue as initial estimates for the structure to be determined. The method 
involves superimposing the phasing model onto the target data, and is highly dependent on 
the level of sequence identity between the two proteins. The higher the level of sequence 
correlation between the model and the target structure the easier it is to superimpose. Once 
the models are superimposed the phase information can be extracted and used for the target 
structure.   
However, in cases with proteins exhibiting novel folds, molecular replacement is not possible 
and phase information must be determined experimentally. One technique used to calculate 
experimental phases is multiple isomorphous replacement (MIR) which involves collecting 
data on a native protein crystal and a crystal that has been soaked in a solution containing 
heavy atoms.  Since heavy atoms are electron dense they have a higher atomic scattering factor 
and this in turn alters the intensity of the X-ray reflections. These differences in intensity can 
be used to experimentally determine phase information. Heavy atoms include mercury, gold 
and platinum which are highly reactive towards cysteine, histidine and methionine, and 
lanthanides and actinides which bind to glutamic acid and aspartic acid. For this technique to 
work the unit cell dimensions of the derivative crystal must remain isomorphous to the native 
crystal. X-ray data is collected on the derivative crystal and the difference between the native 
and derivative data sets provides the positions of the heavy atoms. A second isomorphous 
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crystal is then generated using a different heavy atom, to give definitive phase information. 
MIR is useful for generating phase information for novel structures however the processes 
involved are time consuming and there is no guarantee that heavy atoms will bind to the 
atoms after soaking.  
Another method used to determine the phase information is multi wavelength anomalous 
dispersion (MAD). This technique uses anomalous scattering measurements at appropriate 
energies taking into account the strong variations of the scattering factor near an absorption 
edge [151], providing useful phase information which in turn can be utilised to solve 
structures. MAD involves the incorporation of a heavy atom such as selenium into the protein 
sample prior to crystallisation; a single protein crystal is then exposed to X-rays at three 
different wavelengths which can be achieved using a tuneable X-ray source such as a 
synchrotron.  
4.4.6 Model building and refinement 
The combination of amplitude and phase can lead to calculation of electron density maps. An 
electron density map is a map showing the distribution of electrons. Since the electrons 
surround the protein atoms it is possible to interpret the map and build in amino acid side 
chains of the target protein. Model building is usually performed on a computer graphics 
display. The model is then refined with refinement software programmes which adjusts the 
model to best fit electron density and to ensure that bond lengths and angles are correct. 
Alternate cycles of model building and refinement take place before the refined structure is 
determined. Crystals that diffract X-rays to a higher resolution have more detailed electron 
density and therefore amino acid side chains can be placed with a greater degree of certainty.  
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4.5 Structure determination of AMIGO-1 ectodomain 
4.5.1 Crystallisation of AMIGO-1 ectodomain 
AMIGO-1 at a concentration of 10mg/ml was used in small scale crystallisation trials with the 
hanging drop method using 3 sparse matrix based screens; JCSG+ (MDL), INDEX (Hampton 
Research) and Wizard I+II (Emerald Biosystems). In total 288 different buffer conditions were 
screened. Positive ‘hits’ were identified in 3 conditions; JCSG+ condition 20 (0.2M MgCl2, 0.1M 
Tris pH7, 10% PEG 8000) (Figure 4.5a), INDEX condition 66 (0.2M ammonium sulphate, 0.1M 
Bis- Tris pH 5.5, 25% PEG 3350) (Figure 4.5b) and INDEX condition 67 (0.2M ammonium 
sulphate, 0.1M Bis- Tris pH 6.5, 25% PEG 3350) Figure 4.5c). The crystals formed using INDEX 
conditions 66 and 67 were sparse and non-uniform in shape. In contrast, the crystals formed 
grown in JCSG+ condition 20 were higher in number and more uniform shape. Negative 
controls were also set up where the crystallisation buffer was added but protein was excluded 
to ensure that any crystals formed were not crystallised salt. These controls contained no 
crystals indicating that the crystals formed in the trials were derived from protein and not salt. 
Further small-scale crystallisation trials with JCSG+ condition 20 consistently yielded crystals, 
suggesting that this condition was highly reproducible for producing crystals.  Typically, 
these showers of crystals appeared after 1 day and grew to approximately 40μm x 40μm in 
size. The size of these crystals was unsuitable for X-ray diffraction experiments and therefore 
optimisation trials were set up using JSCG+ condition 20.   
The optimisation trials were initially set up on a small scale in an attempt to reduce the 
number of nucleation sites per drop which contributed to the shower of crystals observed. A 
common strategy employed to reduce the number of nucleation sites is to reduce the 
precipitant or protein concentration or both.  However, equilibration of human AMIGO-1 at 
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lower protein concentration (7 mg/ml) against home-made screens incorporating reduced 
concentrations of PEG 8000 (from 10% to 7.5%) failed to generate any crystals. The subsequent 
strategy involved setting up trials using custom made JCSG+ condition 20 in which the PEG 
8000 was unaltered. This large-scale optimisation utilised both hanging and sitting drop 
techniques and drops were set up using differing ratios of protein: crystallisation buffer 
including 1:1 (Figure 4.5d), 1:2 and 1:3 (Figure 4.5e). These large-scale optimisation trials 
resulted in seven large diffraction-grade crystals being formed which were typically 100μm x 
100μm in size.  
Prior to X-ray diffraction experiments the seven crystals were soaked in cryoprotectants that 
had previously been used in the structure determination of proteins that had grown in similar 
crystallisation conditions. Based on this information, four of the crystals were soaked in 
glycerol and three in ethylene glycol. The crystals were soaked in increasing concentrations 
of cryoprotectant, spending 5 minutes in 5%, 5 minutes in 15%, 5 minutes in 20% and finally 






Figure 4.5. Generation of AMIGO-1 ectodomain micro-crystals and large-scale 
optimisation.  
Micro-crystals of the AMIGO-1 ectodomain were identified using the hanging drop method 
with JCSG+ (a) and Index screens (b, c) commercial screens.  Drops were set up by mixing 
100nl of AMIGO-1 ectodomain protein with 100nl reservoir solution and micro-crystals 
appeared after approximately 1 week.  Large diffraction-grade crystals were produced by 
optimising JCSG+ condition 20 (0.2M MgCl2, 0.1M Tris pH7, 10% PEG 8000). Drops were set 





4.5.2 Data Collection and Processing 
X-ray diffraction experiments were performed as described in Chapter 2 (materials and 
methods). Initial experiments revealed that the ethylene glycol cryoprotectant was sub-
optimal compared to glycerol as crystals vitrified with 25% ethylene glycol diffracted to 2.9Å 
whereas those soaked in 25% glycerol diffracted X-rays to 2.4Å resolution. Approximately 6 
data sets were collected (Figure 4.6). Initial data was auto indexed with XDS [116], and the 
crystal was found to belong to the trigonal/hexagonal space group with unit cell dimensions 
of; a= 99Å, b= 99Å, c= 103.4Å and α= 90o, β= 90o, γ= 120o. Diffraction data were integrated, 
scaled and merged using programmes of the XDS suite [116]. The relevant data processing 
statistics are listed in Table 4.1. 
Table 4.1 Data processing statistics for human AMIGO-1 ectodomain. 
X-ray data for AMIGO-1 was integrated, scaled and merged using programmes of the XDS 
suite.  Numbers in parentheses represent statistics associated with the highest resolution shell.  
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In order to circumvent space group ambiguity the data were processed in the lower symmetry 
space group (P3) and input into POINTLESS [123]. Based on POINTLESS the best possible 
space group was highlighted to be P3121 however, unequivocal space group determination 






Figure 4.6 X-ray diffraction pattern of human AMIGO-1 ectodomain. 
A 0.5° oscillation image of the human AMIGO-1 crystal which diffracted X-rays to 2.4Å 
resolution. The data was collected using an in house Micro-Max 007HF rotating anode X-ray 
generator (Rigaku) using a Saturn CCD detector (University of Birmingham Macromolecular 




4.5.3 Determination of Phase Information 
Assuming the AMIGO-1 crystals possess a dimer in the asymmetric unit, a solvent content 
of 31.9% was calculated [152]. Initial determination of phase information for AMIGO-1 was 
carried out by molecular replacement using the mouse AMIGO-1 ectodomain (PDB ID code: 
2XOT) as a search model with MOLREP [117]. The choice of search model was based on the 
high degree of sequence identity (89%) that exists between mouse and human AMIGO-1. 
Unsurprisingly, molecular replacement calculations yielded unambiguous rotation and 
translation function solutions (data not shown) for two AMIGO-1 molecules consistent with 
AMIGO-1 crystallising as a dimer. However, the resulting model failed to refine with R-
factors stalling at around 50% suggesting that there were significant differences between the 
human and mouse AMIGO-1 structures. One possibility was that the AMIGO-1 protein had 
become cleaved during the crystallisation process, and the crystals corresponded to a 
fragment of either the LRR or Ig domain. To investigate this further, samples of AMIGO-1 at 
10mg/ml were stored at either -20oC or at 23oC for 17 days and analysed by SDS-PAGE. The 
samples were run alongside each other on an SDS-PAGE gel which illustrated a noticeable 
size difference between the two samples (Figure 4.7). The sample stored at -20oC ran at the 
predicted size of the AMIGO-1 ectodomain, 40.8Kda, but the sample stored at 23oC 
appeared to run at ~30 kDa. This lower sized band probably corresponds to the LRR domain 
of human AMIGO-1 which is predicted to be 28.7 kDa in size, indicating that the protein has 
been cleaved; this could be tested by removing the band and analysing it by mass 
spectrometry. Interestingly the band appearing at ~30 kDa is made up of multiple bands 
which is also a sign of degradation. The Ig domain of AMIGO-1 is predicted to be 9.1 kDa in 






Figure 4.7 Cleavage of  the AMIGO-1 protein under crystallisation conditions.  
SDS-PAGE analysis of AMIGO-1  (10mg/ml) stored at  either-20oC or at 23oC for 18 days. The 
sample of AMIGO-1 stored at -20oC  continued to run at  ~40kDa, however, the protein 
stored at 23oC  appeared to shift in size to  ~30kDa.  This band is believed to represent  the 
LRR domain of the protein which is 28.7kDa in size which indicates that the protein has 




that the AMIGO-1 protein had become cleaved during storage under X-ray crystallography 
conditions, illustrating the protein is not stable at this temperature. 
With this in mind, molecular replacement was repeated using the mouse AMIGO-1 model 
with the Ig domains omitted. Once again significant rotation and translation function peaks 
were determined for two human AMIGO-1 molecules (Tables 4.2, 4.3 and 4.4). Following the 
first round of refinement of the model the R-factors dropped to 28.7 and R-free to 32.2 with a 
revised solvent content of 45.9% for the AMIGO-1 LRR domain. 
 
Table 4.2 Rotation function statistics for human AMIGO-1 ectodomain.  
The table shows the 5 highest rotation function peaks using the mouse AMIGO-1 (LRR 
domain) monomer as the search model. The correct solutions are shown in red as determined 
by an increase in RF/σ scores.  
 
 
Table 4.3 Translation function statistics for human AMIGO-1 LRR ectodomain. 
The table shows the 5 highest translation function peaks using rotation function angles from 




Table 4.4 Translation function statistics for human AMIGO-1 ectodomain.  
The table shows the 5 highest translation function peaks after fixing the first molecule. The 
correct solutions are shown in red as determined by a further decrease in R factor.   
The molecular replacement solution was validated further by examination of the resulting 
electron density maps which showed distinct features that were associated with human 
AMIGO-1 ectodomain but absent from mouse AMIGO-1 ectodomain (Figure 4.8). For 
example, clear and unambiguous electron density can be observed for residue 123 which is an 
Arginine in human AMIGO-1 but a histidine in the mouse form.  
Model building and refinement demonstrated that the crystals formed and the data that was 
collected was on the LRR domain of the human AMIGO-1 protein; however, data could not 
be collected on the full-length protein (containing the Ig domain) as this did not crystallise.  
Following several rounds of refinement interpreted with manual model building the structure 
of human AMIGO-1 was built. The relevant refinement statistics are listed in Table 4.5. The 
structure was verified using PROCHECK [153] and revealed that most residues were present 
in the allowed regions of the Ramachandran plot (Figure 4.9). Ser-42 of both molecules was 
found in disallowed regions despite well-defined electron density. The residue is located in a 
hairpin loop within the N-terminal capping domain which may account for the distortion.  










Figure 4.8 Electron density maps showing differences between the mouse AMIGO-1 
phasing  model and the human AMIGO-1 target structure following molecular 
replacement. 
Confirmation of the correct molecular replacement solution for hAMIGO-1. The pictures 
display 2Fo-Fc density contoured at 2σ for features that are present in the hAMIGO-1 model 
and not apparent in the mAMIGO-1 structure. In the hAMIGO-1 structure 2Fo-Fc density for 
the Arginine side chain can be seen at position 123, whereas in the mAMIGO-1 structure there 
is Histidine. Similarly, in the hAMIGO-1 structure 2Fo-Fc density for the Valine side chain at 





Figure  4.9  Ramachandran Plot for human AMIGO-1 ectodomain  
The Ramachandran plot allows visualisation of the angles Phi and Psi of amino acids in a 
peptide. The top left quadrant is the region where β sheets lie, the bottom left quadrant is 




4.6  Discussion  
This chapter will be discussed in greater detail in Chapter 5, where we will analyse the 




















































Analysis of the hAMIGO-1 LRR domain structure 
5.1 Overall structure of the hAMIGO-1 LRR domain.  
The crystal structure of the hAMIGO-1 LRR ectodomain (R29-C270) was solved at 2.4 Å 
resolution with R factors of Rcryst/Rfree = 21.4/25.7%.  The crystallographic asymmetrical unit 
contains two molecules in an anti-parallel dimeric arrangement (Figure 5.1). The two 
monomers display an extremely similar conformation with a root mean square deviation of 
0.35Å for 241 Cα atoms. Therefore, unless otherwise stated, molecule A was subjected to 
structural analysis.  Strikingly, no electron density was observed for the Ig domain (G271-
T362) of each monomer despite the fact that the hAMIGO-1 Drosophila construct incorporated 
residues G29-H359. Consistent with the structures of mAMIGO-1[120], hLINGO-1 [69] and 
hNgR [32, 46], hAMIGO-1 adopts a typical curved LRR domain fold with the LRR module 
flanked by cysteine rich capping domains (Figure 5.2a, Table 5.1). The N-terminal capping 
subdomain (LRRNT, residues G29-L59) is characterised by two β-strands that run anti-
parallel to each other and is stabilised by two disulphide bridges mediated between residues 
C34 and C40 and C38 and C47.  
 
The LRRNT domain is followed by six LRRs (Figure 5.2). Each repeat consists of an 11 residue 
fragment with the consensus sequence LxxLxLxxNxL, followed by a variable stretch of 10-12 
residues (Figure 5.2b). The concave side of this LRR domain encompasses one β-strand per 
repeat which run parallel to each other forming a banana shape, consistent with previously 
determined structures of LRR domain- containing proteins with similar length repeats [94].  
The location of the β strands on the concave face is a defining feature of LRR domains. 
Typically these strands are interwoven with various forms of helices, β turns and even short 
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β strands, which are predominantly found at the convex face of the protein [154]. In hAMIGO-
1 each LRR contains the 21-23 residue conserved repeat motif; xLxxLxLxxNxLxxLxxxxFxxLx 
(Figure 5.2b), where L can be substituted with V, I, F, M and T, and F (Phenylalanine) can be 
interchanged with L, V and T.  The length of LRRs determines the type of secondary structural 
motif adopted at the convex face. Indeed, longer repeats (27-29 residues) tend to contain an α 
helix on the convex side whereas shorter repeats are more likely to possess a main chain 
arrangement with interwoven polyproline II helices [154].  Consistent with these 
characteristics, the hAMIGO-1 convex surface is composed mainly of variable loops with three 
short helices. During the course of this study, a crystal structure of mouse AMIGO-1 (referred 
to as mAMIGO-1 from now on) was published. During this chapter, I shall analyse the 
structure of hAMIGO-1 alongside mAMIGO-1 and, later, alongside other structural 
homologues.  
 
Similar to mAMIGO-1, the C-terminal capping subdomain (LRRCT) of hAMIGO-1 (residues 
G215-C270) adopts an irregular fold containing a 12-residue alpha-helix and several short 310 
helical segments [120, 155]. The LRRCT is stabilised by two disulphide bridges, the first of 
which is located immediately after the LRR domain (mediated by C225 and C253) and the 
second at the C-terminal end of the LRRCT (formed by residues C227 and C270). These 
capping domains have important functional roles which include shielding the hydrophobic 









Figure 5.1 Overall structure of the hAMIGO-1 LRR dimer.  
The hAMIGO-1 crystal possesses two molecules in the asymmetric unit (highlighted in orange 
and green). Each monomer adopts a banana shaped fold, with a parallel β-sheet contributing 
to the inner concave face and various secondary structural elements forming the outer convex 








Figure 5.2 Structural characteristics of the hAMIGO-1 LRR domain.  
a) LRR domain structure showing LRRNT (red) LRR1 (pink), LRR2 (blue), LRR3 (grey), LRR4 
(cyan), LRR5 (green) LRR6 (orange) and LRRCT (beige). Disulphide bridges that stabilise the 
LRRNT and LRRCT are highlighted (yellow). b) Sequence alignment of the six leucine rich 
repeats of hAMIGO-1 calculated by PRALINE. The consensus motif for LRR’s is also 
highlighted. The hAMIGO-1 sequence was obtained from Uniprot (accession number 






5.2 Identification of hAMIGO-1 LRR structural homologues   
Proteins with similar structural homology to hAMIGO-1 were identified using DALI software 
[158]. With the exception of mAMIGO-1, the most structurally homologous proteins to 
hAMIGO-1 included Variable Lymphocyte Receptor A [159], Leucine-rich repeat-containing 
G-protein coupled receptor 4 (LGR4) [160], Biglycan [161], Toll Like Receptor 4 (TLR4) [162], 
glycoprotein 1bα [163] and Decorin [94] (Figure 5.3). The Z scores for these proteins, which 
correspond to degree of structural identity, ranged between 21.7 and 25.5 (35.1 for mAMIGO-
1). Despite all homologues encompassing an LRR module, there was a striking variability in 
the number of LRRs found within these domains which ranged between 6 and 22 (Figure 5.3). 
Consequently, this impacts on the overall shape of the LRR domain with proteins 
encompassing a large number of repeats adopting a horseshoe arrangement, whereas those 
with fewer repeats form a banana-like fold. Also, these proteins exhibit contrasting functions 
relative to neuronally-associated hAMIGO-1. For example, LGR4 has been shown to be crucial 
in mediating signalling during both embryonic development and in the adult organism. 
Additionally, it regulates adult stem cell maintenance by associating with proteins involved 
in Wnt signalling [160].  In contrast, biglycan is found in cartilage and plays a key role in 
osteogenesis [161]. Decorin is found in most connective tissues where it regulates the 
formation and organization of collagen fibrils. A second role attributed to decorin is that it 
inhibits calcification of soft connective tissues, thereby preventing calcinosis [161].  Finally, 
TLR4 is an important immune receptor that binds to lipopolysaccharide, which activates the 
innate immune response to microbial infection [162].  Interestingly, neuronally expressed 
proteins that also encompass the LRR fold, namely LINGO-1 and NgR, were found further 
down the DALI-derived list of structurally homologous proteins to hAMIGO-1 with Z scores 





Figure 5.3 Structurally homologous proteins to hAMIGO-1. 
 The six most homologous proteins to hAMIGO-1 identified with DALI are highlighted a) Sea 
lamprey variable lymphocyte receptor (pdb code 3M19), b) Western clawed frog LGR4 (pdb 
code 4LI1), c) bovine biglycan (pdb code 2FT3), d) Mouse TLR4 (pdb code 3VQ2), e) Human 
glycoprotein 1bα (pde code 1U0N) and f) Bovine decorin (pdb code 1XCD). All adopt a 
banana-shaped fold except for TLR4 which exhibits a horse shoe arrangement. The number of 




5.3 Comparison of the overall structures of mouse and human AMIGO-1 LRR 
Structural comparisons between mouse and human AMIGO-1 have revealed striking 
similarities for the LRR domain (Figure 4.4). This is not entirely unexpected given the high 
levels of sequence identity (89%) that exists between the homologues. Comparison of 
hAMIGO-1 LRR monomers A and B with the equivalent domains of mAMIGO-1 provided an 
r.m.s.d of 0.88 Å (for human A versus mouse A; 237 C atoms), 1.05 Å (for human A versus 
mouse B; 240 C atoms), 0.96 Å (for human B versus mouse A; 237 C atoms) and 1.11 Å (for 
human B versus mouse B; 240 C atoms). The most significant difference occurs between 
residues 180-182, where the Ca positions deviate by as much as 2.4 A˚. This corresponds to 
the LRR5 loop found on the convex side which adopts a distinct conformation in mAMIGO-1 
monomer B and is absent in monomer A, suggesting extreme flexibility in this segment of the 
molecule (Figure 5.4). The equivalent region of hAMIGO-1 participates in crystal contacts 
which may account for the contrasting conformations. In addition, further conformational 
differences between mouse and human AMIGO-1 are observed at the extreme C-terminal end 
of the LRRCT in the vicinity of the LRR-Ig linker region (Figure 5.4).  
 
The hAMIGO-1 LRR structure was subjected to temperature factor analysis to further 
investigate the conformational flexibility of this molecule. Temperature factors (also referred 
to as B-factors) are a measure of thermal vibration and provide useful information with 
respect to the degree of flexibility exhibited by different regions of a protein. For example, 
regions with higher B- factors reflect considerable flexibility or poor fitting of the model into 
the electron density, whereas areas exhibiting lower B-factors are less mobile and increasingly 
ordered. It was possible to rule out poor fitting as well-defined electron density was observed 
for the LRR domains of each molecule. Consistent with the mAMIGO-1 structure [120], 
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temperature factor analysis for hAMIGO-1 revealed lower B-factors (<15 Å2) for regions that 
contribute to stabilising the core dimer interface, particularly the β-sheet on the concave face 
(Figure 5.5). In contrast, higher B-factors (> 30Å2) were observed predominantly in the cysteine 
rich capping domains and in several loop segments found on the outer convex face, 
particularly in LRR5. Hence, extended conformational flexibility exists in specific parts of the 
outer convex face and also with the C-terminal LRR-Ig domain linker region. Consistent with 
this, the lack of the Ig domain within the hAMIGO-1 crystal lattice is presumably due to the 
LRR-Ig linker region exhibiting higher conformational flexibility which renders it increasingly 
susceptible to proteolytic cleavage during crystallisation trials [32]. Strikingly, although there 
was no data published on the B factors in the linker region for  mAMIGO-1, the temperature 
factor analysis of the Ig domain of mAMIGO-1 highlighted higher B-factors associated relative 
to the LRR module [120],  
 
Finally, comparison of the human and mouse AMIGO-1 LRR at the primary sequence level 
revealed 27 amino acid differences of which 9 are non-conservatively substituted and 18 are 
conservatively substituted (i.e. the hydrophobicity of the amino acids and molecular bulk of 
the side chain are similar). The majority of these differences when mapped onto hAMIGO-1 
are located on the convex face of the LRR domain (Figure 5.6), further demonstrating that the 






Figure 5.4 Comparison of the human and mouse AMIGO-1 LRR homodimer.  
The mAMIGO-1 LRR structure (teal, PDB code 2XOT) was superimposed onto hAMIGO-1 
LRR (orange) using Pymol. Regions that significantly differ are highlighted (red dotted 
circles). 





Figure 5.5 Temperature factors analysis of the hAMIGO-1 LRR domain. 
a) Temperature factors were plotted against hAMIGO-1 residue number. There are several 
regions with above average B-factors which include the N- and C- terminus capping domains 
and several loops found on the outer convex surface. The red line indicates the average B 
factor. b) Residues with high B-factors (highlighted in red) are mainly located on the outer 
convex face of each monomer and at the extreme C terminal end. Residues with low B-factors 







Figure 5.6 Mapping of mAMIGO-1 LRR residues that differ from hAMIGO-1.  
a) Structure of hAMIGO-1 with residues that differ from mouse highlighted (blue stick 
format). b) Molecular surface representation of hAMIGO-1 (orange) with regions that differ 
from mAMIGO-1 highlighted (blue). The concave face is more conserved relative to the 




5.4 Molecular interactions at the hAMIGO-1 LRR dimer interface 
The hAMIGO-1 structure exists as a dimer within the crystal lattice (Figure 5.7a), consistent 
with size exclusion data described in Chapter 3. The hAMIGO-1 dimer interface is centred on 
the concave face of each LRR module and buries a total of 2964 Å2 solvent accessible surface 
area. The buried surface area in the mAMIGO-1 dimer is 1350Å2 [120]. Interestingly a number 
of other LRR domain containing proteins have also been crystallised as dimers, including 
decorin and the fourth Slit2 domain (D4) whose buried surface areas are ~2300 Å2 and 2480Å2 
respectively [94, 155]. Both decorin and Slit2 D4 dimerize via their concave face, but in distinct 
modes. The decorin dimer is predominantly mediated by contacts involving the N-terminal 
capping domain, LRR1 and the central LRRs (Figure 5.7b). In contrast, similar to hAMIGO-1, 
the entire ectodomain of Slit 2 D4, including the C-terminal cap, contributes to stabilizing the 
dimer interface (Figure 5.7c). Interestingly, the ectodomain of LINGO-1 crystallises as a 
tetramer which buries a very extensive surface area that corresponds to 9200Å2 (Figure 5.7d) 
[69]. It has been proposed that large contact surfaces are associated with high binding affinities 
between individual monomers [94].  
The overall mode of dimerization adopted by hAMIGO-1 is very analogous to that of its 
mouse counterpart. Indeed, with the exception of S30A substitution, the majority of residues 
that contribute to stabilising the hAMIGO-1 interface are conserved with mAMIGO-1 (Figure 
5.8). The hAMIGO-1 dimer interface is stabilised by nine hydrogen bonding interactions 
located in three distinct clusters between the concave face of each monomer (Figure 5.9, Table 
5.2). The first of these clusters is formed by LRRNT of monomer A and the LRR5, LRR6 and 
LRRCT regions of monomer B. More specifically, the main chain of V32 and S42 in monomer 




Figure 5.7 Homo oligomerisation of LRR containing proteins.  
a) hAMIGO-1 forms a homodimer via association with the concave face. Each monomer is 
depicted in orange and green. b) Decorin forms a homodimer mediated by residues of its 
concave face (pdb code 1XCD).  Each monomer is depicted in brown and sky blue. c) Slit-
2 domain 4 (pdb code 2WFH) also forms a homodimer via its concave face. Each molecule 
is coloured in teal and light pink. d) Crystal lattice of the LINGO-1 ectodomain (pdb code 
2ID5) is comprised of a tetramer formed by residues of the convex face. The LRR module 







monomer B. In addition, N43 of monomer A forms a hydrogen bond with Y164 (LRR5) of 
monomer B. The second cluster is focused on the centre of the dimer interface and is 
comprised of residues S48, K49 and H70 which are located in the LRRNT and LRR1 on 
monomer A and form polar interactions with residues H70 and S48 on monomer B (LRR1 and 
LRRCT). The third cluster is the reverse of the first cluster with residues at the C-terminal end 
of monomer A packing against residues at the N-terminal end of monomer B. Comparison 
with the mAMIGO-1 dimer interface reveals subtle differences in the number of polar 
contacts. For instance, mAMIGO-1 surface exposed residues R29, C40, Q167 and N220 
mediate hydrogen bonding interactions that are absent in the human counterpart. Conversely, 
K49 and H70 in hAMIGO-1 form a polar interaction that is lacking in the corresponding region 
of mAMIGO-1. 
 
In addition to the polar contacts, the hAMIGO-1 interface is further stabilised by a series of 
non-polar interactions chiefly mediated by core hydrophobic residues that include V31, I44, 
Y62, L140, Y142, Y217, H219 and F247 (Figure 5.10). These hydrophobes form comparable 
contacts within the mAMIGO-1 dimer interface. Despite these similarities, the mAMIGO-1 
interface exhibits a greater number of non-polar interactions relative to hAMIGO-1 (271 
versus 243 contacts) and is likely to be more stable in solution. Finally, 29 well-ordered water 
molecules mediate an extensive network of hydrogen bonds, which further stabilize the 






Figure 5.8 Polar interactions that stabilise the hAMIGO-1 LRR dimer interface.   
There are nine hydrogen bonding interactions within the hAMIGO LRR dimer interface. 
Residues that contribute to hydrogen bonds are shown in stick format and labelled. The polar 
contacts at the interface are predominantly mediated by the upper region of LRR and the N- 





Figure 5.9 Hydrophobic interactions that stabilise the hAMIGO-1 LRR dimer interface.  
There are several core aromatic residues that mediate non-polar interactions within the 
hAMIGO LRR dimer interface. Residues that chiefly contribute to hydrophobic interactions 
are shown in stick format and labelled. The non-polar contacts at the interface are mainly 








Figure 5.10 Sequence alignment of human, mouse and rat AMIGO-1 LRR domain.  
Sequences were obtained from Uniprot (accession numbers Q86WK6 (hAMIGO-1), Q802D8 
(mAMIGO-1) and Q802D7 (rAMIGO-1) and aligned with Praline. The colour scheme of the 
alignment is for amino acid conservation. Residues that contribute to stabilising the AMIGO-







5.5 Sequence comparison of the hAMIGO family 
Similarity at the primary amino acid sequence level for the LRR domain between hAMIGO-1 
to hAMIGO-2 is 52%, hAMIGO-1 to hAMIGO-3 is 50%, and hAMIGO-2 to hAMIGO-3 is 44% 
(Figure 5.11a). The most highly conserved residue positions map to the concave dimerization 
surface of the molecule, whereas the convex face is considerably less conserved (Figure 5.11b). 
Strikingly, the majority of residues that mediate non-polar contacts in the hAMIGO-1 dimer 
are invariant across the hAMIGO family. In contrast, out of the 9 residue positions that 
mediate hydrogen bonding interactions, seven are either identical (residues Y164 and D191) 
or demonstrate highly conservative (residues S42, N43, S48, H70 and D250), substitutions 
across homologues (Figure 5.11a).  Only two positions (residues V32 and K49) demonstrate 
chemically distinct variations and these reside in the LRRNT. Notably, the residue at position 
32 participates in dimer formation exclusively through main-chain atoms. Hence, variation at 
this position is unlikely to significantly compromise dimerization. In summary, the 
conservation of residues in the hAMIGO-1 interface along with the large accessible surface 
area buried on dimerization, strongly suggest that all AMIGO family members dimerize in an 






Figure 5.11 Sequence comparisons of the human AMIGO-1/-2/-3 LRR domain.  
a) Sequences were obtained from Uniprot (accession numbers Q86WK6 (hAMIGO-1), Q865J2 
(hAMIGO-2) and Q86WK7 (hAMIGO-3) and aligned with Praline. The colour scheme of the 
alignment is for amino acid conservation. Residues that contribute to stabilising the AMIGO-
1 dimer interface are shown (polar contacts (orange circles) and core hydrophobic interactions 
(green circles)). b) Molecular surface representation of the hAMIGO-1 LRR (orange) with 
residue positions that are non-conservatively substituted across the hAMIGO family mapped 





5.6 Identification of putative ligand binding sites for the hAMIGO family 
Information garnered from previously reported structures of LRR containing proteins in 
complex with their ligands has offered indications of putative hAMIGO ligand binding sites.  
Generally, the solvent exposed concave face of LRR proteins provides an ideal surface for 
ligand binding [95, 154]. Indeed, such an arrangement has been documented for ribonuclease 
inhibitor-angiogenin [164], glycoprotein 1bα-von Willebrand factor [165, 166], Slit2-D2-Robo 
[166] and netrin G2-NGL2 [167] protein-ligand complexes (Figure 5.12). Further evidence that 
the concave surface of LRR domain is involved in ligand binding is provided by LINGO-1, 
which forms a tripartite complex with NgR and p75 and is structurally analogous to AMIGO-
1. Based on the LINGO-1 structure, the convex face is buried upon tetramer formation (Figure 
5.13a), raising the question of whether the concave face may be used in binding to other 
ligands such as NgR and p75NTR (discussed in further detail in Chapter 6). Consistent with the 
importance of the convex face in oligomerisation, LINGO-1 in complex with Li81 (Figure 
5.13b), an anti-LINGO-1 antibody used therapeutically in repairing damaged CNS neurons, 
revealed that it binds to the convex face of the LRR domain and prevents LINGO-1 tetramer 
formation [77].  Furthermore, binding of Li81 to LINGO-1 reduced the affinity of LINGO-1 for 
the non-competitive antibody, 1A7 [77].  
 
To examine these issues further, the hAMIGO-1 structure was used as a template to generate 
molecular models of hAMIGO-2 and hAMIGO-3 LRR domains with I-TASSER [168]. These 
molecular models together with the crystal structure of hAMIGO-1 were subjected to 
electrostatic potential analysis to identify putative ligand binding sites for NgR and 
p75NTR/TROY. The convex surface of hAMIGO-1 LRR domain exhibited no remarkable 
electrostatic properties. In contrast, the concave surface of hAMIGO-1 LRR module 
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demonstrated a striking electrostatic potential distribution, with the centre surface being 
highly negatively charged (Figure 5.14). Contributing to this negatively charged patch are 
residues D67, D116, D191, D246, E249 and D250. Next to this patch there is another remarkable 
electrostatic surface characterised by a single negative patch surrounded by three positively 
charged regions. Here, the contributing residues include E137, R113, K162 and K186. Notably, 
the equivalent region of hAMIGO-3 also demonstrated a similar striking electrostatic potential 
distribution despite the fact that it  exhibits ~50% sequence identity to hAMIGO-1. The 
electrostatic surface profile for hAMIGO-2 slightly resembles that of hAMIGO-2 and 3 
suggesting that it may exhibit a different function.  Moreover, this prominent pattern was also 
a characteristic feature of the concave mAMIGO-1/2/3 molecular surfaces (Figure 5.15). In 
summary, the conservation of residues that contribute to this unique motif across the human 
and mouse AMIGO family suggest that it may represent a potential evolutionary conserved 






Figure 5.12 Structures of LRR containing protein/ligand complexes.  
a) Structure of ribonuclease inhibitor (salmon) in complex with angiogenin (pale yellow). b) 
Structure of glycoprotein 1bα (deep blue) in complex with its ligand von Willebrand factor 
(grey). c) Structure of Slit S2 (limon) in complex with Robo (violet). For each complex the 
concave face of the LRR module mediates interactions with the ligand.  D) Structure of 





Figure 5.13 Human LINGO-1 ligand binding.  
a) Structure of the hLINGO-1 ectodomain (pdb code 21D5). hLINGO-1 forms a tetramer 
through the convex faces of its LRR domains leaving the concave faces potentially available 
for ligand binding. b) Structure of the hLINGO-1 in complex with anti-hLINGO-1 antibody 
Li81 (pdb code 4OQT). The anti-hLINGO-1 antibody (brown) binds to the convex face of the 




Figure 5.14 Identification of putative ligand binding sites for human AMIGO-1/-2/-3 LRR. 
 a) Comparison of the molecular surface electrostatic potential for human AMIGO-1/-2/-3 
LRR. The molecular models of hAMIGO-2 and hAMIGO-3 were generated with I-TASSER. 
The electrostatic potential was calculated using Delphi. There are two striking electrostatic 
patches (residues labelled, black dashed circles) observed on the concave face which may 
represent a putative ligand binding site. The potential scale ranges from -7 (red) to +7 (blue) 
in units of kT/e.  b) Sequence alignment of the human AMIGO-1/-2/-3 LRR domain. Sequences 
were obtained from Uniprot (accession numbers Q86WK6 (hAMIGO-1), Q86SJ2 (hAMIGO-2) 
and Q86WK7 (hAMIGO-3) and aligned with Praline. The colour scheme of the alignment is 
for amino acid conservation. Residues that contribute to hAMIGO-1 homodimerisation 




Figure 5.15 Identification of putative ligand binding sites for mouse AMIGO-1/-2/-3 LRR. 
a) Comparison of the molecular surface electrostatic potential for mouse AMIGO-1/-2/-3 LRR. 
The molecular models of mAMIGO-2 and mAMIGO-3 were generated with I-TASSER. The 
electrostatic potential was calculated using Delphi. There are two striking electrostatic patches 
(residues labelled, black dashed circles) observed on the concave face are conserved across the 
mouse and human AMIGO family and may represent a putative ligand binding site. The 
potential scale ranges from -7 (red) to +7 (blue) in units of kT/e.  b) Sequence alignment of the 
mouse AMIGO-1/-2/-3 LRR domain. Sequences were obtained from Uniprot (accession 
numbers Q802D8 (mAMIGO-1), Q802D9 (mAMIGO-2) and Q8C2S7 (mAMIGO-3) and 
aligned with Praline. The colour scheme of the alignment is for amino acid conservation. 





In this chapter, the crystal structure of the hAMIGO-1 LRR domain was determined and 
analysed with the aim of gaining an in depth understanding of the molecular basis of 
hAMIGO function as part of the NgR-p75NTR receptor complex, and how it compares to other 
related receptors including LINGO-1. 
 
The structure of the hAMIGO-1 LRR-Ig ectodomain was determined to 2.4Å resolution but 
was found to lack the Ig domain. To explore this further, purified hAMIGO-1 LRR-Ig domain 
was incubated at a temperature mimicking the crystallisation trials (22 °C) for several weeks 
and subsequently analysed by SDS-PAGE.  The resulting SDS-PAGE analysis highlighted a 
major band corresponding to the LRR domain (~30 kDA) but no band at the desired molecular 
weight for the fully intact ectodomain (40.8 kDa) suggesting that the protein was susceptible 
to significant proteolytic cleavage. Indeed, temperature factor analysis of the extreme C-
terminal end of hAMIGO-1 LRR revealed high B-factors relative to the core LRR domain.  It 
is possible that these high B-factors can be solely attributed to the lack of the LRR domain. 
However this can be ruled out as  high B-factors were observed  in the equivalent region of  
the mAMIGO-1 counterpart [120] which contains the entire LRR-Ig module. It is possible that 
the short LRR-Ig hinge region within human and mouse AMIGO-1 is uniquely flexible and in 
the absence of ligands adopts a conformation that is prone to cleavage.   
 
Consistent with gel filtration data (see Chapter 4), structural studies of the hAMIGO-1 LRR 
domain have established that the protein exists as a dimer. This dimer assembly is facilitated 
by residues that protrude from the concave face of each LRR domain. This arrangement is 
consistent with previous structural studies for the closely related mAMIGO-1 [120] and other 
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LRR containing proteins including decorin [94], and biglycan [161].  In addition, the LINGO-
1 crystalline state revealed a tetramer that was assembled via the convex face of each LRR 
module.  This poses a key question as to whether the dimeric or tetrameric forms of these 
neuronal proteins represent a crystal packing artefact or exhibit a physiological role. There is 
considerable evidence that points to the latter. Firstly, the dimer interfaces identified in the 
crystal lattice of hAMIGO-1, mAMIGO-1 have robust interfaces with an extensive surface 
area. Secondly, mutagenesis studies have demonstrated that mAMIGO-1 dimerisation is 
necessary for stable folding and cell surface expression [120]. Thirdly, the oligomeric state of 
LINGO-1 in solution is highly dynamic as monomeric, dimeric and tetrameric states were 
readily detected using dynamic light scattering, size exclusion chromatography and SDS-
PAGE [69]. Finally, there is a high degree of evolutionary conservation in residues that 
contribute to stabilising the dimer interface, across the AMIGO and LINGO family members, 
despite low sequence identity. Collectively, this suggests that oligomerisation of these 
neuronal associated proteins plays a precise biologically relevant function.  
 
The crystal structure of hAMIGO-1 was also used to identify putative hAMIGO-1 ligand 
binding sites. This involved consideration of evolutionary conserved regions, electrostatic 
surface potentials, N-linked glycan exposure and extrapolating from knowledge of previously 
determined LRR-ligand complex structures. Generally, the concave surface of LRRs are 
predominantly involved in ligand binding [154] as observed for the ribonuclease inhibitor-
angiogenin [164], glycoprotein 1bα- von Willebrand factor [169] and Slit2-D2-Robo [166] 
protein-ligand complexes. These studies have highlighted the critical role of both electrostatic 
attraction and non-polar interaction following protein-ligand complex engagement. Mapping 
the calculated electrostatic surface potentials on the molecular surface of hAMIGO-1 crystal 
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structure has provided potential indications as to the p75NTR and/or NgR ligand binding site.  
This analysis revealed a striking electrostatic potential distribution which is dominated by a 
negative patch that runs along the concave face. More importantly, the equivalent regions of 
the Phyre derived hAMIGO-2 and hAMIGO-3 molecular models demonstrated a comparable 
electrostatic potential distribution in spite of exhibiting low sequence identity to hAMIGO-1. 
This remarkable electrostatic potential distribution also appeared to be conserved across the 
mouse AMIGO family.  Collectively, this suggests that both the mouse and human AMIGO 
family all have the potential capability of binding NgR and/or p75NTR. Indeed, a recent limited 
study using closely related rat AMIGO-3 constructs revealed interactions with NgR andp75NTR 
in non-neuronal cells and in brain lysates, culminating in RhoA activation in response to 
stimulus with CNS myelin [107].  
 
Interestingly, the amino acid side chains contributing to the proposed ligand binding site on 
the concave face differed from residues implicated in the dimerisation motif. Despite this there 
is a distinct possibility that the hAMIGO-1 dimerisation site could also correspond to or 
overlap with the putative ligand binding site. Therefore, an unresolved issue is whether 
dimerisation of hAMIGO-1 is important in the formation of the tripartite complex with NgR 
and p75NTR. Molecular and biochemical studies of decorin, which adopts a similar mode of 
dimerisation to hAMIGO-1, provide further insights on this issue [94]. Since decorin forms a 
tight dimer via the concave face of its LRR domain, it was initially inferred that the outer 
convex face represented the likely collagen binding site [94]. However, there have been 
suggestions that decorin may transition from dimeric to monomeric in order to allow ligand 
binding at the concave face [94]. Indeed, decorin is easily denatured and is less stable than 
many other globular proteins. Heat  denaturation of decorin is fully reversible, demonstrated 
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by a reduction in molecular weight by half during thermal denaturation, representing the 
transition from dimer to monomer, followed by the reverse during cooling [161].  This 
indicates that decorin may be able to transition from a dimer to monomer to enable ligand 
binding as suggested previously. Furthermore, more recent studies have established that 
mutations on the concave face of decorin abolished collagen binding irrespective of whether 
the mutants retained their ability to dimerise or not [131]. Here, the authors concluded that 
the concave face of decorin is involved in binding to collagen and the decorin dimer 
dissociates to mediate binding collagen via the concave face [131].  Unfortunately, due to time 
constraints it was not possible to analyse AMIGO-1 by heat denaturation but it may be 
possible that, similar to decorin, hAMIGO-1 can mediate ligand interactions via its inner 
concave surface.  
 
Further evidence supporting the involvement of the concave faces of LRR domains in ligand 
binding is provided by the neuronal LRR-Ig domain containing protein, LINGO-1. LINGO-1 
forms a tripartite complex with NgR and p75NTR and is structurally analogous to AMIGO-1 
[96]. Based on the LINGO-1 structure, the authors reported that the concave face is likely to 
play a significant role in ligand binding since the convex face is buried upon tetramer 
formation. However, an unresolved question is whether the LINGO-1 tetramer represents a 
physiologically relevant form or a crystallisation artefact. More recent data favours the former, 
as tetramers have been observed both in solution and in cells expressing the full-length 
LINGO-1 indicating that the ability to form oligomers is an intrinsic property of LINGO-1 [77]. 
In addition, a recent structure of LINGO-1 in complex with Li81, an anti-LINGO-1 antibody 
used therapeutically to facilitate repair of damaged CNS neurons, revealed the antibody binds 
to the convex face of the LRR domain and prevents LINGO-1 tetramer formation [77]. The 
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tetramer arrangement of LINGO-1 leads to a large surface area being buried, it is suggested 
that it serves as an efficient and stable scaffold for assembly of the LINGO-1/NgR/p75NTR 
complex [170]. Accordingly, knowledge of the LINGO-1 oligomeric status may shed light on 
unresolved questions about the stoichiometry of the LINGO-1/NgR/p75NTR complex; it has 
been hypothesized that each signalling complex may be comprised of four of each receptor 
component (4:4:4) rather than one (1:1:1) [170]. The formation of a supramolecular assembly 
of this type would have significant implications for the binding properties (affinities/avidities) 
for the trimeric complex, likely resulting in signal amplification. This process could increase 
the sensitivity of this molecular “stop” signal dramatically, leading to rapid growth cone 
collapse in the presence of even limited amounts of myelin-derived inhibitors. 
 
Another important factor to consider is whether the orientation of the Ig domain with respect 
to the LRR module could shield the putative ligand binding site on the concave face. 
Unfortunately, this was difficult to determine with the current hAMIGO-1 structure as the Ig 
domain has been cleaved during crystallisation trials. However, for the closely related fully 
intact mAMIGO-1 ectodomain, the Ig module is orientated in a manner that partially covers 
the convex face of the LRR domain, rendering this region unavailable for ligand binding. In 
addition, potential N-linked glycosylation sites map onto the convex surface of hAMIGO-1. 
Collectively, this further reduces the likelihood that the hAMIGO-1 convex face represents a 




























Molecular and structural studies of NgR complex interactions 
6.1. Introduction 
A wealth of studies suggest that interaction of NgR with partner proteins is essential to 
transmission of growth inhibitory signals, with both the signalling adapter P75NTR and the 
neuronally-restricted LINGO-1 protein emerging as critical partners in the NgR complex. 
Interestingly both NgR and LINGO are members of a group of proteins containing both LRR 
and Ig domains (see chapter 1), members of which frequently are involved in interprotein 
interactions via these domains. Notably, the large ectodomains of LRR proteins such as TLRs 
are critically involved in ligand engagement [171], and similarly the ectodomains of LRR and 
Ig domain containing proteins such as LINGO-1 and NetrinG Ligands are known to interact 
with co-receptors or ligands through their LRR domains [75, 172]. This consideration raised 
the possibility that the extracellular domains of NgR are also involved in and may be 
important for NgR complex formation and function. In addition, the results in chapter 5 
suggested that certain members of the AMIGO family may be able to substitute for LINGO-1 
in the NgR complex, however they did not establish a role for the AMIGO ectodomains in 
these interactions. Although some studies have provided evidence for NgR/LINGO-1 
interactions[68, 69], this area is understudied, and no convincing molecular evidence has 
confirmed AMIGO/NgR interactions. A key aim for this chapter was to test whether AMIGO 
ectodomains could interact directly with other components of the NgR complex, as has been 
suggested for LINGO-1. Ultimately, understanding the molecular architecture of the trimeric 
NgR/LINGO-1/P75NTR complex is a significant goal and could shed light on how inhibitory 
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signals are initiated, establishing a key component of the knowledge base from which novel 
therapeutic interventions can be generated.  
 
This chapter aimed to establish whether AMIGO proteins can interact with NgR directly via 
their ectodomains, and also attempted to probe the structural basis of interactions between 
NgR and LRR and Ig domain containing proteins. 
 
6.2 Surface Plasmon Resonance studies of NgR/LINGO and NgR/AMIGO interactions 
The interactions between NgR/LINGO-1 and NgR/AMIGO were examined using a BIAcore 
machine, which exploits the phenomenon of surface plasmon resonance (SPR). SPR relies on 
exploits laser light directed at a sensor surface under conditions of total internal reflection. At 
a specific ‘resonance angle’, there is dip in the intensity of the reflected light, due to some of 
the energy being passed into a wave of delocalised electrons (a ‘plasmon’) in a gold layer 
adjacent to the surface. The angle at which this resonance angle occurs depends on the 
refractive index of the solution adjacent to the sensor, which is directly related to the 
concentration of macromolecules (eg proteins) in the solution itself. As there is a linear 
relationship between the resonance angle and the solution’s refractive index, by detecting 
changes in resonance angle (converted to ‘Resonance Units or RU), SPR provides a powerful 
route to measuring changes in refractive index, and this allows the technique to be exploited 
for the study of ligand binding interactions.  SPR is a powerful and sensitive technique used 
to study diverse ligand binding interactions, and can be exploited as an accurate ‘real time’ 
method to measure protein-protein interactions, and potentially allows quantitative data to 
be collected, allowing measurement of affinity and kinetics. Importantly however, SPR is 
susceptible to a number of different artefacts. These include artificially slow kinetic values, 
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which can result from the presence of protein aggregates in solution, which can be avoided 
with careful experimental design. Valid SPR experiments are also dependent on the 
availability of high quality recombinant protein. 
 
6.2.1 Expression of proteins 
Human AMIGO-1 (G28-H359), AMIGO-3 (T20-H372), LINGO-1 (C42-S516), and NgR (P26-
V311) were expressed in Drosophila S2 cells. Expression of human AMIGO-2 was attempted, 
however the protein failed to express in Drosophilla S2 cells, possibly due to the cleavage of 
the protein identified in Chapter 5, which would be expected to prevent the protein from 
being purified by His tag purification. Human p75NTR was expressed in Drosophilla by the 
University of Birmingham Protein Expression Facility (PEF). Ectodomains including LRR and 
Ig domains were expressed with biotin and histidine tags at the C- terminal end of the protein 
(Figure 6.1).  Constructs were introduced into S2 cells by calcium phosphate transfection as 
described for AMIGO-1 in Chapter 3. Each protein was expressed in the same way. Expression 
was confirmed by western blot analysis of small scale cultures of each protein, before larger 
quantities of S2 cells were grown. Ni-NTA purified proteins were analysed by SDS-PAGE and 
optical density, OD280, was used to determine the quantities of protein produced. From 1 litre 







Figure 6.1. Drosophila expressed protein constructs 
AMIGO-1, AMIGO-3, LINGO-1, NgR and p75NTR proteins were expressed in Drosophila S2 
cells.  The most N- and C- terminus amino acids for each construct are labelled, and each 
protein is followed by a biotin tag and a histidine tag at the C terminal end. For BIAcore, the 




6.2.2 Purification of AMIGO-1, AMIGO-3 and LINGO-1 
AMIGO-1, AMIGO-3 and LINGO-1 were to be used as analytes, and injected over the chip in 
surface plasmon resonance experiments. Following Ni-NTA purification, these proteins were 
loaded onto the Superdex S200 column which had been pre- equilibrated with the appropriate 
buffer. This provided additional separation from impurities. AMIGO-1 was exchanged into 
20mM Tris pH 8.5, 50mM NaCl, AMIGO-3 into 20mM Tris pH 8.5, 100mM NaCl and LINGO-
1 was exchanged into 20mM Tris pH 7.4, 150mM NaCl. Following size exclusion 
chromatography, peak fractions were collected and samples were analysed by SDS-PAGE to 
confirm size and purity. 
Prior to SPR, proteins were required to be concentrated prior to SPR, in order to obtain 
concentrations likely to result in detectable binding. However, this can result in protein 
aggregates, which can cause grossly inaccurate interpretation of SPR results if the data 
generated are assumed to derive from bona fide monomeric protein/ligand interactions. For 
this reason, an additional HR200 ‘polish’ step was introduced, prior to SPR data collection.  
This ensured maximum purity of the samples that were to be analysed, and excluded 
aggregates. For the concentration step, proteins were concentrated using an AMICON Ultra 
centrifugal filter (Millipore 0.5ml, 10kDa) to a volume 245µl and loaded onto the Superdex 
HR200 column pre-equilibrated with appropriate buffer.  Following size exclusion 
chromatography, peak fractions were analysed by optical density (OD280) for use in the SPR 
experiment. Although ideally no further concentration steps would be required, in some cases 
additional post-HR200 concentration (carried out in centrifugal filter units as above) were 
necessary but were kept to a minimum. It was important to keep the samples on ice 
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throughout purification to reduce the likelihood of protein aggregation, which could alter 
binding to the ligand.  
Purification of AMIGO-1 by size exclusion chromatography was described in Chapter 3, the 
elution profile identified that AMIGO-1 was a dimer in solution. The S200 elution profile of 
AMIGO-3 (Figure 6.2a) illustrates two peaks ‘a’ and ‘b’ of 20mAu and 40mAu at 130ml and 
190ml respectively. Peak ‘b’ correlates to a protein of approximately 80kD in size which, like 
AMIGO-1, indicates that AMIGO-3 is a dimer in solution because the predicted size of the 
expressed protein is 42kDa. The HR200 elution profile (Figure 6.2b) illustrates that AMIGO-3 
is eluted at 15-16ml which correlates to a protein of around 80kDa size, again identifying the 
protein as a dimer. Further analysis of peak fractions by SDS-PAGE (Figure 6.2c) revealed 
single bands at approximately 45kDa in reduced and non-reduced forms indicating that the 
protein is not glycosylated, as its predicted size is 42kDa, and demonstrating that the AMIGO-
1 dimer is non-covalent. The S200 elution profile of LINGO-1 (Figure 6.2d) reveals that the 
protein eluted at 200ml, which corresponds to 66kDa, suggesting that it exists in a monomeric 
state in solution (Figure 6.3). Furthermore, the HR200 elution profile (Figure 6.2e) identifies 
two peaks ‘a’ and ‘b’ at 15ml and 23ml respectively; the former corresponds to a protein of 
60kDa in size which confirms the protein is monomeric in solution. The later peak corresponds 
to small cleavage products which are the result of freeze thawing of the sample, indicating the 
buffer that the protein was stored in was perhaps not ideal. When analysed by SDS-PAGE 
(Figure 6.2e), peak fractions were visible as single bands migrating at ~66kDa in size, which 
differs from the expected size of 57kDa. It is possible that this difference can be attributed to 
N-linked glycosylation.  Interestingly, the LINGO-1 elution profile differed from previous 
174 
 
published results in which it was described to exist as a tetramer in solution based on cross-
linking studies and gel filtration [69].     
6.2.3 Biotinylation of NgR  
NgR and p75NTR were biotinylated to enable binding to the surface of the BIAcore CM5 chip. 
Biotinylation involved buffer exchanging the soluble proteins into biotinylation buffer 
containing biotin, ATP and BirA enzyme, after collection from the Ni-NTA column, described 
in Chapter 2. Following biotinylation, excess biotin was removed from the sample by size 
exclusion chromatography. Human NgR was applied to the S200 column which had been pre 
equilibrated with 20mM Hepes pH 7.2 150mM NaCl, following biotinylation. The elution 
profile (Figure 6.2f) revealed a peak at 225ml corresponding to a protein of 35kDa in size 
which is similar to the estimated size of 32kDa for NgR revealing that the protein is a 
monomer in solution, as documented previously [32]. When purified by HR200 (Figure 6.2g) 
two peaks ’a’ and ‘b’ at 16ml and 20ml respectively were detected, peak ‘a’ corresponds to the 
eluted protein being around 30kDa in size, which is in the correct range for the expressed NgR 
protein and again suggests it is a monomer in solution. Peak ‘b’ is probably buffer components 
such as excess biotin and ATP. Peak fractions were analysed by SDS-PAGE in reduced and 
non-reduced forms, which identified the proteins as single bands at approximately 35kDa in 





Figure 6.2. Purification of hAMIGO3, hLINGO-1 and hNGR by size exclusion 
chromatography.  
a) Size exclusion elution profile for hAMIGO-3 using the S200 column. hAMIGO-3 elutes as a 
dimer at ~190ml. b) Size exclusion elution profile for hAMIGO-3 using the HR200 column. 
hAMIGO-3 elutes at ~15ml consistent with a dimeric species. The rationale for dual 
S200/HR200 purification is outlined on page 7. c) SDS-PAGE analysis of hAMIGO-3 peak 
fractions eluted from the HR200 column under reducing (R) and non-reducing (NR) 
conditions. d) Size exclusion profile for hLINGO-1 using the s200 column, the protein is eluted 
as a monomer at ~200ml. e) Size exclusion elution profile for hLINGO-1 using the HR200 
column, two species are eluted at ~15ml (i) and ~22ml (ii) the former corresponds to hLINGO-
1 monomer and the latter corresponds to low molecular weight buffer components. f) SDS-
PAGE analysis of hLINGO-1 peak a fractions eluted from HR200 under reducing (R) and non-
reducing (NR) conditions. g) Size exclusion elution profile for hNgR using the S200 column. 
hNgR elutes as a monomer at ~210ml. h) Size exclusion elution profile for hNgR using the 
HR200 column., two species are eluted at ~18ml (i) and ~20ml (ii), the former corresponding 
the protein in monomeric form and the latter representing buffer components. i) SDS-PAGE 
analysis of hNgR peak a fractions eluted from the HR200 column under reducing (R) and non-





Figure 6.3 Calibration curve for standard proteins eluted from the Hiload 26/60 Superdex 
200 size exclusion column.  









6.3 Testing interaction of LINGO-1 to NgR-Fc and P75NTR-Fc fusion proteins 
Choice of strategy for immobilisation of ligand to the sensor surface is a critical factor in 
establishing an experimental system for SPR analysis. Various different methods are 
commonly used for directly coupling proteins to the sensor surface, including amine coupling, 
sulphydryl group coupling, and a range of tag-based coupling methods including His-NTA 
chips [173]. Alternatively, proteins of interest can be coupled indirectly, by first immobilising 
a protein capable of binding tightly to the protein of interest. Common examples of this 
strategy include immobilisation of biotinylated proteins to chip surfaces to which streptavidin 
has been coupled, and coupling of antibodies to the chip surface, allowing specific target 
antigens to be captured. One important consideration in these experimental systems is 
whether the strategy enables oriented/semi-oriented or non-oriented coupling. Amine 
coupling methods rely on the presence of primary amine groups on the immobilised protein 
(ie Lysine residues). Depending on their location on the protein in question, immobilisation 
via such groups can reduce/eliminate activity of the ligand on the chip surface for binding 
target analytes. In contrast, oriented/semi-oriented methods typically result in higher levels 
of activity of the protein surface, which can be critical to downstream detection of interaction 
with partner proteins. 
 
Before testing interaction of AMIGO proteins with NgR, an experimental system that could 
detect NgR interaction with P75NTR and/or LINGO-1 was established. For these experiments, 
initially LINGO-1 had been expressed, in-house, using a well-established Drosophila 
expression system; in contrast neither the NgR nor P75NTR Fc fusion proteins had been 
produced in-house, and had instead been obtained commercially. The presence of Fc tags on 
both P75NTR and NgR suggested an immobilisation strategy exploiting the presence of this tag. 
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Previously, the anti-human-Fc antibody Rz108e9 has been successfully used to capture Fc-
fusion proteins for BIAcore analysis, by first amine coupling the antibody, allowing Fc-fusion 
proteins to be injected in solution, capturing them in a semi-oriented fashion for subsequent 
binding experiments. This method was therefore selected in a first attempt to establish a 
system to study NgR/LRR domain containing protein interactions. 
 
Reproduction of a previously reported method [174] for amine coupling Rz108e9 successfully 
immobilised relatively large quantities (16-19,000RU) of the antibody on two chip surfaces 
(Fig 6.4a). First, the CM5 chip surface was activated with EDC/NHS, and then Rz108e9 was 
injected over the activated surface at 10ug/ml; subsequently unused groups were quenched 
using ethanolamine, and finally the surface was cleaned to remove any uncoupled Rz108e9 
stuck to the surface. Subsequently, injection of commercially available NgR-Fc fusion protein 
over Fc2 resulted in capture of ~2000RU of bound protein, whereas Fc1 acted as control surface 
(Figure 6.4b).  
 
To test interaction with LINGO-1, recombinant LINGO-1 was injected at 400µg/ml (~3.5µM) 
over both surfaces (not shown). Although a substantial increase in the signal was observed 
during the injection, indicative of the relatively high protein concentration used, almost 
exactly equivalent responses were obtained over both flow cells, indicating that no binding 
was detected. To test if higher concentrations of LINGO-1 were required to detect binding, 
LINGO-1 was injected over both surfaces at a concentration of 1mg/ml (Figure 6.4c). Again, 
no binding was detected, however, interestingly at this concentration of LINGO-1, a relatively 
slow association response was observed, and a higher response was observed over Fc1, 
despite the absence of NgR on this flow cell. This suggested that at this higher concentration 
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of LINGO-1, a weak stickiness to the Rz108e9-coated was occurring, and that this was 
marginally impeded by the immobilisation of NgR-Fc. Following failure to detect LINGO-1 
interaction with NgR-Fc, P75NTR-Fc was immobilised to Fc1 (Figure 6.4d), and following this 
LINGO-1 injected over Fc1 and Fc2, exploiting the lack of interaction with NgR (Fc 2) as a 
control surface (Figure 6.4e). As observed before P75NTR immobilisation, there was a somewhat 
higher signal over Fc1 than Fc2, however the traces closely matched those before P75NTR 
immobilisation, with similar slow association and closely matched dissociation phases 
observed. This indicated that there was no detectable binding to P75NTR.  
 
These experiments failed to detect any convincing binding of recombinant LINGO-1 to 
immobilised NgR-Fc or P75NTR-Fc proteins. One possible explanation for lack of expected 
interaction on BIAcore could be use of an immobilisation method that resulted in a highly 
inactive protein surface. However, in this case, the use of the well-established Rz108e9 
method, allowing semi-oriented coupling of proteins via C-terminal Fc tags, suggested this 
explanation was unlikely. One alternative explanation was that one or more of the proteins 
was not folded correctly. While the quality of in-house-produced LINGO-1 could be tested, it 
was more difficult to establish for the commercially obtained NgR-Fc and P75NTR-Fc proteins, 
although they were clearly able to bind to the Rz108e9 antibody. One concern with fusion 
proteins involving relatively large fusion partners is that even if the target protein is 
misfolded, the presence of a large, highly soluble fusion partner moiety can mask such 
problems, enhancing solubility. In contrast, proteins bearing only relatively short tags are 
likely to rely mostly on correct folding of the target protein itself for acceptable solubility.  
These considerations led us to produce recombinant forms of NgR and P75NTR without the 




Figure 6.4. Establishing NgR/p75NTR/LINGO-1 interactions. 
Prior to testing AMIGO/NgR interactions, it was important to establish an experimental 
method to detect the NgR/p75NTR/LINGO-1 interactions. NgR-Fc and p75NTR-Fc were 
immobilised to the sensor chip via amine coupling using the anti-Fc antibody, Rz108e9. 
LINGO-1, made in house, was then injected over the flow cells and binding detected.  
a) Immobilisation of Rz108e9 over flow cells 1 and 2, indicating activation step (1), 
antibody injection (2), quenching with ethanolamine (3), and surface cleaning steps 
(4,5) to remove protein that was not covalently coupled. 
b) Immobilisation if NgR over flow cell 2 (pink trace) indicates ~ 2000RU of NgRFc 
immobilised in around 300 seconds. 
c) Injection of LINGO-1 over flow cells 1 (control) and 2 (NgR-Fc immobilised), resulting 
in broadly similar traces over both surfaces (marginally high signal was obtained over 
the control surface relative to NgR-Fc surface).   
d) Immobilisation of p75NTR over flow cell 1. Approximately 1000RU of p75NTR was 
immobilised in ~ 900 seconds. 
e) Injection of LINGO-1 over flow cells 1 (p75NTR) and 2 (NgR). Again, broadly similar 
traces are obtained over both surfaces (marginally higher signal was obtained over the 








6.4 Establishing an experimental system for detecting LINGO-1/NgR interaction 
To produce NgR and P75NTR proteins in a form lacking Fc domains, we engineered these with 
C-terminal bt-His tags, permitting both affinity purification via Nickel-NTA chromatography, 
and subsequent enzymatic site-directed biotinylation, via the action of the enzyme BirA on the 
biotinylation tag. These proteins were expressed recombinantly in Drosophila cells, purified, 
and biotinylated, with the aim of capturing them onto streptavidin-coated chips.  
 
To test interaction with NgR, streptavidin was first immobilised to two flow cells, using a 
standard amine coupling protocol (Figure 6.5a). NgR-bt was then injected over a single 
streptavidin-coated flow cell (Fc2), and was captured at relatively high levels (~5000RU). A 
control protein, WT1bt, was immobilised to a second flow cell (Fc1) at similar levels (Figure 
6.5b), and non-biotinylated LINGO-1 was then injected over both surfaces. Injection of 
LINGO-1 (for 1 minute) at 3.5uM resulted in substantially higher responses over Fc2 (with 
NgR immobilised) than over Fc1 (with the control protein WT1 immobilised), indicating 
specific binding (Figure 6.5c). Interestingly, a negative buffer signal was observed, a 
phenomenon observed relatively frequently in BIAcore assays (eg Fig 6.6, due to differences 
in refractive index between the buffer the analyte is in, and the running buffer for the 
experiment), and after subtraction of the buffer signal, a more easily interpretable binding 
trace was revealed, featuring an association phase culminating over 500RU of bound LINGO-
1, after which the dissociation phase lasted around 4mins. Importantly, the interaction did not 
reach equilibrium after 1 minute, and secondly essentially all LINGO-1 protein dissociated 
from the NgR surface ~ 4 minutes after the end of the injection. Notably, essentially no protein 
‘sticking’ was observed to the control surface. This result was reproduced in a separate 
experiment (comparing responses over flow cells bearing NgR-bt, and streptavidin alone 
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(Figure 6.5d). In addition, longer, 2-minute injections were carried out, in an attempt to extend 
the detection period during the association phase such that the interaction reached 
equilibrium (Figure 6.5e). During a 2-minute injection period, the binding detected reached a 
plateau (of around 800RU), indicating that equilibrium had been reached. Non-specific 
sticking of LINGO-1 was observed to the NgR surface with higher signals being seen 2 
minutes after the end of the injection, indicating the presence of aggregates.   
 
These results both confirmed direct interaction of the ectodomain of LINGO-1 with that of 
NgR, but also confirmed that this experimental system was appropriate for detection of 
NgR/LRR interactions, and one that could in principle be sufficiently robust to determine 





Figure 6.5. Establishing NgR/LINGO-1 interactions. 
In order to test the interaction between NgR and LINGO-1, NgR was produced in house with 
a C-terminal Bt-His tag. NgR-Bt was immobilised over the sensor chip via amine coupling 
using streptavidin, LINGO-1 was injected and binding was assessed.  
a) Immobilisation of Streptavidin over flow cells 1 and 2, highlighting activation phase 
(1), streptavidin injection (2), quenching with ethanolamine (3), and clean-up step to 
remove any non-covalently-associated protein (4).  
b) Immobilisation if NgR-Bt over flow cell 2 (purple, ~4800 RU immobilised) and WT1 
(control protein, red, 4800 RU immobilised) over flow cell 1.  
c) Injection of LINGO-1 (3.5µM) over flow cells 1 and 2. Negative buffer signals have 
been subtracted from both flow cell 1 and 2 traces.  
d) Injection of LINGO-1 (3.5µM) over flow cells 3 (NgR-Bt, immobilisation not shown) 
and 4 (Blank control). Negative signals have been subtracted from both flow cell 3 and 
4 traces.  
e) Injection of LINGO-1, diluted 1:2 in HBS-EP over flow cells 1 and 2. Negative signals 






6.5 Detection of AMIGO protein interactions with NgR 
To test interaction of NgR with P75NTR and AMIGO proteins, an additional experiment was 
conducted. Streptavidin-coated flow cells were prepared, and both NgR-bt and P75-bt 
immobilised to separate surfaces, alongside WT1bt control protein. Unfortunately, the 
attempt to immobilise recombinant biotinylated p75NTR was largely unsuccessful, with only a 
relatively small amount of p75NTR protein successfully captured. The reasons for this were 
unclear, but may have related to cleavage of the biotinylation tag after protein purification. 
As a result, subsequent analyses focussed largely on NgR interactions with LINGO-1 and 
AMIGO proteins.  
 
To validate detection of LINGO-1/NgR interactions, LINGO-1 protein was injected over all 
four flow cells, one coated with NgR, one coated with p75NTR, one was coated with WT1 
control protein and one was left blank (streptavidin-alone). LINGO-1 was subjected to size 
exclusion chromatography immediately prior to injection. Interestingly, a 3-minute injection 
0.58µM over NgRbt-coated and control flow cells confirmed specific binding but was not 
sufficiently long to reach equilibrium (Figure 6.6a). The likely explanation for this is the much-
reduced protein concentration (as a result of dilution during size exclusion), which would be 
expected to reduce the speed of the association phase (which is dependent on analyte 
concentration) considerably.  
 
Having established that LINGO-1/NgR binding was detected broadly as expected, AMIGO-1 
was then injected over all four flow cells, at 14.7µM (Figure 6.6b). Clear binding was observed 
to the NgR flow cell, with no binding or sticking observed to other flow cells. Interestingly, 
the interaction failed to reach equilibrium during the injection. In addition, dissociation 
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appeared relatively slow, occurring (essentially to completion) over ~ 4000 seconds (albeit 
under slow flow rate conditions). A subsequent injection at a 5-fold lower concentration (i.e. 
2.9µM) also resulted in clearly detectable interaction (Figure 6.6c). These injections confirmed 
that the ectodomain of AMIGO-1 is capable of directly interacting with the ectodomain of 
NgR.  
 
Following detection of AMIGO-1/NgR interactions, AMIGO-3 was injected over all four flow 
cells 11.8µM (Figure 6.6d). AMIGO-3 injection yielded higher responses over NgRbt-coated 
flow cells, relative to all controls, indicating specific binding to NgR (~500RU of binding). 
Subtraction of negative background signals indicated the interaction did not reach 
equilibrium (Figure 6.6e), and indicated a fast and slow phase to the dissociation period, 
potentially indicative of the presence of aggregated protein in the analyte. Injection of 
AMIGO-3 immediately post-size-exclusion chromatography also yielded detectable binding, 
despite the low concentration used 0.69µM (Figure 6.6f). These experiments provide the first 
direct evidence that the ectodomains of AMIGO-1 and AMIGO-3 are able to directly interact 
with that of NgR, and confirm the results presented in chapter 5 suggesting that NgR can 





Figure 6.6. Establishing NgR/AMIGO interactions.  
In order to test the interaction between NgR and the AMIGO proteins, NgR-Bt was 
immobilised over the sensor chip on the indicated flow cells onto streptavidin-coated CM5 
chips, and following this step, LINGO-1, AMIGO-1 and AMIGO-3 were injected in separate 
experiments, and binding responses were assessed.  
a) Injection of LINGO-1 0.58µM over immobilised NgR (Fc2), and control streptavidin-
coated flow cells. A substantially higher signal is evident over Fc2 compared to Fc1,Fc3 
and Fc4, indicating clear binding of LINGO-1 to NgR.  
b) Injection of AMIGO-1 14.7µM over all flow cells. Again, a far higher signal was 
obtained over Fc2 compared to control flow cells, indicating specific binding to 
AMIGO-1 to NgR.   
c) Injection of AMIGO-1 diluted in HBS-EP 2.9µM over all flow cells, again indicating 
specific binding to NgR.  
d) Injection of AMIGO-3 11.8µM over all flow cells, indicating specific binding of 
AMIGO-3 to NgR.   
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e) Injection of AMIGO-3 11.8µM. Negative signals in the responses over the NgR-coated 
and control flow cells have been subtracted. 
f) Injection of AMIGO-3 0.69µM. Negative signals in the responses over the NgR-coated 
and control flow cells have been subtracted. Data are relatively noisy due to the low 
signals detected, and a blip in the sensorgram is observed, due to pressure effects in 
the internal flow cell.  
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6.6 Structural studies of AMIGO-1/NgR complex.  
Having both confirmed direct interactions of NgR with the LINGO-1 ectodomain and 
established NgR interaction with AMIGO ectodomains, structural studies were then 
attempted to further probe the precise mode of binding between the Nogo tripartite 
complexes comprised of NgR, AMIGO-1, AMIGO-3 and LINGO-1. Initial attempts at 
crystallising AMIGO-3/NgR were hampered by the fact that AMIGO-3 was prone to 
aggregation at high concentrations. To address this issue ThermoFluor stability assays were 
performed to identify buffer conditions that could improve protein solubility and, in turn, 
crystallisation success. This assay provides a fluorescence readout measurement of thermally-
induced protein melting. Briefly, AMIGO-3 was heated in the presence of 96 unique solubility 
reagents (varying buffer, pH and ionic strength) and Sypro Orange dye to identify sample 
buffer formulations that increase the melting temperature (Tm) and therefore relative stability 
of the protein. The fluorescence of the hydrophobic dye Sypro Orange increases considerably 
when the dye binds to internal hydrophobic protein regions that become exposed following 
protein denaturation. Protein stability or Tm is then measured by analysing the temperature 
dependence of protein denaturation and subsequent increase in fluorescence intensity. Using 
this approach, several candidate solubility reagents were identified including 0.1M Na 
cacodylate pH 6.5 (Figure 6.7). However, based on successive spectrophotometric 
measurements of protein concentration and visual evidence of protein precipitation, none of 
these conditions allowed AMIGO-3 to remain in solution at high concentrations sufficient for 
complex crystallisation trials. Additionally, a previous study had highlighted the extreme 
difficulty in crystallising LINGO-1 [69], which was ultimately overcome by subjecting the 
protein to limited proteolysis, where flexible areas of the protein were cleaved to provide a 




Figure 6.7. ThermoFluor stability assay dissociation curve for hAMIGO-3. 
Stability assays were performed to identify buffer conditions that could improve protein 
solubility. The assay provides a fluorescence readout measurement of thermally-induced 
protein melting. AMIGO-3 was heated in the presence of 96 unique solubility reagents and 
Sypro Orange dye. The fluorescence of the hydrophobic dye increases considerably when the 
dye binds to internal hydrophobic protein regions that become exposed following protein 
denaturation. Protein stability or Tm is then measured by analysing the temperature 
dependence of protein denaturation and subsequent increase in fluorescence intensity. Using 
this approach, several candidate solubility reagents were identified including 0.1M Na 







Based on these considerations and due to time constraints my focus was to determine the three 
dimensional structure of the AMIGO-1/NgR complex. Indeed, this endeavour was helped by 
the fact that unlike AMIGO-3, both AMIGO-1 and NgR were not prone to aggregation at high 
concentrations.  
6.6.1 Production of AMIGO-1 and NgR in Drosophila S2 cells 
The hAMIGO-1 ectodomain (residues G28-T362) was expressed in Drosophila S2 cells as 
described in Chapter 3 and was identified as a dimer in solution. The human NgR ectodomain 
comprised of residues Q26-P448 was also expressed in Drosophila, as described above. Both 
proteins were initially purified by Ni-NTA chromatography followed by further purification 
by size exclusion chromatography. Briefly, human NgR was loaded onto the Superdex 200 
column on the FPLC which had been pre-equilibrated with 20mM Hepes pH 7.2, 150mM 
NaCl. Typically, a single peak of 70mAu was observed at ~220ml which is consistent with the 
predicted size of 31kDa for NgR and confirmed that the protein exhibits a monomeric state in 
solution (Figure 6.2). The peak fractions were pooled, concentrated and analysed by SDS-
PAGE under reducing and non-reducing conditions.  Examination of the resulting gel 
revealed a single band for NgR at ~30kDa, suggesting that glycosylation, if present at all, was 
minimal (Figure 6.8a). Moreover, the high purity evident on SDS-PAGE, combined with 
monomeric behaviour in solution, suggested the NgR sample was of sufficient quality for co-
crystallisation screening trials with hAMIGO-1.   
6.6.2 hAMIGO-1/NgR Co-crystallisation trials 
hAMIGO-1and NgR were mixed at a 1:1 molar ratio to a final concentration of 11.5mg/ml, and 
screened against several commercial sparse- matrix based screens with the mosquito nanolitre 
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crystallisation robot. In total 288 conditions were screened (derived from Structure Screen 1 
and 2, MIDAS and JCSG+), using the hanging drop vapour diffusion method. The initial 
screening process identified four conditions (Figure 6.8b-e) that yielded promising 
crystallisation hits; JCSG+ conditions 1.5 (0.2M Mg formate, 20% PEG3350) and 1.42 (0.2M 
MgCl2, 0.1M Tris pH8.5, 20%PEG 8000), MIDAS 1.40 (10% Pentaerythritol ethyoxylate) and 
Structure Screen C9 (0.2M MgCl2, 0.1M Tris pH8.5, 30%PEG 4000). These conditions were 
subsequently screened against AMIGO-1/NgR, AMIGO-1, NgR and buffer alone. Importantly 
no crystals appeared in the drops containing AMIGO-1 and NgR alone suggesting that the 
initial crystal hits were most likely comprised of the AMIGO-1/NgR complex. Additionally, 
no crystals were observed in drops in the absence of protein suggesting that salt crystals could 
be excluded. Of the 4 conditions, JCSG+ 1.5 (0.2M Mg formate, 20% PEG 3350) reproducibly 
yielded micro-crystals which typically appeared after 2-3 days. Hence, in order to grow 
diffraction grade crystals optimisation trials were undertaken.  
The overall aim of the optimisation trials was to reduce the number of nucleation sites per 
drop in order to achieve larger diffraction-grade crystals. This involved varying the AMIGO-
1/NgR complex concentration, the PEG 3350 precipitant concentration and the ratio of the 
protein: reservoir solution. Crystallisation trials were performed with AMIGO-1/NgR 
complex at 11.5, 10 and 9mg/ml and the PEG 3350 concentration was varied between 20-16%. 
These trials were set up on a large scale (1µl + 1µl) using both hanging and sitting drop 
techniques with drops derived from differing ratios of protein: crystallisation buffer (1:1, 2:1, 
3:1, 3:3, 4:1, 4:2 and 4:3). Following these optimisation trials a number of larger crystals were 
observed that were typically 100μm x 100μm in size (Figure 6.9). The condition yielding the 
most optimal crystals comprised 0.2M Mg formate and 17% PEG 3350. These were grown 
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using the sitting drop method with a drop ratio of 4:2 (protein: reservoir solution) at a final 
AMIGO-1/NgR concentration of 9mg/ml. Four of these crystals were soaked in cryoprotectant 
in reservoir solution supplemented with 20% glycerol for 30 minutes as a cryoprotection step 





Figure 6.8 Crystallisation trials of the hAMIGO-1/NgR complex. 
a) SDS-PAGE analysis of purified hAMIGO-1 and NgR for complex crystallisation trials. Both 
proteins demonstrate sufficient purity for crystallisation trials and migrate to their expected 
molecular weights. b-e) hAMIGO-1/NgR co-crystallisation trials with commercial screens 
using the hanging drop vapour diffusion method yielded micro crystals in a number of 
conditions; JCSG+ condition 1.5 (0.2M Mg formate, 20% PEG3350), JCSG+ condition 1.42 (0.2M 
MgCl2, 0.1M Tris pH8.5, 20%PEG 8000), Structure screen condition C9 (0.2M MgCl2, 0.1M Tris 
pH8.5, 30%PEG 4000) and MIDAS condition 1.40 (10% Pentaerythritol ethyoxylate). 100 + 100 




Figure 6.9. Production of diffraction-grade hAMIGO-NgR complex crystals 
a) Large crystals were generated following optimisation of the JCSG+ condition (black arrows). 
These were grown in sitting drops with a 4:2 (protein: reservoir solution) ratio at 9 mg/ml. The 
final optimised crystallisation condition comprised of 0.2M Mg formate and 17% PEG 3350.  
b) Mounted hAMIGO-1.NgR crystal that was soaked for 30 minutes in reservoir solution 
supplemented with 20% glycerol and subsequently flash cooled in liquid nitrogen. c) A 0.05° 
oscillation image of hAMIGO-1-NgR crystal diffracting X-rays to 1.9Å resolution collected at 
the Diamond light source synchrotron facility (Oxford). d) Data processing statistics for 
human AMIGO-1. X-ray data for hAMIGO-1 LRR-Ig was integrated, scaled and merged using 
programmes of the XDS suite.  Numbers in parentheses represent statistics associated with 





6.6.3 Data Collection 
X-ray diffraction data were collected remotely (at University of Birmingham) using the 
Diamond Light Source Synchrotron facility (Oxford). One of the crystals diffracted X-rays to 
1.9 Å resolution and several data sets were collected. The crystal was found to belong to the 
tetragonal space group P43212 with unit cell dimensions of; a= 94.3Å, b= 94.3Å, c= 95.2Å and 
α= 90o, β= 90o, γ= 90o. Diffraction data were integrated, scaled and merged using programmes 
of the XDS suite [116]. The relevant data processing statistics are listed in Figure 6.9d. 
6.6.4 Determining Phase Information, Model Building and Refinement 
Attempts to determine initial phase information for the hAMIGO-1/NGR complex were 
performed with molecular replacement using previously determined hAMIGO-1 (Chapter 3) 
and NgR (pdb code 1OZN) [46] as phasing models. Unfortunately, initial searches with the 
NgR phasing model yielded no significant rotation function solutions with the MOLREP 
[117], AMORE [118] and CNS [119] software packages. However, molecular replacement 
calculations with only the newly refined hAMIGO-1 LRR structure provided a single 
unambiguous rotation and translation function solution, consistent with a monomer in the 
asymmetric unit. The model was subjected to a round of refinement with CNS (simulated 
annealing and individual isotropic B-factor) and the R-factor and Rfree were reduced to 27.8 
and 30.9%, respectively. Examination of the resulting 2Fo-Fc and Fo-Fc maps revealed 
substantial electron density at the C- terminal end the AMIGO-1 LRR domain (Figure 6.10). 
This electron density was attributed to the hAMIGO-1 Ig domain which was manually built 
with COOT (Figure 6.10). Following several rounds of refinement interspersed with manual 
model building the structure of hAMIGO-1 LRR-Ig ectodomain was determined to 1.9Å 
resolution (Figure 6.11). The relevant refinement statistics for the hAMIGO-1 LRR-Ig structure 
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are listed in Table 6.1. All residues were built except for the extreme C-terminal end of the 
LRRCT subdomain (S266-C270) and the C’D loop (E312-V313) of the Ig domain which is 
characterised by a lack of associated electron density. The hAMIGO-1 ectodomain structure 
was verified using PROCHECK [153] and revealed that most residues were present in the 
allowed regions of the Ramachandran plot.  
 








Figure 6.10.  Electron density for the hAMIGO-1 Ig domain 
Substantial electron density was observed at the C terminal end of theAMIGO-1 LRR domain. 
The electron density was assumed to belong to the missing AMIGO-1 Ig domain which was 
manually built in using COOT. All residues were built in except for the extreme C-terminal 





Figure 6.11 Overall structure of the hAMIGO-1 LRR-Ig ectodomain.  
The hAMIGO-1 LRR-Ig crystal possesses one molecule per asymmetric unit  (highlighted in 
orange). The LRR domain (labelled) adopts a banana shaped fold with a parallel β-sheet  
contributing to the inner concave face and various secondary structural elements  forming the 
outer convex face. The Ig domain (labelled) adopts a closely packed β-sandwich 
encompassing two anti-parallel β-sheets. The N- and C- terminus are highlighted. The red 




6.7 Structural analysis of the full length ectodomain of hAMIGO-1  
The crystal structure of the full length hAMIGO-1 ectodomain including the LRR and Ig 
modules has been solved to 1.9 Å with R factors of Rcryst/Rfree = 23.2/25.5 %.  Despite the crystal 
form containing one hAMIGO-1 LRR-Ig monomer per asymmetric unit, the hAMIGO-1 LRR-
Ig exits as a dimer generated through the crystallographic two-fold axis (Figure 6.12). The 
dimer interface is formed by interactions mediated by residues that protrude from the LRR 
module of each monomer as described previously (see Chapter 3). The presence of the Ig 
domain does not affect formation of the dimer through the LRR domain. The linker region that 
connects the LRR and Ig domains also exhibits weak electron density suggesting that it is 
highly flexible, thereby permitting the connecting domains to freely twist and rotate which 
may be essential in the formation of the AMIGO-NgR-p75 tripartate complex.  
 6.7.1 Overall structure of the hAMIGO-1 LRR-Ig ectodomain  
The hAMIGO-1 LRR domain fold has previously been described in detail (see Chapter 3) and 
hence this section will predominantly focus on analysing the Ig module. Structural analysis 
reveals the hAMIGO-1 Ig domain adopts a C2-type immunoglobulin (Ig) fold, consisting of 
eight β stands, with a single 310 α helix positioned between the E-F strands (Table 6.2, Figure 
6.13. Consistent with its homology to the Ig superfamily, the hAMIGO-1 Ig structure adopts 
a compact beta sandwich domain encompassing two anti-parallel sheets (one comprising of 
strands B, D, E, the second A’, C, C’, F, G) (Figure 6.12). A large hydrophobic core, generated 
by inward facing hydrophobic residues from the B (L286 and I288), E (L326, F328 and V331), 
C (W301) and F (Y339) strands, contributes to stabilising the interior of the Ig domain (Figure 
6.14b). The hAMIGO-1 Ig module is further stabilised by an intra-chain disulphide bridge 
(mediated by residues C290 and C341) that links strands B and F (Figure 6.14b). This 
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prominent feature, which connects the beta sheets, is similar to other Ig-like domain 
containing proteins and is a structural hallmark of Ig-folds [175].  
As highlighted with other Ig domain containing proteins, the internal core region of the 
hAMIGO-1 Ig module is further stabilised by a conserved tryptophan residue (W301) that 
packs against the disulphide bond (Figure 6.14).  In addition to these non-polar interactions, 
the core region is further stabilised by a hydrogen bonding interaction mediated by the indole 
ring nitrogen of W301 and the backbone carbonyl group of G324.  
Residue  Secondary structure Residue Secondary Structure 
G271-A277 Random coil L310-G316 Random coil 
W278-A280 β Strand A’ T317-S321 β Strand D 
H281-G283 Random coil K322-D323 Random coil 
D284-C290 β Strand B G324-V331 β Strand E 
D291-M297 Random coil Q332-G336 310 helix  
T298-T303 β Strand C G337-G345 β Strand F 
P304-N306 Random coil A346-T347 Random coil 
E307-V309 β Strand C' F348-H359 β Strand G 
Table 6.2 Secondary structure assignments for the hAMIGO-1 Ig domain  
6.7.2 Sequence comparison of the Ig domain across the hAMIGO family 
Similarity at the primary amino acid sequence level for the Ig domain between hAMIGO-1 to 
hAMIGO-2 is 49%, hAMIGO-1 to hAMIGO-3 is 48%, and hAMIGO-2 to hAMIGO-3 is 39% 
(Figure 6.13). The most highly conserved residue positions map to the Ig core region, whereas 
the surface exposed residues are considerably less conserved (Figure 6.15). Interestingly, the 
majority of residues that contribute to the hydrophobic core are either highly conserved or 
semi-invariant across the hAMIGO family. For example, out of the 7 residues that form 
hydrophobic interactions in AMIGO-1, three are identical (residues L286, W301 and L326) and 
four demonstrate semi-conservative (residues I288 (V and I in hAMIGOs-2 and 3), F328 (I in 
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hAMIGOs-2 and 3), V331 (P in hAMIGO-2) and Y339 (F in hAMIGO-3) substitutions across 
the hAMIGO family (Figure 6.15).  Collectively, this suggests that the internal Ig hydrophobic 
core is stabilized in an analogous manner across the hAMIGO family. The precise role of the 
Ig domain within the AMIGO family is yet to be established. One possibility is that it plays a 
structural role orienting the LRR domains correctly on the cell membrane for optimal binding 







Figure 6.12 Overall structure of the hAMIGO-1 LRR-Ig dimer.  
The hAMIGO-1-LRR Ig dimer is generated by a crystallographic 2–fold axis. Each monomer 
is highlighted (orange and green). The dimer interface is mediated by residues that protrude 
from the LRR module of each monomer. The N- and C- terminus for each monomer is 
highlighted. The membrane proximal region (black dashed line), short transmembrane helix 
segment (elongated tubes; red), and the intracellular domain (thick black line) for each 
monomer are also highlighted. The cell membrane is also shown to indicate the potential 




Figure 6.13 Topology diagram for the hAMIGO-1 Ig domain.  
The secondary structure elements for the hAMIGO-1 Ig domain are labelled (strands 
represented as arrows and helix shown as a short tube). The N- and C- terminus for the Ig 


























Figure 6.14 Stabilisation of the hAMIGO-1 Ig core.  
The beta sheets are stabilised by an inter-chain disulphide bond (mediated by C90 and C341), 
an invariant tryptophan residue (W301) and multiple non-polar interactions mediated by 





Figure 6.15 Sequence alignment of human AMIGO Ig domain.  
Sequences were obtained from Uniprot (accession numbers (hAMIGO-1), (hAMIGO-2) and 
(hAMIGO-3) and aligned with Praline. The colour scheme of the alignment is for amino acid 
conservation. The cysteine residues that form an internal disulphide bridge are highlighted 
(black star). Residues that contribute to stabilising the Ig core are shown (blue circles). 
hAMIGO-1 Ig structure based secondary structural elements are colour coded (β sheets are 








6.7.3 Identification of homologous proteins to hAMIGO-1 Ig domain 
Similarly, to mAMIGO-1, the hAMIGO-1 LRR–Ig structure reveals an arrangement in which 
a C2‐type Ig domain folds slightly back onto the convex face of a horseshoe‐shaped LRR 
domain. This domain composition is also observed, albeit in a rather more extreme fashion, 
with the neuronal Nogo‐66 receptor‐binding glycoprotein LINGO‐1 [69] and netrinG ligand 
2 (NGL2) [167] (Figure 6.16). These differences could be attributed to the considerably larger 
LRR-Ig linker regions which allow LINGO-1 and NGL2 to adopt distinct conformations 
relative to hAMIGO-1. The hAMIGO-1 LRR-Ig linker region (G271-Y273) packs against the 
LRR domain via non-polar interactions involving Y230, H235 and Y238. In addition, the 
hAMIGO-1 LRR-Ig interface is further stabilized by multiple hydrogen bonding interactions 
involving the B-C loop of the Ig domain (D291, T292, K293 and Q295) and the C-terminal 
regions of the LRR (P185, A210, W211 and R239).     
Proteins that were closely related  to the hAMIGO-1 Ig domain were identified using the DALI 
automated structural comparison software [158]. With the exception of mAMIGO-1 (Figure 
6.17), the most structurally homologous proteins included neuronal cell adhesion molecule 1 
(NCAM1; pdb code 5AEA) [176], LINGO-1 (pdb code 2ID5) [69] and NGL2 (pdb code 3ZYI) 
[167], with Z scores (conforming to degree of structural identity) of 12.3, 12.0 and 11.4, 
respectively. Notably, despite displaying very low levels of sequence conservation (> 20 %), 
all structural homologues adopt a C-type Ig fold [177] and the structure of each can be 
superimposed onto hAMIGO-1, resulting in an RMSD of 1.37 Å for Lingo-1 (over 77 Cα 
aligned atoms), 1.47 Å for NGL2 (over 77 Cα aligned atoms) and 1.59 Å (over 82 Cα aligned 
atoms) for NCAM1 (Figure 6.17). Also, barring NCAM1, each homologue associated with a 
LRR domain. The highly conserved feature of the Ig domain within LRR-Ig family members 
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implies that it serves an indispensable function that is yet to be established but most likely 
involves orientating the LRR modules away from the membrane to facilitate ligand 







Figure 6.16 Structurally homologous proteins to hAMIGO-1 LRR-Ig. 
Proteins homologous to the hAMIGO-1 ectodomain, including LRR and Ig domains, are 
highlighted. a) hAMIGO-1 (Orange), b) mAMIGO-1 (PDB code 2XOT), c) LINGO-1 (PDB code 
2ID5) and d) NGL2 (PDB code 3ZYI). All proteins adopt a banana- shaped fold in their LRR 
domains. The largest variation is observed in the LRR-Ig linker region which exhibit distinct 












Figure 6.17 Identification of structural homologues for the hAMIGO-1 Ig domain using the 
Dali server.  
Protein Ig domains homologous to the hAMIGO-1 ectodomain identified by DALI analysis 
are highlighted. a) mAMIGO-1 (PDB code 2XOT), b) NCAM1 (PDB code 5AEA), c) LINGO-1 
(PDB code 2ID5) and d) NGL2 (PDB code 3ZYI). Despite low levels of sequence identity the 
protein domains all adopt a C2-type Ig fold. e) All DALI identified structural homologues 




6.7.4 Comparison with mAMIGO-1 
Structural comparisons between mouse and human AMIGO-1 have demonstrated 
considerable similarities for the Ig module (Figure 6.18). Indeed, structure-based alignments 
of the hAMIGO-1 Ig domain with the equivalent region of mAMIGO-1 revealed a RMSD of 
1.37 Å (for 80 Cα atoms). The largest structural variation was observed in the loop regions 
that flank strand D (Figure 6.18a). These differences could be accounted for by crystal packing 
elements although this region demonstrated considerable sequence variation between the 
homologues (Figure 6.18b).  Consistent with the high levels of sequence identity between the 
Ig domains of hAMIGO-1 and mAMIGO-1, the electrostatic molecular surface properties were 
remarkably similar (Figure 6.18c).   
6.7.5 Temperature factor analysis of hAMIGO-1 LRR-Ig domain 
Temperature factor analysis of the hAMIGO-1 LRR-Ig ectodomain revealed distinct 
differences in the average main chain B-factors for the LRR domain (33.6 Å2) and the Ig 
module (54 Å2) (Figure 6.19a, 6.19b). The highest B-factors were mapped to residues located 
near the LRR-Ig linker leading to a paucity of electron density for residues in this region. 
Interestingly, this difference in the average B-factors between the LRR and the Ig domain was 
also observed for mAMIGO-1 (26.4 Å2 and 38 Å2 for the LRR and Ig domain, respectively; 
Figure 6.19c, 6.19d), but not for other proteins that exhibit a LRR-Ig fold including LINGO-1 
and NGL2. It is possible that within AMIGO-1 the LRR-Ig linker region is highly flexible in 
the unliganded state but rendered more stable following interactions with ligands such as 




Figure 6.18. Comparison of the human and mouse AMIGO-1 Ig domain. 
a) Superimposition of the hAMIGO-1 (orange) and mouse AMIGO-1 (teal) Ig domains.  The 
red dashed circle highlights the area with the largest structural variations. b) Sequence 
alignment of human and mouse AMIGO-1 Ig domains, interestingly the area which 
demonstrates most sequence variation (red dashed box) corresponds to the looped region  
highlighted in a). c) Comparison of the molecular surface electrostatic potentials of human 
AMIGO-1 and mouse AMIGO-1. The electrostatic potential was calculated using Delphi. The 
potential scale ranges from -7 (red) to +7 (blue) in units of kT/e. The electrostatic surface 





Figure 6.19. Temperature factor analysis of hAMIGO-1 and mAMIGO-1 LRR-Ig domains.  
The main chain temperature factors as a function of amino acid residues for the hAMIGO-1 
LRR (a), hAMIGO-1 Ig (b), mAMIGO-LRR (c) and mAMIGO-1 Ig (d) domains. The solid red 
line represents the mean B-factor which comprised of 33.6Å2 (hAMIGO-1 LRR), 54Å2 
(hAMIGO-1 Ig), mAMIGO-1 LRR domain which are around 26.4Å2 (mAMIGO-1 LRR) and 
38Å2 (mAMIGO-1 Ig).  In both cases the B-factors for the LRR domains are considerably lower 





6.7.6 Electrostatic molecular surface properties of hAMIGO and mAMIGO Ig domains.  
Three dimensional models of the hAMIGO-2, and -3 Ig domains were generated with PHYRE 
using the hAMIGO-1 crystal structure as a modelling template. Despite low levels of sequence 
identity between the Ig domains of hAMIGO-1 and hAMIGOs-2 and -3 (26-27%), an extremely 
large degree of structural identity was evident. The majority of the non-conservative amino 
acid substitutions found in hAMIGOs 2 and 3, when mapped onto the hAMIGO-1 structure, 
are located on the surface. Hence, the high level of sequence diversity observed in solvent 
accessible positions suggested the possibility that the Ig domain may not be a conserved 
feature of NgR/p75 interactions with hAMIGO-1, or may not be directly involved at all. . To 
evaluate this further, an electrostatic potential map for the hAMIGO-2 -3 models was 
calculated with DELPHI. Comparison of the surface electrostatics between hAMIGO-1 and 
hAMIGOs-2 and 3 demonstrated distinct electrostatic properties, particularly on each face of 
the β-sheet (Figure 6.20). Similarly, the crystal structure of the Lingo-1 Ig domain, which has 
previously been implicated in binding NgR [77, 84], demonstrated a distinct surface 
electrostatics compared with hAMIGO-1 (Figure 6.17).  
A similar pattern emerged when examining the primary sequence and electrostatic surface 
properties of mAMIGO family members. Indeed, sequence comparison of mAMIGO-1 with 
mAMIGOs 2 and -3 revealed low levels of sequence identity at 21-25% (Figure 6.21). The 
majority of the non-conservative substitutions were focused on the surface when mapped 
onto the mAMIGO-1 structure.  However, similar to the hAMIGO family, there was a distinct 
lack of surface electrostatic conservation across the mAMIGO family (Figure 6.21) further 
leading credence to the notion that the AMIGO Ig domain may not be directly involved in 




Figure 6.20. Comparison of the molecular surface electrostatic potentials of hAMIGO-1/-2/-
3 and LINGO-1 Ig domains.  
The molecular models of hAMIGO-2 and hAMIGO-3 were generated using PHYRE and 
electrostatic potentials were calculated using Delphi. The potential scale ranges from -7 (red) 
to +7 (blue) in units of kT/e. a) front view, b) rear view. Each Ig domain displays distinct 








Figure 6.21. Comparison of the molecular surface electrostatic potentials of mAMIGO-1/-
2/-3 Ig domains.  
The molecular models of mAMIGO-2 and mAMIGO-3 were generated using PHYRE and 
electrostatic potentials were calculated using Delphi. The potential scale ranges from -7 (red) 
to +7 (blue) in units of kT/e. Similar to the hAMIGO family, each Ig domain exhibits distinct 







6.7.7 Comparisons with LINGO-1 
There are six N-linked glycosylation sites (N144, N202, N264, N274, N293, N341) present 
within the LRR of LINGO-1 which are likely to restrict surfaces available for interactions 
between LINGO-1 and its ligand binding partners (Figure 6.22). These sites appear to be 
conserved across LINGOs 2-4. Although the concave surface of most LRR proteins is used for 
ligand engagement and/or dimerization [120, 154], N-linked glycans on N293 and N341 in 
LINGO-1 are expected to block this surface thereby dictating that the convex face represents 
a potential site for binding (Figure 6.22). It is anticipated that this will also hold true for 
LINGOs 2–4. More recent studies have suggested that the Ig domain is important for NgR 
binding based on domain deletional mutagenesis of the LINGO-1 ectodomain [84].  
Furthermore, intact LINGO-1 ectodomain constructs incorporating the RKH to EKV mutation 
within the Ig domain prevented MBP expression in OPC differentiation studies when trying 
to identify functional epitopes in the LINGO-1 ectodomain. . Interestingly, the RKH sequence 
motif is not only absent in LINGOs 2-4 but also from the AMIGO family (Figure 6.22).  
The predicted N-linked glycosylation sites on hAMIGO-1 LRR-Ig ectodomain may also 
provide hints as to which region of the exterior surface is likely to recognise NgR and p75NTR. 
In total there are 5 predicted N-linked glycosylation motifs in the hAMIGO-1 ectodomain; two 
in the LRR domain (N72 and N264) and three in the Ig module (N315, N349 and N360).  
Interestingly, N-linked glycans on N72 and N264 are distal to the putative ligand binding site 
identified on the convex surface and therefore unlikely to interfere with ligand engagement 
(Figure 6.23). The 3 predicted N-linked glycosylation sites present in the Ig domain would 
likely prevent this domain from being able to form protein-ligand interaction. Also, the 
predicted LRR N-linked glycans of hAMIGO-2 (N58 and N104) and hAMIGO-3 (N107) can be 
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mapped on to the convex face suggesting that these surfaces do not contribute to protein-
protein interactions. Furthermore, the Ig domains of hAMIGO-2 and hAMIGO-3 are likely to 
be heavily glycosylated as they exhibit 6 and 4 predicted N-linked glycosylation motifs, 





Figure 6.22. Comparison of AMIGO-1 and LINGO-1 ectodomains. 
a) The LINGO-1 ectodomain including LRR and Ig domain with N-linked glycosylation 
sites mapped on. Two N-linked glycosylation sites are located on the concave face of 
the LRR domain indicating that this area is unavailable for ligand binding.  The RKH 
motif in the Ig domain is also highlighted (blue box), which has been identified as 
being necessary for binding to NgR [77].  
b) Sequence alignment of hAMIGOs-1/-2/-3, LINGO-1 and mAMIGO-1. The RKH motif 
is highlighted with red asterisks; these residues are not conserved between LINGO-1 





Figure 6.23. The hAMIGO-1 ectodomain with N-Linked glycosylation sites mapped.  
The hAMIGO-1 ectodomain including LRR and Ig domain with N- linked glycosylation sites 
mapped in green. Two N-linked glycosylation sites (N72 and N264) are located on the convex 
face of the LRR domain indicating that this area is likely to be unavailable for ligand binding. 
Three other N-linked glycosylation sites (N315, N349 and N360) are located on the Ig domain. 
N-linked glycosylation site N315 is located within the C’-D loop which is disordered. 
N-linked glycosylation sites present on AMIGO-2 (N58, N104, N281, N288, N345, N373 and 
N381 and AMIGO-3 (N107, N272, N301, N362 and N368) can also be modelled onto their 
predicted structures.  In both cases, the N-linked glycosylation sites are either on the convex 
face of the LRR domain or on the Ig domain indicating, that similar to AMIGO-1, the concave 
face represents the most likely ligand binding site.  
220 
 
6.8 Discussion  
In this chapter protein-protein binding assays and structural techniques were used to probe 
interactions of key components of the NgR receptor complex.  
6.8.1 BIAcore 
A key aim was to establish whether the AMIGO proteins studied in chapters 3-5 are able to 
interact directly with NgR via their ectodomain regions, as has been demonstrated for LINGO-
1, and as immunoprecipitation results suggested in Chapter 5. The BIAcore studies first 
established an experimental system involving immobilisation of recombinant NgR protein to a 
streptavidin-coated chip surface, via a site specific biotinylation incorporated into a C-terminal 
tag. In contrast to other approaches tried, this enabled oriented coupling, enabling interactions 
between NgR and putative partners in the Nogo receptor complex, LINGO-1, and the AMIGO 
family proteins, to be tested.   
These BIAcore experiments provided the first unequivocal evidence that AMIGO proteins 
directly interact with NgR, and indicate the AMIGO ectodomains are involved in such 
NgR/AMIGO interactions. In doing so, they provide independent validation of the IP 
experiments in chapter 5, which suggested AMIGO proteins associate with NgR, and extend 
the findings by establishing a direct interaction. Specifically, both AMIGO-1 and AMIGO-3 
bound immobilised NgR, and LINGO-1 was also confirmed as capable of directly binding 
immobilised NgR. Unfortunately, data on AMIGO-2 were not collected, as recombinant 
AMIGO-2 was not successfully produced using the Drosophila-based expression system 
employed. Similarly, binding to p75NTR could not be tested satisfactorily, as the recombinant 
protein was poorly expressed. In addition, despite detecting both AMIGO and LINGO-1 
interaction with “in-house” recombinant NgR, commercial NgR-Fc and p75NTR both failed to 
interact with these target proteins. These observations underline the importance of high quality 
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recombinant proteins for meaningful direct protein-protein binding assays. The reasons why 
AMIGO-2 and p75NTR were not successfully expressed in the Drosophila expression system 
are unclear, but could include misfolding, and/or the requirement for human-specific 
glycosylations.  
Although this was not the primary aim, in principle, the experimental BIAcore system 
established could be exploited to shed further light on NgR/ligand interactions. One possibility 
would be to develop it further to carry out quantitative measurements of NgR/ligand 
interactions and determine affinity and kinetic measurements. This was not carried out largely 
due to time constraints. Notably, affinity measurements have been reported previously for 
LINGO-1/NgR interaction [69] (Kd of ~1µM), although the activity levels of immobilised NgR 
was extremely low in this study, and far higher in the experimental system I established; 
AMIGO/NgR interaction has not previously been tested by BIAcore and the affinity of such 
interactions is unclear. Future experiments to determine affinities could include equilibrium 
binding. Although higher concentrations of LINGO-1/AMIGO injections reached equilibrium, 
suggesting such approaches might be feasible, some sticking to flow cell surfaces was observed 
– likely resulting from protein aggregation under these conditions. These could be eliminated 
by size exclusion chromatography, after which much less sticking was observed, however the 
low concentrations meant that binding responses did not reach equilibrium, and therefore 
kinetic analyses might be preferable in order to determine Kd values. Although kinetic 
measurements would have been interesting, these can be time-consuming to obtain robust 
measurements and other workpackages, some of which required large amounts of recombinant 
protein (like NgR/LINGO and NgR/AMIGO complex trials) were prioritised over these 
experiments. However, in the future, kinetic measurements would require high flow rates and 
low levels of immobilised ligand (NgR) in order to eliminate mass transport effects that limit 
efficient delivery of analyte to (or removal from) the surface, artefactually constraining the 
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kinetic constants measured.   This may be of interest in the future, and might potentially allow 
AMIGO-1/-2/-3 affinities/kinetics for NgR to be correlated with functional potency in the 
Nogo receptor complex.  
 
A second possible use of the system would be to use it in conjunction with mutational studies 
on NgR and AMIGO/LINGO-1 proteins to test hypotheses regarding NgR/ligand binding 
modes. These would include testing the hypothesis (Chapter 4) that AMIGO proteins use the 
concave face of their LRR domain to interact with NgR. Site-directed mutants could be 
selected based on their amino acid type, phylogenetic conservation and location on the surface 
of the domain. The mutant proteins could be expressed and their ability to bind NgR (and also 
p75NTR if direct binding could be established) could be assessed by BIAcore and parallel 
functional assays. Initially, it would also be beneficial to produce whole domain deletion 
mutants to assess if the Ig domain of AMIGO-1 is redundant or critical for binding to NgR 
and p75NTR. More in-depth analysis would follow, by selecting a residue or group of residues 
to mutate in order to pinpoint a ligand binding site. In determining where to commence these 
more in depth mutational studies it would be prudent to start at the concave face which we 
have suggested is the most likely ligand binding site.  
6.8.2. Co-crystallisation and Structural studies 
Structural studies initially aimed to determine the crystallographic structure of AMIGO/NgR 
complex, with a series of co-crystallisation trials. Although crystals were obtained from 
AMIGO-1/NgR trials, a lack of molecular replacement solutions for NgR in the processed data, 
combined with a successful solution for AMIGO-1 LRR, suggested the crystals may only 
contain AMIGO-1. Initial inspection of electron density maps indicated unaccounted for 
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density that appeared to be the AMIGO-1 Ig domain. The favourable statistics for refinement 
of a protein model consisting solely of AMIGO-1 LRR-Ig confirmed that the crystals had 
resulted from selective crystallization of the AMIGO-1 LRR-Ig from the AMIGO-1/NgR 
complex trial conditions. This ultimately resulted in structure determination of the full-length 
AMIGO-1 ectodomain including the LRR and Ig domain to 1.9Å. In Chapters 3 and 4, the Ig 
domain of AMIGO-1 was cleaved under crystallization conditions meaning only the structure 
of the LRR domain was determined. One possibility is that the presence of NgR in the 
crystallization trials helped to stabilize the AMIGO-1 protein ectodomain, preventing 
cleavage of the Ig domain. However, other possibilities, such as differences in buffer 
composition or contaminants from the NgR preparation inhibiting proteases responsible for 
cleaving the AMIGO-1 LRR-Ig domain cannot be excluded. It is also unclear why AMIGO-1 
selectively crystallised rather than crystallising as complex with NgR as intended, however 
this might conceivably relate to AMIGO-1 LRR-Ig intermolecular protein-protein interactions 
being particularly favourable.  Given more time for additional recombinant protein 
production, more efforts could have been devoted to obtaining either AMIGO-1/NgR or 
LINGO-1/NgR complexes. Despite this, the full length AMIGO-1 LRR-Ig domain structure 
provided additional information relative to the AMIGO-1 LRR structure.  
The full length, LRR and Ig domain containing structure, like the LRR domain structure, is a 
dimer in crystallographic form. The Ig domain is a C2- type Ig domain containing a large 
hydrophobic core which helps stabilise the domain with hydrogen bonding and a disulphide 
bridge also contributing.  Temperature factor analysis of the hAMIOGO-1 ectodomain 
demonstrates differences between the LRR and Ig domain components with higher B factors 
seen in the Ig domain and the highest B factors observed in the linker region, indicative of 
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increased flexibility. Therefore, it is possible that there is considerable flexibility in LRR-Ig 
linker under physiological conditions, and this may allow AMIGO-1 to accommodate 
different ligands, such as NgR and p75NTR. Consistent with this, conformational flexibility has 
been observed with mAMIGO-2 based on SAXS analysis [120].  Furthermore, the finding that 
the hydrophobic core residues of AMIGO-1 Ig are conserved across AMIGO-2 and -3, whereas 
non-conservative substitutions are predominantly surface localised, suggests a conserved 
core structure of this domain across the AMIGO family, but also hints that the electrostatically 
diverse Ig domain surfaces may have a limited role in binding to NgR. Interestingly, LINGO-
1 does not share the same pattern indicating the protein has a less flexible Ig domain despite 
the fact the linker region is shorter in AMIGO-1 than LINGO-1. 
Among the more interesting structural findings was the location and orientation of predicted 
N-linked glycosylation sites on the hAMIGO-1 ectodomain, which may provide hints as to 
which region of the exterior surface is likely to recognise NgR and P75NTR. In total there are 5 
predicted N-linked glycosylation motifs in the hAMIGO-1 ectodomain; two in the LRR 
domain (N72 and N264) and three in the Ig module (N315, N349 and N360).  Previously in 
chapter 4, it was shown that the N-linked glycans on N72 and N264 were located on the 
convex face of the LRR domain, distal to the putative ligand binding site identified on the 
concave surface (see chapter 4). In addition, comparable predicted N-linked glycans on the 
LRR of hAMIGO-2 (N58 and N104) and hAMIGO-3 (N107) were also mapped on to the 
convex face. The full length LRR and Ig domain containing structure of AMIGO-1 reveals the 
localisation of these sites with respect to the Ig domain, and also reveals the likely orientation 
of N-linked glycosylations on the Ig domain itself (N315, N349 and N360). N-linked 
glycosylation sites on the Ig domain (N315, N349 and N360) were distal to the concave face of 
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the LRR domain, but oriented in different directions. This is consistent with the idea that the 
concave face of the AMIGO-1 ectodomain is used for binding and is also consistent with the 
idea that the Ig domain may play a limited role in ligand interactions.  
Crystallographic studies also shed light on the key question of which region of hAMIGO is 
responsible for binding NgR and p75NTR. Sequence analysis of the hAMIGO-1 Ig domain 
reveals very low levels of sequence identity compared to other family members. However, the 
minority of conserved amino acids were preferentially localised to the hydrophobic core. In 
contrast, the surface of the Ig domain preferentially comprises residues that are chemically 
distinct between each AMIGO family members, suggesting the Ig domain is highly unlikely 
to form a common ligand binding site.  In contrast, the concave exterior surface of the LRR 
module, which unlike that of LINGO-1 is devoid of N-linked glycosylation sites, contains a 
region of evolutionarily conserved patches of charged residues, possibly suggestive of 
common ligand binding sites. It is therefore possible that LINGO-1 and the AMIGO proteins 
use distinct regions of their homologous domains to achieve comparable functions in 
hindering neuronal regeneration. In the last decade LINGO-1 binding to NgR1 and p75NTR to 
form the inhibitory tripartite LINGO-1–NgR1–p75NTR signalling complex through RhoA 
activation has been subject to in-depth investigation [52, 68, 69, 178]. Indeed, epitope mapping 
data, which employed ELISA assays to study which domains of LINGO-1 were involved in 
ligand interactions, revealed that individual LINGO-1 LRR- and Ig constructs bound NgR1 
with relatively lower affinity (EC50 values of 120 and 60 nM, respectively) compared to the 
full-length ectodomain (EC50 value of 6nM). In addition, mutation of an RKH-to-EKV motif 
within the Ig domain of the intact ectodomain (residues 462-464) led to a 20-fold reduction in 
EC50, suggesting that the RKH within the Ig domain contributes to the binding [77]. Bourikas 
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et al. (2010) [84] also used domain truncation analysis to map binding of p75NTR and 
demonstrated that the LINGO-1 LRR module was not essential for the inhibitory actions of 
the protein but that the Ig domain and stalk region were sufficient in inhibiting 
oligodendrocyte progenitor cell (OPC) differentiation.  While these studies may shed some 
light on LINGO-1/ligand interactions, the crystallographic data presented here indicate that 
the AMIGO proteins may use a completely different binding mode (relative to LINGO-1) to 
bind ligands, employing the concave rather than the convex surface of the LRR domain. Based 
on the evidence provided, we suggest that it is most likely that the AMIGO family of proteins 
bind ligands using their concave faces, similar to the majority of LRR domain containing 
proteins. In contrast, it is less clear which face of LINGO-1 is most heavily involved in ligand 
engagement. 
Finally, recent studies have shown that rat AMIGO-3, an LRR- Ig domain containing protein 
implicated in CNS axon growth inhibition, also forms NgR–p75NTR and NgR–Troy signalling 
complexes [107]. I have shown in Chapter 5 that human AMIGO- 1 and -3 co-localise, based 
on IP analysis, with NgR and p75NTR in cell membranes. In this chapter, I was able to confirm 
direct AMIGO-1/-3 interaction with NgR via BIAcore technology. Unfortunately, I was unable 
to concentrate AMIGO-3 to high enough levels to allow crystallography studies, due to the 
instability of the protein at high concentrations, despite solubility screens giving clues as to 
an appropriate buffer for the protein. As mentioned previously, limited proteolysis was used 
to enable crystallisation of LINGO-1 [69], this established method could be employed in the 
future to facilitate crystallisation of hAMIGO-3.  
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Collectively, these results now provide a detailed framework for future structure-function 
studies aimed at assessing the physiological relevance of AMIGO-mediated protein-protein 

















































7.1. Understanding the role of the AMIGO family in the Nogo receptor complex 
Central Nervous System tissues exhibit only limited regeneration after tissue injury resulting 
from trauma, stroke or inflammatory conditions (such as Multiple Sclerosis). The key 
constraints on CNS regeneration and the underlying molecular mechanisms have emerged in 
the last decade, involving myelin derived breakdown products, such as the “Nogo” protein, 
transmitting potent anti-regenerative signals to adjacent neurons by binding to a tripartite 
receptor complex comprised of NgR, p75NTR/TROY and LINGO-1 on the neuronal cell surface. 
Disruption of the NgR inhibitory signalling axis via either antibody approaches or small 
molecule inhibitors represents a major therapeutic avenue for potentiating CNS regeneration 
after injury or disease. However, inhibition of LINGO-1 alone does not completely reverse 
neuronal inhibition [68, 73, 74] and it has been suggested that the AMIGO proteins may also 
be critical in modulating the negative response to regeneration after injury. However, a 
comprehensive understanding of the molecular basis of human AMIGO receptor function is 
currently lacking, but is likely to be critical to such efforts. In this thesis, I investigated the 
hypothesis that AMIGO proteins are key members of the NgR complex, and carried out 
molecular, structural and cellular experiments to probe both the involvement of AMIGO 








7.2. Structural studies on AMIGO-1 
In Chapters 3 and 4 I employed X-ray crystallography to shed light on the structure of 
AMIGO-1, which culminated in solving the structure for the LRR domain of AMIGO-1. The 
resolution of the structure (2.4Å) was sufficient to allow detailed structural comparisons with 
other proteins, to analyse involvement of surfaces in oligomerisation, and to assess molecular 
surface properties that might be involved in ligand binding interactions.  
 
Aside from establishing a domain architecture for the AMIGO-1 LRR domain broadly in 
keeping with those of other LRR proteins, two key findings emerged from this work. Firstly, 
the structure supported the idea that AMIGO-1 is a dimer, as it highlighted a dimer interface 
within the crystal.  As outlined in chapter 4, several reasons suggest this dimer is 
physiologically relevant, not least the substantial size of the interface region, the conservation 
of amino acids involved across AMIGO family members and in LINGO-1, and also the 
observation that the size exclusion profile of AMIGO-1, which is consistent with a dimeric 
oligomerisation state. These considerations support the idea that human AMIGO-1 can form 
a dimer that is biologically relevant, although its precise role in engagement of ligands is 
currently unclear.  
 
A second key area the structure has contributed to is consideration of which areas of AMIGO-
1 might be involved in engaging ligands. A substantial body of studies on LRR proteins has 
established that ligand engagement often occurs via the concave face of the LRR domain, and 
electrostatic analyses of the structure suggests this may also be the case for AMIGO-1, 
highlighting notable electronegative patches on the concave face of the molecule, in contrast 
to a somewhat electrostatically featureless convex face. Consistent with involvement of the 
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concave face of the molecule,  N-linked glycosylation sites on the LRR domain mapped to the 
convex face, leaving the concave face unhindered for potential protein-protein interactions. 
Importantly, the electronegative patches observed on this concave face were not only distinct 
from those residues involved in AMIGO-1 dimerisation, but were also conserved strongly 
across the AMIGO family. These observations provide strong circumstantial evidence for the 
importance of the concave face of AMIGO-1 in ligand interactions, and suggest that this 
involvement is likely to apply to other AMIGO proteins.  
 
Although I was not able to test these hypotheses in the work presented in this thesis, the 
availability of the hAMIGO-1 structure can now facilitate a number of experiments to address 
whether they are correct. To systematically evaluate whether any of the proposed AMIGO-1 
ligand binding residues are critical (or to probe importance of the AMIGO-1 dimerisation site) 
directed mutagenesis could be used to generate a series of hAMIGO-1 mutants,  each 
incorporating a specific point mutation, and assessed for binding candidate partners using 
either immunoprecipitation methods in whole cells (see Chapter 5 discussion below) , or  
using a direct protein-protein assay such as SPR (see Chapter 6 discussion). These analyses 
would identify and define the limits of such functionally important ‘hot spot’ regions, 
including residues highlighted as important for AMIGO-1 dimerisation and putative ligand 
binding regions, and in doing so provide further insights into how hAMIGO-1 recognition of 
binding partners might modulate neuronal regeneration. In addition, where structures of 
partner candidate ligands are available, approaches such as computational docking might 





7.3. Characterising involvement of AMIGO proteins in the NgR complex 
In Chapter 5, I extended my approaches to a set of cellular experiments aimed at directly 
assessing the involvement of AMIGO proteins in the NgR complex. Initial expression studies 
successfully achieved expression of AMIGO- 1,-2 and -3 in HEK293T cells, and also 
highlighted a novel cleavage product for AMIGO-2.  
 
Subsequent cell fractionation studies were then carried out, and confirmed that the AMIGO 
proteins are present in cell membranes. Although this would be expected given they are type 
I transmembrane glycoproteins, this finding is important because as both NgR and p75NTR are 
membrane-associated, localisation to membranous compartments is likely to be a prerequisite 
for physiological association with either protein as part of the NgR complex. In addition, the 
finding that LINGO-1 was mainly cytoplasmic supports previous findings on LINGO-1 [126], 
and raises questions as to which subcellular compartments are involved in mediating LINGO-
1 association with p75NTR and NgR.   
 
Arguably the most important set of findings were based on immunoprecipitation assays 
applied to HEK293T cells expressing various combinations of AMIGO proteins and NgR 
complex components, utilising recombinant tags, namely FLAG and HA. These studies have 
provided the first evidence that each individual human AMIGO family member is able to 
interact with both NgR and p75NTR. These findings are potentially important, particular given 
the observation that following injury, expression of AMIGO family members (eg AMIGO-3) 
can be increased to levels that are substantially higher than LINGO-1 in rat neuronal injury 
models. However, various caveats should be noted, particularly the use of overexpression 
systems and tags, which can potentially affect localisation of transfected components, and 
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could conceivably lead to artefactual results. Attempts were made to use AMIGO-specific 
mAbs to detect these interactions in human tissue samples, however the results were 
somewhat ambiguous and clearly further studies are required in this area. In addition, 
immunoprecipitation approaches provide little information about whether interactions 
detected are direct or whether they are indirect. To resolve this, direct protein-protein binding 
assays are more informative and this was part of the reason for developing SPR-based 
approaches to directly test AMIGO/NgR/p75NTR interactions, as outlined below in relation to 
Chapter 6.  
 
One promising avenue for future studies would be to combine the immunoprecipitation 
approaches developed in this chapter to assess AMIGO/NgR/p75NTR interactions, with 
structurally informed mutagenesis approaches (see above). This could help confirm which 
regions of AMIGO-1 (or other family members) are important for interactions with either NgR 
or p75NTR, and could reciprocally be used to identify regions of NgR or p75NTR that might also 
be involved in NgR complex interactions.    
 
A second important development would be to address whether AMIGO interactions with 
NgR complex proteins could mediate Nogo receptor signalling in response to myelin 
breakdown products.  In principle this is relatively feasible and would exploit identical co-
expression systems developed in this chapter with commercially available Rho signalling 
assays following exposure to myelin-associated inhibitory proteins. Attempts were made to 
establish these assays, however despite the fact they have been successfully applied to confirm 
the contribution of rat AMIGO-3 proteins to NgR complex signalling [107]; unfortunately 
substantial background signals were evident, precluding their use on the human AMIGO 
234 
 
proteins I have focussed on. However, additional efforts focussed on establishing systems 
with which to validate the importance of human AMIGO proteins to NgR complex signalling 
are clearly warranted.  
 
7.4. Understanding AMIGO/ligand interactions in the NgR complex 
Following my studies that highlighted human AMIGO proteins could be co-
immunoprecipitated with both NgR and p75NTR, I exploited surface plasmon resonance (SPR) 
to test whether these associations were the result of direct protein-protein interactions. A 
significant achievement was to establish an experimental system that enabled oriented 
coupling of NgR components, facilitating detection of ectodomain interactions. Importantly 
this enabled me to both confirm direct interaction of LINGO-1 ectodomain with NgR, and also 
to establish for the first time that AMIGO-1 and AMIGO-3 are able to interact directly with 
NgR. Unfortunately, poor expression of both p75NTR and AMIGO-2 precluded interactions 
with these proteins being analysed.  
 
While these experiments were important in both confirming the co-immunoprecipitation 
results outlined in Chapter 5 and establishing direct AMIGO/NgR interactions, future studies 
could extend these findings by exploiting the BIAcore experimental system established to 
carry out quantitative measurements of the relevant interactions, including affinity and/or 
kinetic measurements. In addition, as highlighted earlier, SPR could be combined with 
mutagenesis approaches to define which regions of the AMIGO-1/-3 and LINGO-1 proteins 
are involved in NgR interaction, and to define regions of NgR involved. The importance of 
AMIGO-1 residues involved in dimerization could also be probed using this approach. 
Parallel information on the relative potency of the proteins in NgR complex signalling would 
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also be desirable (see above) and could be correlated with affinity and kinetics of the 
underpinning interactions.  
 
Having established direct AMIGO/NgR interaction using SPR, a key additional aim was to 
carry out co-crystallisation experiments with the aim of determining an AMIGO/NgR 
complex structure. These efforts were focussed on AMIGO-1, and yielded crystals, although 
these ultimately transpired to contain only AMIGO-1, illustrating the challenge of successful 
complex crystallisation. Nevertheless, the structure obtained is the first structure of the 
complete ectodomain of human AMIGO-1 (Chapter 4 described the structure of the LRR 
domain alone), and allowed the LRR and Ig domain components to be analysed in the context 
of each other. Importantly, the AMIGO-1 LRR-Ig protein remained a dimer in the crystal, 
consistent with the suggestion that AMIGO-1 dimers may be physiologically important. 
Notably, the core of the Ig domain, but not its surface amino acids, was conserved across the 
AMIGO family, suggesting the Ig domain may have a limited role in engaging ligands. In 
addition, the full length structure enabled all N-linked glycosylations to be mapped on the 
structure, including three located on the Ig domain. Importantly, all of these glycosylation 
sites were distal to the concave face of the molecule hypothesised to be important for ligand 
engagement, highlighting that the concave face is a likely surface for ligand interactions.  
 
Clearly major questions remain to be answered before a clear molecular understanding of the 
NgR complex is achieved. A solid knowledge base of the structural basis of key interactions 
involved is critical, and future studies could devote additional efforts to achieving either 
LINGO-1/NgR or AMIGO/NgR crystal complexes. While the structural results in Chapters 4 
and 6 strongly implicate the concave face of AMIGO-1 in ligand binding, it is still somewhat 
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unclear how LINGO-1 ligand engagement takes place. In addition, studies on other LRR 
domain proteins, including decorin, which forms a dimer analogous to AMIGO-1, have 
suggested that decorin may transition from a dimer to a monomer to enable ligand binding 
[94]. Structural studies on LINGO-1/NgR or AMIGO/NgR complexes could clarify how 
LINGO-1 and AMIGO-1 oligomerisation relates to ligand interaction. A coordinated approach 
aligning such studies to functional assays and mutagenesis would have a significant impact 
on understanding of the NgR receptor complex, and would undoubtedly shed light on 
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Primer sequences used for PCR 
Restriction sites that were incorporated into the primers are highlighted in red, start codons 
are boxed and stop codons are underlined.  
 Primer Sequence Restriction site Length of product 
Amigo1 forward 5’GATCGAATTC|ATG|CA 
CCCCCACCGTGACCCG 3’ 
EcoR1 1476bp 
Amigo1 reverse 3’AGACTATGCGGGTAA 
CACCACGAGCTCCTAG 5’ 
Xho1 1476bp 
Amigo2 forward 5’GATCGGATCC|ATG|TC 
GTTACGTGTACACACT 3’ 
BamH1 1569bp 
Amigo2 reverse 3’ TGTGGAAAACACCGC 
AGGTGAGAGCTCCTAG 5’ 
Xho1 1569bp 
Amigo3 forward 5’GATCGGATCC|ATG|AC 
CTGGTTGGTGCTGCTG 3’ 
BamH1 1509bp 
Amigo3 reverse 3’AGGCTCCCAGGGTAC 
TGTTGGGAGCTCCTAG 5’ 
Xho1 1509bp 
Lingo1 forward 5’GATCGGATCC|ATG|CA 
GGTGAGCAAGAGGATG 3’ 
BamH1  
Lingo1 reverse 3’ TTCAAGTTGTACTTC 
TACTATGAGCTCCTAG 5’ 
Xho1  
NgR forward 5’GATCGAATTC|ATG|AA 
GAGGGCGTCCGCTGGA 3’ 
EcoR1 1461bp 
NgR reverse 3’TGTCACGAACCCGGG 
ACGACTGAGCTCCTAG 5’ 
Xho1 1461bp 










Internal primer sequences used for DNA sequencing  
Name Primer sequence 
hAmigo1 int 1 5’ATGGCCCAGCTGCAGAAA 3’ 
 
hAmigo1 int 2 5’AACGGGTGCTAGATGAGG 3’ 
hAmigo2 int 1 5’TATGTTGGAAGGTTCAAG  3’ 
 
hAmigo2 int 2 5’GAAAGCCCTCGTTTTGAG 3’ 
 
hAmigo2 int 1-2 5’ TATGTTGGAAGGTTCAAG 3’  
 
hAmigo3 int 1 5’ACGAGCATGCCTTCCACG 3’  
 
hAmigo3 int 2 5’ATAGGCAACGTACAGGAG 3’ 
 
hNgR int 1 5’ATGACACCTTCCGCGACC 3’ 
hNgR int 2 5’TTACCATCCCATCTGGAC 3’ 
 
hp75 int 1 5’TGTGCGAGGACACCGAGC 3’  
 





Primer sequences used for overlap extension PCR 




hAM1HA OLR 5’ GCTAACCACGGCTCGGCCAGCATAATCTGGAAC 
ATC 3’ 
hAM1 rev 5’ GATCCTCGAGTCACACCACAATGGGCGTATCAGA 3’ 
hAM2HA OLF 5’ GATGTTCCAGATTATGCTGTGTGCCCCACCGCT TGC 
3’ 
hAM2HA OLR 5’ GCAAGCGGTGGGGCACACAGCATAATCTGGAAC 
ATC 3’ 
hAM2 rev 5’ GATCCTCGAGTTAAGTGGACGCCACAAAAGGTGT 3’ 
hAM3HA OLF 5’ GATGTTCCAGATTATGCTACCCCGGACTCCGAG GGT 
3’ 
hAM3HA OLR 5’ ACCCTCGGAGTCCGGGGTAGCATAATCTGGAAC 
ATC 3’ 
hAM2 rev 5’ GATCCTCGAGCTAGGTTGTCATGGGACCCTCGGA 3’ 
hNgRHA OLF 5’ GATGTTCCAGATTATGCTTGCCCAGGTGCCTGCGTA 
3’ 
hNgRHA OLR 5’ TACGCAGGCACCTGGGCAAGCATAATCTGGAAC 
ATC 3’ 
hp75HA OLF 5’ GATGTTCCAGATTATGCTAAGGAGGCATGCCCCACA 
3’ 
hp75HA OLR 5’ TGTGGGGCATGCCTCCTTAGCATAATCTGGAAC ATC 
3’ 
HAEco FOR 5’ GATCGAATTCATGTCTGCACTTCTGATCCTA 3’ 
HABamHI FOR 5’ GATCGGATCCATGTCTGCACTTCTGATCCTA 3’ 
 
 
 
 
 
